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Considerate la vostra semenza: 
Fatti non foste a viver come bruti, 
Ma per seguir virtute e conoscenza. 
  
Consider well the seed that gave you birth: 
You were not made to live your lives as 
brutes, 
But to be followers of worth and knowledge. 
 
                                                         (Dante Alighieri, Inferno, Canto 26, vv. 110-116)   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Abstract  
 
AMKL (acute megakaryoblastic leukaemia) accounts for at least 50% of all 
cases of acute myeloid leukaemia (AML) associated with Down Syndrome 
(DS). 
Every tenth neonate with DS develops Transient Myeloproliferative Disorder 
(TMD), a self-regressing neoplasia with features that closely resemble AMKL. 
Despite the vast majority of TMD cases self-regressing within a few weeks, 
approximately 30% of DS infants with TMD develop by the age of 2-4 years a 
more aggressive, full-blown AMKL. Both DS-TMD and DS-AMKL are 
associated with trisomy of human chromosome 21 (HSA21) and with acquired 
mutations of GATA-1 (a transcription factor essential for 
erythroid/megakaryocytic lineage specification) leading to the exclusive 
production of a short form of the protein known as GATA-1s. Additional 
molecular events involved in the progression from TMD to AMKL remain 
largely unknown.  
The aim of this project was to shed new light on the critical events involved in 
the pathogenesis of DS-TMD and AMKL utilizing an innovative in vitro model 
that mimics Down syndrome, a murine embryonic stem cell line carrying an 
extra copy of human chromosome 21 (HSA21). 
Using this transchromosomic ES cell system, I explored the effect of trisomy 
21 (t21) on the generation of megakaryocytes in vitro, and showed that 
trisomic megakaryocyte precursors display increased levels of GATA-1 
compared to euploid controls and exhibit the tendency of forming macroscopic 
colonies without overt GATA1 mutations. Furthermore, I genetically 
manipulated the transchromosomic ES cell system by retrovirally 
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overexpressing GATA1s and demonstrated that trisomy 21 is required for 
GATA-1s to exert its full hyperproliferative potential.  
The influence of the supernumerary HSA21 on the ontogenesis of 
haematopoietic stem cells (HSCs) from mesodermal precursors was also 
studied in the transchromosomic system. In this thesis, I present evidence that 
mesodermal colonies derived from transchromosomic ES cells give rise to an 
increased number of immature haematopoietic progenitors compared to 
euploid controls. I demonstrate that at least two independent genes on HSA21 
contribute to this effect, and that trisomy of RUNX-1 (a master regulator of 
primitive haematopoiesis encoded on chromosome 21) is required for an 
increased haematopoietic commitment from the mesodemal precursors.  
This thesis shows that t21 influences haematopoiesis (in general) and the 
megakaryocytic lineage (in particular) at several levels and that it is 
responsible for an overall increase in levels of immature cells that are targets 
for acquisition of further leukaemogenic mutations. 
Finally, in this study I clarify the role of JAK3, a gene whose mutations have 
been reported in AMKL, in the progression from TMD to AMKL. 
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1. Introduction  
1.1. Overview 
 
Acute Leukaemias are clonal malignancies of the haematopoietic system. 
They are characterised by a block in the lineage specification from 
haematopoietic stem cells (HSCs) to mature blood cells, which can occur at 
different stages of the haematopoietic development causing the abnormal 
accumulation of immature progenitors or of more committed cells in the bone 
marrow and in the peripheral blood. 
In human acute leukaemias, this block is very frequently caused by the 
abnormal function of transcription factors (TFs), which are vital players in the 
sophisticated regulation of physiological formation of blood cells. Abnormal 
function of TFs can be due to mutations or to chromosomal translocations 
leading to genetic rearrangements, which result in alternative, dysfunctional 
forms of TFs, alteration in TFs levels or complete loss of TFs production. 
According to the multi-step model of leukaemogenesis, cells bearing the first 
malignant lesion (dysplastic clone) acquire further hits (activating mutations) 
inducing abnormal activation of pro-survival or anti-apoptotic pathways, which 
ultimately lead to the uncontrolled proliferation of these cells and their 
selective advantage over “normal” cells in the bone marrow (Kelly and 
Gilliland, 2002; Gilliland and Tallman, 2002). 
Leukaemias can be associated with predisposing conditions, such as bone 
marrow failure syndromes or congenital disorders. Even more than sporadic 
cases, these situations provide an ideal background to elucidate the onset and 
the progression of the malignant transformation. Leukaemia arising in Down 
syndrome (DS) provides one such example. Down syndrome is a genetic 
disorder caused by trisomy of human chromosome 21 (HSA21) that induces a 
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wide variety of clinical phenotypes. These include a peculiar type of paediatric 
leukaemia of the megakaryocytic lineage (acute megakaryoblastic leukaemia, 
AMKL) characterised by mutations of the transcription factor GATA-1 
(encoded on the X chromosome) and by the presence of an extra copy of 
HSA21 in the malignant clone. Within the first weeks of life, as many as 10% 
of newborns with DS present with a transient myeloproliferative disorder 
(TMD), which is also associated with mutations of GATA-1. In the vast majority 
of children with DS, TMD spontaneously self-regresses. However, almost 30% 
of DS patients affected by this transient leukaemia (TL) will develop within 3 
years a frank AMKL, which requires treatment. 
Mechanisms by which trisomy 21 predisposes for development of leukaemia 
and how the increased gene dosage caused by the supernumerary 
chromosome cooperates with mutations of GATA-1 in the development of 
TMD and AMKL are unclear. 
The high frequency of the predisposition to a myeloproliferative disorder 
among children with DS and the limited time frame when the malignant 
transformation occurs make DS leukaemia even more puzzling, and establish 
a unique paradigm to dissect the sequential steps of leukaemogenesis. 
These reasons, and the availability of an exceptionally innovative mouse 
model of DS generated by introducing an extra copy of human chromosome 
21 (HSA21) into a mouse euploid context, prompted us to investigate the 
generation of HSCs and the properties of the megakaryocytic lineage in Down 
syndrome. Utilizing the potential to explore early developmental phenomena 
offered by embryonic stem cells (ES cells) and the relevance of embryonic 
stages to the onset of leukaemia in DS, this thesis aims to address whether 
trisomy 21 perturbs HSCs formation from ES cells engineered to carry an 
extra copy of HSA21 (transchromosomic ES cells) and the extent to which 
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differentiation and proliferation of megakaryocytes derived from 
transchromosomic ES cells is impaired by trisomy 21.  
Evidence of early disturbances in the generation of HSC from ES cells in DS 
are presented and genetic dissection of this in vitro phenotype is provided, 
harnessing the potential of the transchromosomic model to explore the 
contribution of individual genes to the phenotypes of DS.  
Generation of megakaryocytes from the transchromosomic ES cells is also 
investigated in this thesis, leading to the conclusion that terminal differentiation 
of megakaryocytes is not impaired in this system. Further characterisation of 
the properties of the transchromosomic megakaryocytes is shown, with 
respect to their clonogenic property and their cooperation with GATA-1 
mutations.  
Finally, using primary clinical samples, this thesis attempts to clarify the role of 
JAK3, a gene whose mutations have been reported in DS leukaemia, in the 
progression of this disease. 
1.2. Features of Down syndrome  
 1.2.1. Euploidy and aneuploidy 
  
         In humans the number of chromosomes is 46, including 22 pairs of autosomes 
and 2 sex chromosomes, X and Y. The presence of the entire set of 
chromosomes normal for a given species is a condition known as euploidy. 
Conversely, aneuploidy is defined by the presence of an abnormal number of 
chromosomes. The presence of an extra copy of a whole chromosome is 
called trisomy, whereas monosomy indicates the absence of one or more 
chromosomes from the number that is normal for the species. Both of these 
situations are classified as aneuploidies, and they result in an abnormal copy 
number of the genes residing on the chromosome that is acquired or lost. The 
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number of copies of a gene can also be affected by structural changes of a 
portion of it, such as deletions or duplications. These changes are said to 
result in segmental aneusomy when causing pathological conditions.  
Approximately 12% of the genome, including several genes, varies in copy 
number within the human population without causing pathologic 
consequences (so called copy number variation, or CNV) (Redon et al., 2006; 
Shaikh et al., 2009).  
 
        
Type of aneuploidy  
 
Chromosome 
    
 Syndrome and phenotypes  
 
Frequency 
 
Trisomy  
 
 21 
 
Down syndrome.  
Highly variable phenotypes, mental 
retardation and other abnormalities. 
Life expectancy of >55 years 1. 
 
 
 
1/750 
Trisomy   18 Edward syndrome.  
Severe developmental disorder. 
Children usually die within the first 
few months after birth. 
 
1/7500 
Trisomy    13 Patau syndrome. 
Rarely compatible with life, severe 
neurological and cardiac deficits 
usually leading to death within a few 
weeks after birth. 
 
 
1/12000 
Trisomy   X (XXX) Normal sexual development, 
sometimes menstrual abnormalities. 
 
1/975 
Trisomy  (Y disomy)  Y (XYY) Increased risk of learning impairment 
and delayed language skills. 
 
1/975 
Trisomy  XXY Klinefelter syndrome. 
Small testicles and reduced fertility. 
. 
 
1/5000 
Monosomy   X Turner syndrome. 
Variable features including short 
stature and ovarian dysgenesis. 
 
 
1/8000 
       
          Table 1.1. Human aneuploidy syndromes and associated chromosomal abnormalities, 
with clinical features caused by the gene dosage imbalance and frequency in live birth 
(frequencies derived from Hassold et al., 2002 and Crider et al., 2008). 1 Life expectancy data 
for individuals with DS were taken from Glasson et al., 2002.    
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In the remaining cases, aneuploidy and segmental aneusomy are prominent 
causes of pregnancy loss, with approximately 30% of all spontaneous abortion 
and approximately 6% of all infant death resulting from aneuploidy (Hoffmann 
et al., 1986). When compatible with life, gene dosage imbalance is a well-
known cause of human disease (Jacobs, 1992; Templado et al., 2005), 
resulting in a variety of phenotypes as summarized in table 1.1.  
         About 0.5-1% of live births have a numerical chromosomal abnormality 
(Aardema et al., 1997). The most common viable human aneuploidy, with a 
frequency of 1 in 750 live births (Antonarakis et al., 2004), is Down syndrome 
(DS) (Down, 1995), a congenital disorder caused by trisomy of chromosome 
21 (HSA21) (Lejeune et al., 1959). According to the National Down Syndrome 
Cytogenetics Register (NDSCR), the diagnoses of DS in England and Wales 
in 2008 were 1843, 1112 of which were antenatal. Of the latter ones, 92.5% 
lead to termination of pregnancy, whereas 4.8% lead to the birth of a DS 
individual (Morris and Alberman, 2009).  
 
1.2.2. Etiology of Down syndrome 
 
 
Trisomy 21 (t21) can be full, involving the acquisition of a complete extra 
HSA21, or partial, involving three copies of specific HSA21 regions. Almost 
95% of individuals with DS have full trisomy 21 (Thaline, 1982), which is 
caused by non-disjunction during maternal meiosis (Antonarakis, 1991; Brown 
et al., 2000), whereas only ~5% of trisomy 21 cases are attributable to errors 
occurring during spermatogenesis (Antonarakis, 1991; Savage et al., 1998). 
The predominant maternal meiotic errors that lead to full trisomy 21 mainly 
occur during meiosis I, when homologous chromosomes are supposed to 
separate from each other (Sherman et al., 1994). This intricate process has a 
few error prone stages, such as the maintenance of physical connections 
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between homologous chromosomes during prophase I and metaphase I, and 
the appropriate segregation of sister chromatids to the opposite poles of the 
meiotic spindle (Hassold and Hunt, 2001). 
The significant bias towards maternal meiosis I errors in DS seems to be 
related to the delayed meiotic division that oocytes undergo. In fact, in 
females, meiosis is initiated in the foetal ovary but arrests before birth in 
meiotic prophase I and only resumes at puberty, many years after birth. 
Following completion of the first meiotic division, meiosis is arrested again, 
early in the second meiotic division and is completed only after fertilisation of 
the oocyte by a sperm cell. Male meiosis, instead, is initiated at puberty and it 
progresses continuously to its completion. Furthermore, unlike in females 
where there is a limited pool of oocytes that progressively depletes in 
successive menstrual cycles, sperm production does not cease during a 
male’s lifetime (Hassold and Hunt, 2001).   
The increased incidence of DS with increasing maternal age has been 
recognised for many years. Furthermore, an augmented risk of recurrence of 
DS in young women was observed a long time ago (Penrose, 1933); 
mechanisms underlying this increased risk are unexplained. While the 
segregation and recombination events that are required for the completion of 
meiosis I, and its delayed completion in the oocyte, are an extremely intricate 
process, the reasons for the positive correlation that exists between meiosis I 
errors and maternal age are not fully understood. An explanation for the 
increased incidence of maternal meiosis I errors is the possible association 
between reduced recombination and the non-disjunction of HSA21 that 
causes t21 (Brown et al., 2000; Lamb et al., 1996; Sherman et al., 1991). 
Recent studies have tried to define the mechanisms responsible for this effect 
and its relationship with maternal age. A widely accepted view postulates that 
multiple pathways lead to non-disjunction, some age-dependent, and others 
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age-independent. For young women, the greatest risk factor for meiosis I non-
disjunction has been identified as the presence of a susceptible exchange 
pattern in the oocyte (Lamb et al., 2005). Over time, the proportion of non-
disjunction due to normal exchange configurations increases as age-
dependent risk factors exert their influence (Sherman et al., 2005).  
Maternal meiosis II errors constitute 20–24% of all maternal meiosis errors, 
and 18– 23% of all cases of t21 (Antonarakis et al., 1992). Similar to meiosis I 
errors, meiosis II errors also have an associated maternal age effect (Hassold 
and Jacobs, 1984). The small numbers (about 5%) of paternally derived errors 
in meiosis leading to trisomy 21 (Antonarakis, 1991) are approximately equally 
distributed between the meiosis I and meiosis II. Unlike maternally derived 
errors, paternal errors do not have an age-associated effect. However, 
paternal non-disjunction in the first meiotic division is associated with a 
significant reduction in recombination similar to maternal meiosis I non-
disjunction. There is no effect of recombination amongst paternally derived 
meiosis II errors (Savage et al., 1998).  
Maj Hulten et al. have recently challenged the view that trisomy 21 is caused 
by non-disjunction of homologous chromosomes 21 during the first meiotic 
division by screening ovarian cells from eight phenotypically normal female 
foetuses. All foetuses analysed in this study were found by fluorescence in situ 
hybridization (FISH) to be mosaics, containing ovarian cells with an extra copy 
of HSA21. If every woman is a mosaic in her ovary, this could explain 
simultaneously the maternal age effect and the recurrence in younger women. 
In normal development, there is a dramatic reduction in the number of oocytes 
due to apoptosis, but trisomic oocytes lag behind in this process and they 
accumulate comprising a larger proportion of the ovarian reserve at later 
maternal ages. It is also logical to postulate that some women might have a 
high proportion of trisomic oocytes in their ovary, which might account for the 
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increased recurrence of DS pregnancies in young women (Hulten et al., 
2008). 
Only 3–5% of all cases of full trisomy 21 are attributable to errors in mitosis. 
These errors show no parental age effect and there is no preference for either 
the maternal or paternal HSA21 to be duplicated (Antonarakis et al., 1993).  
In approximately 5% of full t21 cases, one copy of HSA21 is translocated to 
another HSA21 or to another acrocentric chromosome, usually chromosome 
14 (Petersen et al., 1991; Shaffer et al., 1992). In most cases of a 
translocation involving two chromosomes 21, the t(21;21) is an 
isochromosome consisting of two long arms of HSA21 (Grasso et al., 1989). 
The distribution between maternally- and paternally-derived t(21;21) 
isochromosomes is approximately equal (Antonarakis et al., 1990). A minority 
of t(21;21) cases arise from Robertsonian translocations where exchanges 
between the proximal short arms of two chromosomes 21 produces a 
chromosome with two centromeres which function as one, thereby conferring 
stability to the resulting metacentric chromosome. In these cases the extra 
chromosome is maternally derived (Antonarakis et al., 1990; Shaffer et al., 
1992). Trisomies caused by parental Robertsonian translocations involving 
chromosomes 14 and 21 (t(14;21)) also originate exclusively in maternal germ 
cells (Shaffer et al., 1992). 
Approximately 3% of trisomy 21 cases occur as a result of post-zygotic 
mitosis, thereby producing t21 mosaicism (Mikkelsen, 1977). The final class of 
t21 individuals is comprised of partial trisomics, who have three copies of parts 
of HSA21 as a result of translocation events. These patients have been 
fundamental in mapping the phenotypic characteristics of t21 to specific 
HSA21 regions.  
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1.2.3. Phenotypes of Down syndrome  
 
 
An English physician, John Langdon Down, first described Down syndrome in 
1866 (Down, 1995). The mental and physical abnormalities Down described in 
his original report were resembling the facial characteristics of the Mongolian 
population, though he observed that these characteristics could appear at 
equal frequency in children of any race and ethnic group. The term “Mongolian 
idiocy” was therefore subsequently employed to describe Down syndrome, 
and “Mongoloids” was used to refer to people affected by this condition. It was 
not until 1961 that Langdon Down’s original observations were officially 
credited to him. A late recognition came in the form of a letter to the scientific 
journal “The Lancet”, signed by twenty prominent genetic experts (Allen et al., 
1961) who suggested four alternative names for the condition. As a result, the 
editor of the Lancet ruled “Down’s syndrome” as an appropriate term for the 
phenotypes described by Langdon Down, and a few years later (in 1965), the 
World Health Organisation officially designated “Down’s syndrome” a the term 
for the phenotypes of trisomy 21 (Ward, 1999). 
The causative link between trisomy 21 and DS came almost one century after 
Langdon Down’s original observations (Jacobs et al., 1959; Lejeune et al., 
1959) and since then there have been a variety of studies aiming to dissect 
the pathogenesis of DS and the mechanisms by which one extra copy of all, or 
a subset of HSA21 genes, leads to the broad spectrum of phenotypes 
collectively known as DS. 
Phenotypes of DS can greatly vary within the affected population, however the 
characteristic combination of physical attributes that result from trisomy of 
HSA21 are collectively so indicative of the condition, that a diagnosis of DS 
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can often be preliminarily established based on the physical features alone 
(Rex and Preus, 1982). The physical characteristics of DS are summarized in 
Figure 1.1 with the average relative frequency and include: upslanting 
palpebral fissures, narrow palate, flat nasal bridge, a gap between the first and 
second toes and a protruding tongue (Rahmani et al., 1989; Delabar et al., 
1993). As shown in table 1.2, phenotypes of DS are found in many different 
tissues. Approximately 40% of all DS individuals have some form of congenital 
heart defect. The ones that occur most commonly are endocardial cushion 
defects and an atrioventricular canal (Epstein, 2001). Congenital heart defects 
are one of the leading causes of death in the DS population, accounting for 
30–35% of all deaths (Baird and Sadovnick, 1989). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. Physical features of DS and average frequency of reported phenotypes. Data in 
this figure are derived from Epstein, C.J. in The Metabolic and Molecular Basis of inherited 
Diseases, 8th edition, 2001). 
 
Duodenal stenosis is observed in 4-7% of Down syndrome patients. 
Approximately 90% of children with Down syndrome develop skin disorder 
such as hyperkeratosis, which may later in life lead to atopic dermatitis and 
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fungal infections of skin and nails (Roizen and Patterson, 2003). Between 38% 
and 78% of people with Down syndrome suffer from hearing loss which can be 
conductive, sensorineural or mixed (Balkany et al., 1979). Women with Down 
syndrome are able to conceive, whereas men have an impaired capacity to 
reproduce (Bovicelli et al., 1982). 
The most significant and characteristic phenotypes of DS are those affecting 
the nervous system. Mental retardation and a histopathological signature 
indicative of Alzheimer’s disease (AD) can be considered the hallmark 
manifestations of this class of phenotypes, occurring invariably in all DS 
individuals (Wisniewski et al., 1985; Williams and Matthysse, 1986).  
 
 
 
Phenotypes 
  
   Average frequency (%) 
 
Skeletal abnormalities 
Pelvic dysplasia 
Atlantoaxial or atlantoccipital instability 
Mental retardation 
Hypothyroidism 
Neurological features 
Hypotonia 
Alzheimer like brain pathology 
Delayed disappearance of early reflexes 
Congenital abnormalities 
Congenital heart defects (CHD) 
Atrioventricular canal (of total CHD) 
Ventricular septal defect (of total CHD) 
Atrial septal defect (of total CHD) 
Fallot's tetralogy (of total CHD) 
Patent ductus arteriosus (of total CHD) 
Gastrointestinal abnormalities 
Duodenal atresia 
Imperforated anus 
Hirschsprung disease 
Infertility in males 
Leukaemia 
AMKL 
AML/ALL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
15 to 20 
100 
7 to 17 
 
100 
100 
80 
 
30 to 40 
40 
31 
9 
6 
9 
 
2.5 
1 
0.6 
100 
 
200-400x normal 
10-20x normal  
 
    
         
Table 1.2. Phenotypes of DS and frequency in percentage (data from Epstein, C.J. in The Metabolic 
and Molecular Basis of Inherited Diseases, 8th edition, 2001). 
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The trisomic status of one, or most likely several, HSA21 genes are likely to 
be a major predisposing factor for the neurological features of Down 
syndrome. Support for the direct or indirect role of HSA21 in the neurological 
defects of DS has been provided by the identification of several genes on 
HSA21 whose functions may be important in the development of the central 
nervous system (Agarwala et al., 2001; Hammerle et al., 2002; Sanchez-Font 
et al., 2003). Mental retardation in Down syndrome may be a result of a 
reduced number of neurons in all layers of the cerebral cortex. Furthermore, 
an impaired synapse formation and a synaptic plasticity defect were observed 
in individuals with Down syndrome (Ferrer and Gullotta, 1990). The post-
mortem brains of DS adults aged 35 years or older display all the pathological 
and neurochemical hallmarks of the AD that occurs in euploids (Mann, 1988), 
including the deposition of neurofibrillary tangles and amyloid plaques in the 
brain (Teller et al., 1996). The order in which specific brain regions are 
affected as the disease progresses is equivalent in DS and euploid subjects 
(Epstein, 2001). 
         Immune system defects in DS individuals render them significantly more 
susceptible to infectious diseases, including pneumonia, meningitis and 
influenza, accounting for the greatest number of deaths amongst DS 
individuals (Scholl et al., 1982). Different classes of antibodies may be 
elevated or decreased in comparison to their serum levels in euploid 
individuals (Ugazio et al., 1990). A minor reduction in the number of peripheral 
blood (PB) lymphocytes is also observed, with the proportion of T-helper cells 
(CD4+) to suppressor cells (CD8+) being markedly reduced (Ugazio et al., 
1990; Philip et al., 1986). These findings, together with observations of the 
altered expression profiles of T-cell receptors by PB T-cells (Murphy and 
Epstein, 1992), suggest that the ability of the DS thymus to generate 
functionally mature T-cells is impaired. Haematological abnormalities are 
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common in DS, especially in the first weeks of life. Apart from an increased 
risk of leukaemia compared to the euploid population (discussed extensively in 
1.2.), DS newborns can present with thrombocytopenia, polycythemia and 
neutropenia. The frequency of these abnormalities is so high that it has been 
recommended to perform a routine blood cell count in all neonates with DS 
(Henry et al., 2007). 
  
1.2.3. Gene dosage imbalance and its phenotypic effects in Down 
syndrome 
 
Human chromosome 21 (HSA21) is one of the smallest human chromosomes, 
but contains almost 400 known genes; this number is estimated to increase 
integrating new information based on ESTs sequencing and comparative 
genome analysis (Antonarakis et al., 2004; Wiseman et al., 2009). A key goal 
of DS research (and in general of aneuploidy research) is to define how an 
increased dosage of normal genes can cause a clinical condition and a variety 
of associated phenotypes with different degrees of penetrance. Since the 
correlation between the presence of an extra copy of HSA21 and Down 
syndrome was discovered in 1959, it has been proposed that genes that are 
trisomic are expressed 1.5 fold more in DS individuals than in the euploid 
population. In spite of this assumption, it has been showed in human DS 
tissues (Ait Yahya-Graison et al., 2007; Prandini et al., 2007) and in mouse 
models of DS (Chrast et al., 2000; Sultan et al., 2007) that the increased 
expression of some of the genes caused by an extra copy of HSA21 does not 
significantly differ from the natural variation of gene expression in euploid 
controls, excluding these genes as candidate for the dosage-sensitive effect of 
trisomy in the tissues investigated. Based on a gene expression study, 
Prandini et al. proposed to classify genes on HSA21 in three groups: group A 
contains genes with minimal expression overlap between DS and control 
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samples, group B contains genes with partial overlap, and group C contains 
genes that show extensive overlap of expression values between DS and 
normal samples. This classification implies that genes of group A are 
candidates for involvement in DS phenotypes that are present in all affected 
individuals, such as mental retardation, muscle hypotonia, and Alzheimer 
disease; genes of group B are likely to be involved in the variable features of 
DS and if their level of expression reaches a given threshold (that must be 
above the highest value observed for unaffected individuals), then the 
probability of the manifestation of a given phenotype is very high; genes of 
group C are less likely to be involved in DS phenotypes, although some of 
them may still be responsible for DS phenotypes and change their expression 
through regulatory mechanisms that are specific to cell type or developmental 
stage (Prandini et al., 2007). In light of the latter consideration, it is arguable 
that a spatial and temporal map of the HSA21 gene expression is crucial to 
the understanding of the DS phenotypes.  
Phenotypic variations in the DS population might also be caused by genomic 
variability, as suggested by a recent genome wide association-study (Lyle et 
al., 2009). The determination of SNPs involved in gene expression variation 
and in the predisposition to different variable phenotypes of DS is very likely to 
become a prominent avenue of investigation in the field in the near future. 
Positional cloning and “candidate gene” approaches are another powerful 
strategy used to narrow down the contribution of genomic regions that harbour 
genes associated with a specific phenotype in DS. Once a physical map of a 
chromosome region is established, candidate genes for a particular phenotype 
can be identified by in vitro and in vivo assays. The study of rare patients with 
partial trisomy has been very important in this direction, and mouse models of 
DS provide an invaluable tool to dissect the contribution of candidate genes to 
a given phenotype. In studying DS phenotypes, genetic variations and gene 
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expression mechanisms should be integrated with the candidate gene 
approach, providing additional evidence for the contribution of a specific gene 
to one or more of the DS phenotypes.  
Based on genotype-phenotype correlations, investigators have proposed the 
existence of a “DS critical region” (DSCR), which has been narrowed down to 
a region within 21q22 of about 4.3 Mb in length (Delabar et al., 1993; 
Korenberg et al., 1994; Arron et al., 2006; Ronan et al., 2007). The DSCR 
contains genes that contribute to mental retardation, heart defects and other 
common features of DS; however, the definition of such a region is 
controversial as patients with partial triplication outside of this region also 
manifest features of DS. 
In conclusion, how the presence of a supernumerary copy of a normal allele 
results in the phenotypes associated with DS remains to be fully addressed. 
Elucidating the effect of gene dosage imbalance in DS will deepen our 
understanding not only of this condition, but also of the pathogenesis of other 
aneuploidy syndromes. 
1.3. Down syndrome and cancer  
1.3.1. Under-representation of solid tumours in DS 
 
 
The incidence of solid tumours is strikingly reduced in DS individuals (Oster et 
al., 1975). A large American study of death certificates of millions of US 
citizens including 18.000 individuals with Down Syndrome showed that DS 
individuals have up to 100-fold lower likelihood of dying from many types of 
solid tissue cancer. Only testicular cancer was found slightly elevated in the 
Down syndrome population (Yang et al., 2002). Other studies have reported 
an increased incidence of some solid tumours such as gastro-intestinal tract 
cancers, lymphomas and retinoblastomas in DS compared to the euploid 
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population and a decrease incidence of all other solid tumours subtypes 
(Boker et al., 2001; Satge et al., 2003; Hill et al., 2003), or a reduction of the 
incidence of all solid tumours but GI tract cancers (Hermon et al., 2001; 
Goldacre et al., 2004). 
The direct role of HSA21 in conferring protection from solid tumour formation 
has been demonstrated by observation of loss of HSA21 material in several 
solid cancers. Loss of heterozygosity (LOH) on HSA21 has been reported in 
breast cancer (Ohgaki et al., 1998), oral squamous cell carcinoma (Yamamoto 
et al., 2001), lung cancer (Groet et al., 2000; Kohno et al., 1998) and gastric 
cancer.  
Judging by the variety of solid tumours that are suppressed in DS individuals 
and by the different regions of the chromosome that are deleted in different 
solid cancers, it is likely than one or more tumour suppressor genes exist on 
HSA21. A very exciting study has recently reported that crossing mouse 
models of DS with mice with an increased incidence of colon cancer (mice 
heterozygous for the APCmin mutation) reduced the formation of tumours of the 
colon, providing a role for ETS-2 (a gene present in three copies in the DS 
models which is known to be a powerful oncogene in other contexts) as a 
tumour suppressor gene (Sussan et al., 2008). 
 
1.3.2. Down syndrome and leukaemia 
 
 
DS children show an increased risk of developing leukaemia compared to their 
euploid counterpart. This is most prominent in early childhood, with the vast 
majority of cases of the disease occurring in children during the first four years 
of life (Hasle et al., 2000; Zipursky et al., 1992). 
The most frequent form of leukaemia during childhood is B-cell precursor 
Acute Lymphoblastic Leukaemia (“common ALL”) (Pui et al., 1993; 
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Ravindranath, 2005). The incidence of this type of leukaemia is approximately 
20-fold higher in children with DS than in the euploid population. The peak age 
(about 5 years old) and the immunophenotype (blasts expressing the surface 
antigens CD10, CD19, and CD79a) of DS-ALL are indistinguishable from the 
ones of the sporadic childhood common ALL (Malinge et al., 2009). Because 
trisomy or tetrasomy of human chromosome 21 are the most common 
acquired somatic chromosomal abnormalities in sporadic common ALL, it is 
reasonable to speculate that constitutional and somatic trisomy 21 may 
facilitate leukaemogenesis with the same mechanisms. Therefore, studying 
DS-ALL may have direct implications for understanding sporadic childhood 
ALL as well. The most frequently observed cytogenetic abnormality in DS-ALL 
is the acquisition of an extra chromosome X (Forestier et al., 2008); other 
lesions include the t(8;14) translocation and the deletion of chromosome 9 
(del(9p)). Mutations in PTPN11 and N-RAS have been described in DS-ALL 
samples (Yamamoto et al., 2006). An exciting breakthrough in the history of 
DS-ALL came from the finding that almost 20% of DS-ALL is associated with 
mutations in the tyrosine-kinase JAK2. The mutations described in DS-ALL 
occur in the JH2 pseudokinase domain affecting Arg683 and surrounding 
residues (Malinge et al., 2007; Bercovich et al., 2008; Kearney et al., 2009) 
and they are different from the V617F mutation associated with 
myeloproliferative disorders. Interestingly, these mutations were absent from 
the remission samples analysed, suggesting that they are a “second hit” 
acquired by trisomic progenitors and that they might constitute a promising 
therapeutic target in DS-ALL. 
The form of leukaemia with the most remarkably increased incidence in DS 
children is AMKL (FAB-M7 subtype of Acute Myeloid Leukaemia) (Hitzler and 
Zipursky, 2005). The relative risk of developing AMKL is estimated to be 500 
times higher in children with DS than in the general population (Zipursky et al., 
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1992) and this type of leukaemia arises at a younger median age in DS 
children (2 years) than in euploid children (8 years) (Lange et al., 1998). 
AMKL is characterised by the accumulation of megakaryoblasts, precursors of 
megakaryocytes, which are the cellular substrate of production of platelets. As 
in other types of leukaemia, the blasts in AMKL replace the normal bone 
marrow population causing a reduced production of erythrocytes, leukocytes 
and platelets. This leads to the main clinical aspects of the disease, which 
include anaemia, an impaired capacity to mount an immune response and a 
reduced capacity to fight infections as well as a decreased ability of the blood 
to clot after injuries. In young children and infants, FAB M7 leukaemia occurs 
as two separate entities. The first type is characterised by a very aggressive 
progression with bone marrow fibrosis and a poor prognosis and is associated 
with the translocation t(1;22)(p13;q13) (also known as OTT-MAL) (Ma et al., 
2001). The second type of M7 occurs in DS (DS-AMKL) and is characterised 
by a good response to treatment and a better prognosis. In DS, a reversible 
form of megakaryoblastic leukaemia known as Transient Leukaemia (TL), or 
Transient Myeloid Disorder (TMD) usually precedes AMKL. At least 10% of 
infants with DS develop TMD, a disease in which immature megakaryoblasts 
accumulate in liver, bone marrow and peripheral blood. Even though this 
disorder undergoes spontaneous remission in most cases (Zipursky, 2003), 
approximately 30% of DS children with TMD develop AMKL within 3-4 years.  
Megakaryoblasts of TMD are morphologically indistinguishable from the AMKL 
blasts. Immunophenotyping shows that both type of blasts express the 
myeloid markers CD33 and CD13, in addition to at least one platelet-
associated antigen (CD41 or CD61) and frequently the haematopoietic stem 
cell marker CD34. As these blasts also express erythroid-specific mRNAs, 
such as globin and erythroid δ-aminolevulinate-synthase (Ito et al., 1995), it is 
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logical to postulate that TMD and AMKL arise from a disturbance in the 
maturation from a common erythroid-megakaryocytic progenitor (MEP).  
The process resulting in TMD begins in utero and in most cases does not 
cause clinical symptoms in newborns, although the liver, the bone marrow and 
the blood are filled with a large number of blast cells. Only a small percentage 
(<5%) of TMD cases are severe and might be fatal as a result of liver damage 
or heart and lung complications. 
 
1.4. Haematopoiesis, leukaemogenesis and trisomy 21  
1.4.1 Developmental stages of haematopoiesis 
            Haematopoiesis is a complex process that starts from a multipotent stem cell 
capable of differentiation and self-renewal (haematopoietic stem cell, HSC), 
and leads to a hierarchy of progenitor cells with increasingly restricted 
potential of differentiation, ending with the fully differentiated blood cells 
(Weissman et al., 2001). During embryogenesis, the original pool of HSCs is 
formed in a developmentally regulated fashion that involves multiple 
anatomical sites (Mikkola and Orkin, 2006). The shift from one location to 
another is required as the embryo grows and supports the development of 
undifferentiated HSCs, which can replenish the “stemness” pool while giving 
rise to maturing blood cells that are exposed to different inductive signals from 
multiple locations with distinct microenvironments. In mice, where this process 
has been extensively characterised, embryonic haematopoiesis starts in the 
primitive streak, a specialized subset of mesodermal cells, and in the yolk sac. 
Yolk sac is the main site of embryonic red blood cells production (embryonic 
haematopoiesis) (Dzierzak and Speck, 2008; Lux et al., 2008). HSCs capable 
of forming all the haematopoietic lineages (definitive haematopoiesis) arise 
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subsequently in the aorta-gonad-mesonephros region (AGM) (de Bruijn et al., 
2000; Jaffredo et al., 2005) and migrate to colonize the foetal liver. Seminal 
work from Ottersbach et al. and Rhodes et al. identified the placenta as a 
reservoir of HSC generation at the same developmental stage of the AGM 
region, and Rhodes et al. have also demonstrated that HSC development is 
initiated at this site independently from circulation (Ottersbach and Dzierzak, 
2005; Rhodes et al., 2008). Finally, the bone marrow becomes the principal 
site of haematopoiesis after birth and it persists in this function through 
adulthood (Figure 1.2). 
 
 
             Fig. 1.2. Anatomical sites harbouring HSCs in mouse and human embryos.  Data and 
figure modified from Mikkola et al, Development, 2006. Numbers indicate embryonic days. 
Figure shows the developmental migration of anatomical sites of haematopoiesis before birth. 
Primitive embryonic haematopoiesis starts in the primitive streak and in the yolk sac. Definitive 
haematopoiesis (with cells capable of giving rise to all haematopoietic lineages) first originates 
in the in the aorta-gonad-mesonephros region (AGM), then colonizes the foetal liver, and finally 
moves to the bone marrow, where it persists throughout adult life. Recent data suggest that 
definitive haematopoiesis arises simultaneously in the AGM and in the placenta. 
 
 
Apart from the anatomical site of production, foetal HSCs differ from adult 
HSCs because they have to complete a maturation process that, whilst 
permitting their engraftment and survival in future haematopoietic niches, 
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allows the expansion of their number in order to provide an adequate supply of 
HSCs throughout adult life. Therefore, foetal HSCs are largely cycling and 
undergo symmetric cell division to expand the HSC pool (Lessard et al., 
2004). In contrast, in homeostasis condition, adult HSCs are quiescent and 
only rarely divide to maintain an adequate supply of differentiated blood cells 
and to renew the HSCs pool. 
         Mechanisms underlying the complex task of producing blood cells and 
replenishing the stemness pool are not completely defined. Possible models 
include asymmetric cell divisions, in which every dividing stem cell forms one 
new stem cell and one differentiated cells, or environmental asymmetry, in 
which the daughter cell leaves the niche that sustain HSC self-renewal and 
through specific external environmental signals undergoes lineage 
differentiation (Wilson et al., 2004).  
 
 1.4.2. Transcription factors and lineage commitment 
 
 
All the processes described above are widely controlled by cell-restricted 
transcription factors (TFs) (Weissman et al., 2001; Cantor and Orkin, 2002). 
TFs can directly regulate gene expression by their DNA binding properties but 
also influence lineage decisions by inhibition of competing TFs through direct 
protein-protein interactions. TFs are essential for haematopoietic cell 
development from the earliest stages, as illustrated in figure 1.3.  TFs required 
for the initial specification and formation of HSCs include GATA-2, SCL/Tal1, 
c-MYB and RUNX-1 (Orkin and Zon, 2008). 
The expression of lineage-specific TFs is required for the specification and the 
maturation of different lineages. The classical “hierarchical view” of 
haematopoiesis (based on prospective isolation of progenitors) is indeed 
based on the idea that the expression or the inhibition of specific TFs 
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corresponds to the progressive maturation of cells of each lineage, and that 
this process has a molecular correspondent in the expression of specific 
cellular surface markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. A schematic view of haematopoiesis in the mouse, with the indication of some of 
the most well characterised transcription factors and their role in lineage specification 
(modified from Weissman et al, Annu Rev Cell Dev Biol, 2001). HSCs can be divided into long-
term HSCs (LT-HSCs), which are highly self-renewing, and short-term HSCs (ST-HSCs), which 
have a more limited self-renewal potential and differentiate into oligolineage-restricted 
progenitors that ultimately give rise to differentiated progeny. Common lymphoid progenitors 
(CLPs) give rise to T-lymphocytes, B-lymphocytes, and natural killer (NK) cells. Common 
myeloid progenitors (CMPs) give rise to granulocyte-macrophage progenitors (GMPs), which 
then differentiate into monocytes, macrophages and granulocytes, and to megakaryocytic-
erythroid progenitors (MEP), which produce megakaryocytes, platelets and erythrocytes. All of 
these stem and progenitor populations are separable as pure populations by using cell surface 
markers. Each stage of the haematopoietic process is tightly regulated by the combined action 
of transcription factors (TFs). Main TFs playing a role at each haematopoietic stage are 
indicated in boxes.    
 
 
  34 
For example, GATA-1 is highly expressed in the MEPs (megakaryocytic-
erythroid progenitors) compartment, whereas C/EBPα expression specifies a 
commitment towards granulocyte-macrophage progenitors (GMPs). 
The one-to-one correspondence of the expression of transcription factors and 
progenitors is a simplified view, which has been challenged by new models, 
such as the “lineage priming effect“ (Fisher, 2002). This is a mechanism by 
which HSCs and early progenitors express markers of disparate lineages at a 
single cell level (albeit at low levels) (Orkin, 2003), and maintain the chromatin 
of genes involved in crucial haematopoietic programs in an open configuration 
that confers to these cells the plasticity to choose molecular fates rather than 
adhering to a single pre-established program. Furthermore, new techniques of 
progenitor separation and purification of TF complexes have rapidly 
progressed, deepening our understanding of the haematopoietic development. 
For example, the recent findings that short-term repopulating HSCs 
expressing GATA-1 or PU.1 may be committed to the myelo-erythroid or 
myelolymphoid lineage (Arinobu et al., 2007) has challenged the traditional 
view of HSCs and TF-restricted lineage commitment, suggesting that lineage 
specification decisions can be made at different branching points of the 
haematopoietic hierarchy.  
Of the more than 20 haematopoietic TFs whose functions have been 
characterised, virtually all are associated with haematopoietic malignancy, and 
are often involved in chromosomal translocations present in leukaemia. 
Indeed, many were first studied for their pathogenic role in human disease. 
The aberrant expression of TFs, as well as their abnormal activation or 
inactivation caused by translocations or rearrangements have multiple 
downstream effects, including altered repression or derepression of target 
genes and inhibition of other critical factors, which all contribute to the 
execution of the malignancy program (Rosenbauer and Tenen, 2007). 
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In conclusion, TFs, epigenetic mechanisms and recently identified additional 
levels of control (such as that provided by micro-RNAs and other small RNAs) 
coordinate an extraordinary intricate and yet remarkably functional biological 
process, whose deregulation is directly associated with cancer and 
leukaemogenesis and whose understanding is the basis of crucial therapeutic 
implications.   
 1.4.3. GATA -1 mutations and Down syndrome leukaemia 
 
          GATA-1 is a transcription factor encoded on the X chromosome. It is 
physiologically expressed in erythroid and megakaryocytic cells, eosinophils 
and mast cells (Martin et al., 1990; Romeo et al., 1990; Zon et al., 1993). 
         The GATA-1 protein has three functional domains (Figure 1.4). The C-terminal 
zinc finger domain is required for binding to specific DNA motifs. The N-
terminal zinc finger domain increases the affinity of the protein for complex 
DNA binding motifs and interacts with the cofactor FOG1 (Muntean and 
Crispino, 2005).             
         
          
 
 
 
 
Fig.1.4. Structure of the GATA-1 protein. The diagram shows the three functional domains (in 
purple and dark green and the alternative translational start site (Met84) of the GATA-1 protein. 
Different mutations of GATA-1, which generally cluster within exon 2, have the same protein 
consequence, i.e. the production of a short form of GATA-1 (translated starting from Met84) that 
lacks the N-terminal “transactivation” domain. 
 
Insights into the functions of the third domain of GATA-1 (the N-terminal 
transactivation domain) came from the finding that both DS-AMKL (Wechsler 
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et al., 2002) and DS-TMD (Groet et al., 2003; Hitzler et al., 2003) present 
acquired mutations in GATA-1.           The majority of the reported mutations in DS-TMD and AMKL involve point 
mutations, small deletions or insertions in the sequence encoding GATA-1 
exon 2. Each of these alterations has been shown to result in a disruption of 
the normal reading frame of GATA-1, and an invariable introduction of a 
premature stop codon. As a consequence, full-length GATA-1 is not 
expressed in the leukaemic cells, but a short isoform of GATA-1, described as 
GATA-1s, remains the only form expressed in both DS-TMD and AMKL blasts. 
GATA-1s (that is physiologically expressed alongside full length GATA-1 in 
humans) arises by alternative translation from Met84, downstream of each of 
the patient mutations and lacks the N-terminal transactivation domain, but 
retains both zinc fingers and the entire C-terminus domain (Martin and Orkin, 
1990; Calligaris et al., 1995). 
 
1.4.4. GATA-1, GATA-1s and haematopoiesis 
 
 
GATA-1 is essential for erythroid and megakaryocytic development and 
maturation (Ferreira et al., 2005). Both lineages arise from a common 
progenitor, the megakaryocytic-erythroid progenitor (MEP), which in turn is 
derived from a common myeloid progenitor (CMP). Similar to other TFs, the 
role of GATA-1 in haematopoietic development was determined through 
conventional gene knockouts. GATA-1- ES cells produce no mature erythroid 
cells in vitro (Simon et al., 1992) and in vivo (Fujiwara et al., 1996).  
Using yeast, Crispino et al. demonstrated that this effect on the erythroid 
lineage is mediated by a critical interaction with the FOG factor that requires 
the presence of the GATA-1 N-terminus domain (Crispino et al., 1999).  
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Fig.1.5. From MEP to megakaryocytes. Schematic view of the differentiation of the 
megakaryocytes from their precursors, with the indication of TFs essential for the specification 
of the lineage. GATA-1 is highlighted in red.    
 
The role of GATA-1 in megakaryocytic development (Figure 1.5) was initially 
discovered through the creation and analysis of several lines of mutant mice 
expressing reduced  level of GATA-1. One of these lines, the ΔneoHS GATA-
1-targeted mouse, expresses normal levels of GATA-1 in erythroid cells but 
undetectable levels of GATA-1 in megakaryocytes (Shivdasani et al., 1997).  
ΔneoHS mice displayed marked, persistent thrombocytopenia, with platelets 
reduced to approximately 15% of normal counts, and a remarkable expansion 
of immature megakaryocytes in the bone marrow. GATA-1 deficient 
megakaryocytes are smaller than wild type cells and have multiple 
abnormalities, including a scant cytoplasm with paucity of granules, reduced 
proplatelet processes and an excess of rough endoplasmic reticulum (rER), as 
well as a reduced polyploidization. Platelets derived from these mice are also 
abnormal, containing few α-granules and an excess of rER. Loss of GATA-1 in 
the MK lineage leads to an abnormal proliferation of immature 
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megakaryocytes in vitro and in vivo (Vyas et al., 1999). Two other studies 
found that GATA-1s expression could not completely rescue megakaryocyte 
growth in foetal murine GATA-1-deficient progenitors compared with re-
expression of full length GATA-1 (Muntean and Crispino, 2005; Kuhl et al., 
2005). These two studies showed that the ability of GATA-1 to restrict 
megakaryocytic growth was not dependent on the critical interaction between 
GATA-1 and its cofactor FOG-1, because this interaction requires the N-
terminal zinc finger that is also present in GATA-1s. In contrast, differentiation 
of megakaryocytes into proplatelets in vitro was critically dependent on this 
interaction and much less influenced by the N-terminal transactivational 
domain residues. These results further defined a requirement for different 
domains of GATA-1 in megakaryocytic development and suggested that the 
production of GATA-1s uncouples megakaryocytic growth from differentiation. 
During normal human haematopoiesis both GATA-1s and GATA-1 are 
translated, whereas in the leukaemic blasts of the DS-TMD and AMKL only 
the short form is produced because of the inactivating mutations, of the clonal 
nature of the malignant proliferation and of the X chromosome inactivation.  
The fact that GATA-1s can bind DNA and interact with FOG-1, but shows a 
less efficient transactivation potential than the full length protein, suggests it 
might act as a dominant negative protein in the context of the Down syndrome 
leukaemia. Further work is needed to fully address the function of GATA-1s in 
humans. An obvious limitation of mouse model studies is the possible species-
specificity of GATA-1s function, since GATA-1s is physiologically expressed in 
humans, but not in the mouse. A recent report has described a family with a 
germline mutation in GATA-1 leading to the constitutive production of GATA-
1s but not of GATA-1 full length. Strikingly, members of this family display 
postnatal anaemia, thrombocytopenia and neutropenia, but there was no 
record of haematological malignancies (Hollanda et al., 2006). 
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1.4.5. The role of trisomy 21 
 
 
Several models have been proposed to explain the increased incidence of 
AMKL and TMD in DS. It is reasonable to hypothesize that trisomy 21 could 
result in increased levels of a leukaemia-predisposing gene (or genes) 
regulating haematopoiesis, encoded on chromosome 21 (Huret and Leonard, 
1997). Alternatively, overexpression of a gene present on HSA21 may alter 
expression of genes on other chromosomes involved in haematopoiesis and 
megakaryopoiesis. 
The following is a brief description of genes residing on HSA21 with known 
functions relevant to normal and/or malignant haematopoiesis. 
RUNX-1 
Probably the most interesting candidate leukaemia-predisposing gene on 
HSA21 is RUNX-1 (AML1). RUNX-1 is a transcription factor whose 
rearrangements are involved in some of the recurring translocations present in 
leukaemia, including t(8;21) in AML- M2, t(3;21) in CML blast crisis and 
t(12;21) in childhood ALL. Mutations of the DNA-binding Runt domain of 
RUNX-1 are present in approximately 10% of sporadic cases of de novo AML 
(Osato et al., 1999) and in myeloid malignancies with acquired trisomy 
(Preudhomme et al., 2000), but they were not detected in blast samples from 
patients with DS-AMKL (Bourquin et al., 2006). Even if RUNX-1 is most 
frequently inactivated in human leukaemias, an increased dose of this gene 
has also been suggested as a basis for several kinds of leukaemias of the 
lymphoid and of the myeloid lineage (Yanagida et al., 2005) and therefore may 
play a role in the mechanism underlying leukaemogenesis in Down syndrome.  
RUNX-1 is crucial for normal haematopoiesis. RUNX-1-/- embryos die at 
embryonic day 12-13 (E12-E13) with a complete lack of AGM and FL-based 
definitive haematopoiesis (Okuda et al., 1996; Wang et al., 1996). 
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Haploinsufficiency of RUNX-1 results in reduced adult repopulating ability and 
alters the temporal and spatial distribution of HSCs in mice (Cai et al., 2000). 
Until recently, two conflicting theories about the in vivo generation of HSC 
existed. The first postulated that endothelial cells and HSC developed from a 
common progenitor, the haemangioblast (Choi et al., 1998), whereas the 
second (Jaffredo et al., 1998) suggested that HSCs are directly derived from a 
specialized subset of endothelial cells (i.e. the “haemogenic endothelium”). 
Lancrin et al. have recently unified the two theories, proposing that the 
haemangioblast generates HSCs through the formation of an intermediate 
haemogenic endothelium. The authors also demonstrate that whereas the 
establishment of the haemogenic endothelium requires the TF SCL/Tal1, 
RUNX-1 has a crucial role for the emergence of HSCs from the haemogenic 
intermediate (Lancrin et al., 2009). Another study also reported that RUNX-1 
function is essential for the formation of HSC and haematopoietic progenitors 
from the vasculature, but that the requirement for RUNX-1 in this process 
ends when VAV-1 (a pan-haematopoietic gene) is expressed (Chen et al., 
2009). 
RUNX-1 is a master regulator of the physiologic lymphoid and megakaryocytic 
development (Ichikawa et al., 2004a). RUNX-1 null mice show impaired 
maturation, morphological abnormalities and hypoploidy of megakaryocytes, 
and reduced platelet counts (Ichikawa et al., 2004b). Since RUNX-1 and 
GATA-1 are known to physically interact with each other and to promote 
megakaryocytic specific gene expression (Elagib et al., 2003), it is likely that 
an alteration of this network of transcription factors can be responsible for the 
observed lineage-specific phenotype. It is also noteworthy that 
haploinsufficiency of RUNX-1 caused by loss-of-function mutations results in 
an autosomal dominant congenital platelet defect (familial platelet disorder, 
FPD) characterised by qualitative and quantitative defects of the platelets and 
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by an increased propensity to develop AML (Dowton et al., 1985; Ho et al., 
1996; Song et al., 1999). Song et al. analysed leukaemic blasts of two 
FPD/AML patients without finding evidence for mutations in the remaining 
RUNX-1 allele during the progression to AML, and concluded that additional 
mutations outside the RUNX-1 locus are required for the development of 
leukaemia in these patients. However, very recent data obtained by analyzing 
further patients with FPD with progression to AML suggest that, in addition to 
the germline RUNX1 mutation, a second RUNX1 alteration is often associated 
with progression to AML (Preudhomme et al., 2009). Of the 6 FPD/AML cases 
reported in this new study, 4 cases presented acquired point mutations in 
RUNX-1, and 2 cases displayed duplication of the altered RUNX1 allele 
associated with acquired trisomy 21. 
         ERG and ETS-2 
ERG and ETS-2 are both members of the ETS family of transcription factors 
mapping to the Down Syndrome Critical Region on HSA21. Together with the 
closely related gene FLI-1 they share overlapping functions in megakaryocytic 
differentiation (Bouilloux et al., 2008; Ge et al., 2008). ERG is a potent proto-
oncogene in cancer (prostate cancer, Ewing’s sarcoma, acute leukaemias) 
and it constitutes a prominent candidate for a leukaemogenic effect in Down 
syndrome. Rainis et al suggested that the overexpression of ERG, in 
cooperation with other HSA21 genes such as RUNX-1 and ETS-2, facilitates 
the occurrence of megakaryoblastic leukaemia through a shift towards the 
megakaryoblastic lineage in haematopoietic progenitor cells (Rainis et al., 
2005). Furthermore, a recent study has for the first time highlighted a 
physiological role for ERG in haematopoiesis (Loughran et al., 2008). Based 
on the results from an N-ethyl-N-nitrosourea (ENU) mutagenesis screening, 
the authors studied the effects on the haematopoietic system of an ERG 
mutation (Mdl2) inducing loss of its transactivation potential. The 
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consequences of this loss-of-function mutation were profound, including an 
impaired number and repopulation ability of HSCs, and a quantitative defect in 
the megakaryocytic lineage. Mdl2-/- mice showed a marked defect in the 
establishment of definitive haematopoiesis, which seemed to be independent 
from known ERG binding targets such as SCL/Tal1.  
Similarly, a role in regulating the megakaryocytic gene expression has been 
suggested for ETS-2 (Lemarchandel et al., 1993). As for ERG, overexpression 
of ETS-2 in the leukaemic cell line K562 induced an erythroid to 
megakaryocytic switch, which was shown to be independent from GATA-1 
levels (Ge et al., 2008). The authors of this study also demonstrated that 
GATA-1 and ETS-2 interplay to modulate sensitivity of leukaemic cells to 
anthracyclines. ERG and ETS-2 (together with FLI-1) have also been recently 
shown to facilitate the expansion of megakaryocytes from wild type and 
GATA-1s knock-in foetal liver progenitors (Stankiewicz and Crispino, 2009). In 
this study ETS-2 and ERG could only partially rescue the maturation block of 
the megakaryocytic lineage characteristic of the GATA-1 knockdown 
progenitors. Overexpression of ERG or FLI-1 (but not ETS-2) was also shown 
to immortalize GATA-1 knockdown and GATA-1s knock-in (but not wild-type) 
foetal liver progenitors, suggesting a synergistic effect between alterations in 
GATA-1 and increased levels of ETS proteins in malignant megakaryopoiesis. 
         DSCR1 
DSCR1 is a member of the calcipressin family of calcineurin inhibitors and has 
been showed to be expressed 1.5 fold more in tissues from DS patients 
compared to euploid controls (Fuentes et al., 1995).  A study from Arron et al. 
showed that increased dosage of DSCR1 and of the neighbouring kinase 
gene DYRK1A on HSA21 are responsible for the deregulation of NFAT 
(Nuclear Factor of Activated T cells) levels and activity in DS mouse models 
and in human trisomy 21 samples, with effects on the correct execution of 
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developmental programs (Arron et al., 2006). Furthermore, DSCR1 has been 
shown to be a calcium-induced NFAT target gene in megakaryocytes (Kyttala 
et al., 2009). This study suggests that the NFAT pathway activation might be 
controlled by DSCR1 with an auto feedback mechanism and through this 
mechanism DSCR1 might influence lineage specific gene expression in 
megakaryocytes. 
TIAM1 and BACH1 
TIAM1 (T-cell lymphoma invasion and metastasis-1) is a Rac specific guanine 
nucleotide exchange factor (GEF) that can mediate Ras activation of Rac. 
When simply amplified or overproduced, TIAM1 causes invasiveness of 
mouse lymphoma cells (Habets et al., 1994). A study from Ives et al. showed 
that TIAM1 is threefold more expressed in DS AML-M7 samples compared to 
the remission samples or samples from normal individuals (Ives et al., 1998).  
BACH1, a transcriptional repressor expressed in the megakaryocytic lineage, 
was also shown to be overexpressed in DS-AMKL blasts compared to non 
DS-AMKL blasts (Bourquin et al., 2006). An interesting report has also 
elucidated a role for BACH1 in megakaryocyte development and platelet 
formation (Toki et al., 2005). BACH1 transgenic mice show thrombocytopenia 
associated with impaired maturation of megakaryocytes, and these effects 
seem to be linked to the function of BACH1 as a transcriptional repressor of 
megakaryocytic genes containing specific recognition motives.  
Although the altered expression of TIAM1 and BACH1 is intriguing, their 
functional role in DS leukaemogenesis has not yet been investigated. 
Other candidate genes  
Other putative candidates for a leukaemogenic predisposition on HSA21 
include the interferon α/β receptor (IFNAR), cytokine family 2-4 (CFR2-4), 
GART and SON (Legare et al., 1997). 
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In addition to protein-coding genes, there are at least 5 known microRNAs 
encoded by chromosome 21. Micro-RNAs are small non-coding RNAs, which 
can regulate gene expression through degradation of mRNA transcripts and 
inhibition of mRNA translation. Strong evidence suggests that some 
microRNAs, such as miR-181, miR-223, and miR-142 are differentially 
expressed in haematopoietic tissues, and their expression is regulated during 
haematopoiesis and lineage commitment in mice (Chen et al., 2004). A recent 
article (Garzon et al., 2006) has highlighted a role for microRNAs during 
human megakaryopoiesis. When comparing expression levels of several 
microRNAs between CD34+ haematopoietic progenitors, AMKL cell lines and 
megakaryocytes differentiated in vitro, the authors observed that miR-99a, a 
microRNA residing on HSA21, was up-regulated in AMKL and down-regulated 
in CD34+ progenitors and megakaryocytes. This inverse correlation could be 
an exciting starting point for the involvement of microRNAs in the 
pathogenesis of AMKL. 
DS-AMKL shows a superior response to treatment with chemotherapy 
compared to AMKL in the general population. DS-AMKL blasts display an 
increased sensitivity to chemotherapeutic agents in vitro (Tchernia et al., 
1996). The gene responsible for this feature is on HSA21 (in the region 
21q22.3) and encodes for the enzyme cystathionine β-synthase (CBS), which 
is involved in cytosine arabinoside metabolism (Taub et al., 1999; Zwaan et 
al., 2000). 
General remarks  
        Despite several attempts to dissect the contribution of individual genes to 
leukaemogenesis in Down syndrome, so far none of the genes on HSA21 has 
been unequivocally defined as critical for the predisposition to DS-TMD and 
AMKL. Recent findings have revealed that DS-ALL is characterised by 
acquired mutations of the tyrosine kinase JAK2, creating a situation that 
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mirrors the GATA-1 mutations in DS-TMD and AMKL. In view of this similarity, 
it is reasonable to postulate that the presence of the chromosome 21 as a 
whole (or part of it) might deregulate haematopoietic development through 
multiple mechanisms, and predispose different lineages to acquire mutations 
(GATA-1, JAK2) that cause abnormal proliferation and/or selective blocks in 
differentiation. The individual variations in the level of expression of the genes 
present in a third copy might explain why some of the DS individuals are more 
prone to get leukaemia than others. In spite of the tremendous progress made 
towards an understanding of the general mechanisms of leukaemogenesis in 
DS (derived from in vitro and in vivo models), a lot still needs to be done to 
explain the real biological relevance of some of the described (or suggested) 
phenotypes caused by genes on HSA21 to the pathogenesis of DS leukaemia.          
 
1.4.6. Down syndrome Leukaemia: where does it arise from? 
 
 
Both DS-TMD and AMKL occur within a limited time frame (neonatal and early 
childhood, respectively). This raises the question of whether a 
developmentally restricted cellular target mediates the GATA-1s oncogenic 
effect. The physiological down-regulation of this target during development 
would explain why older DS individuals do not get leukaemia with an 
increased incidence compared to the euploid population. 
         This fascinating hypothesis has been recently developed by Li et al., who 
have shown that knock-in mutations leading to the exclusive production of 
GATA-1s in place of full-length GATA-1 in the absence of trisomy 21, result in 
excessive proliferation and abnormal differentiation of an embryonic/foetal 
megakaryocytic progenitor population, suggesting a stage-specific 
requirement for the N-terminus of GATA-1 in haematopoietic progenitors (Li et 
al., 2005). If this foetal liver progenitor is the cellular origin of the 
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leukaemogenic program initiated by GATA-1s, then trisomy 21 might be 
providing a selective advantage for the proliferation of this mutated clone. 
Alternatively, trisomy 21 might be responsible for an abnormal accumulation of 
this precursor that predisposes it to acquire GATA-1 mutations (Izraeli, 2008). 
In other words, there could be an abnormal foetal haematopoietic programme 
in DS, which is responsible for a skewing of the haematopoietic lineages that 
promotes an abnormal number and/or function of the megakaryocytic 
precursors. Tunstall-Pedoe et al. and Chou et al. have both recently tested 
this hypothesis by comparing second trimester human foetal liver 
haematopoiesis in DS to gestational age matched euploid controls (Chou et 
al., 2008; Tunstall-Pedoe et al., 2008). In colony forming assays, both groups 
demonstrated that DS foetal livers have three times more megakaryocyte-
erythroid progenitors than disomic controls, and that these progenitors have 
increased proliferation and self-renewal properties. The observed phenotype 
was independent of the presence of GATA-1 mutations and (at least in the 
observations from Tunstall-Pedoe et al.) was not present in bone marrow from 
DS foetuses. These reports further highlight the contributions of trisomy 21 to 
the development of leukaemia in DS and contribute to explaining why TMD 
often involves the liver but not the bone marrow. However, these studies also 
raise a question, about whether abnormal foetal haematopoiesis in DS is 
caused by specific properties of the foetal liver microenvironment or by cell 
intrinsic mechanisms deregulated by the trisomy. This is likely to be an intense 
area of investigation in the field in the near future. 
 
1.4.7. A unique model of leukaemogenesis 
  
GATA-1 mutations in DS leukaemia are acquired: they have been detected in 
both TMD and AMKL but are absent in the remission samples. Identical 
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mutations of GATA-1 have been reported in sequential samples from the 
same patients that progressed from TMD to AMKL (Hitzler et al., 2003). This 
suggests that AMKL arises after the initial TMD clone has acquired additional 
abnormalities (Ahmed et al., 2004). If different GATA-1 mutations, resulting in 
similar effects on GATA-1 protein, were restricted to a specific point of the 
differentiation process towards the megakaryocytic lineage, these mutations 
would be expected to arrest the affected clones at the same stage of 
differentiation. However, a report from Groet et al. demonstrates that 
independent clones with different mutations of GATA-1, each leading to the 
production of GATA-1s, can be arrested at different phases of the 
differentiation process in the same patient (Groet et al., 2005). An intriguing 
explanation of these results is that GATA-1 mutations do not arrest 
megakaryocytic differentiation completely, but trigger an abnormal proliferation 
of the mutant clone, as suggested in the murine GATA-1 knock-in model (Li et 
al., 2005). The transient and self regressive nature of TMD could be explained 
postulating that a transient myeloproliferation arises in the foetal liver and 
when the haematopoiesis migrates to the bone marrow the loss of a 
“permissive” environment causes the disappearance of the proliferating cells 
(Gamis and Hilden, 2002). Alternatively, the regression of the transient 
disorder might be due to the clearance of proliferating blasts by the immune 
system (Hitzler and Zipursky, 2005). 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Fig. 1.6. A schematic view of leukaemogenesis in DS. Trisomy 21 might cause abnormal 
proliferation of megakaryocytic precursors. Mutations in GATA-1 uncouple differentiation and 
proliferation of these precursors and are responsible for the appearance of TMD. Additional 
events responsible for the self-regression of TMD or the recurrence of AMKL within 3-4 years 
are currently unknown. 
 
 
It is clear that, besides the presence of the GATA-1 mutations and of the 
trisomy of chromosome 21, a “third hit” is necessary to trigger the progression 
of TMD to AMKL (Figure 1.6). For all the above reasons, TMD and AMKL in 
DS provide a unique paradigm for the study of different stages of 
leukaemogenesis in general. 
 
1.4.8. Other mutations in DS Leukaemia 
 
 
Several genes have been implicated as potential culprits of the evolution of 
TMD to AMKL. Analysis of the most common alterations found in acute 
myeloid leukaemia failed to confirm a role for FLT3, N-RAS and c-KIT 
mutations (Hirose et al., 2003). p53 mutations were found in a few cases of 
both AMKL and TMD, but these data were in contrast with a previous report 
(Malkin et al., 2000) suggesting the involvement of p53 mutations in the 
evolution from TMD to AMKL.   
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Mutations in JAK2 (Walters et al., 2006), which are reported in 
myeloproliferative disorders of adults, and of c-mpl, have also been screened 
in DS-TMD and DS-AMKL samples without any evidence of contribution to 
these malignancies (Norton et al., 2007). 
A recent twist in the search for a “third hit” was the finding that mutations in the 
tyrosine kinase JAK3 are present in AMKL (Walters et al., 2006). Activating 
mutations of JAK3 were reported in AMKL from both Down syndrome and non 
Down syndrome patients. This finding prompted the proposal of using a JAK3 
inhibitor, clinically approved in autoimmune diseases (Changelian et al., 
2003), for the treatment of DS AMKL. A more detailed analysis is required to 
ascertain the role of mutations of JAK3 in the pathogenesis of DS leukaemia 
and in the progression of malignancy of the DS-TMD clone.  
 
1.4.9. Molecular profile of DS Leukemia 
  
To explore the molecular differences between TMD and AMKL blasts, which 
are immunophenotypically and morphologically indistinguishable, McElwaine 
et al. made use of comparative analysis of gene expression (McElwaine et al., 
2004), which led to the identification of the tumor antigen PRAME 
(PReferentially expressed Antigen in MElanoma) as a specific marker for 
AMKL with no expression in TMD. The same type of analysis has revealed 
that CDKN2C (p18), the effector of GATA-1-mediated cell cycle arrest, was 
increased in AMKL but not TMD, whereas MYCN (neuroblastoma–derived 
oncogene) was expressed in TMD at a greater level than in AMKL, potentially 
contributing to the proliferative state and self-regressing features of TMD 
(Hitzler and Zipursky, 2005). 
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Another study has revealed a differential expression between the two 
diseases of other genes, such as Apolipoprotein C1, the MYL4 component of 
myosin and spermidine/spermine-N-acetyltransferase (Lightfoot et al., 2004).  
To date, none of the differentially expressed genes has been proven to be 
responsible for the progression of leukaemia in DS. Nevertheless, the 
comparison between sequential stages of the leukaemic transformation is a 
very important approach likely to result in the definition of the specific genetic 
events that underlie the development of AMKL from the precursor lesion TMD 
(Hitzler, 2007).   
Gene expression profiling has also been carried out comparing 24 DS and 39 
non-DS AMKL samples (Bourquin et al., 2006).  The main finding of this study 
is that there is a deregulation of a subset of genes in DS-AMKL, which is 
probably due to the absence of GATA-1 and to the exclusive presence of 
GATA-1s in the DS-AMKL blasts. However, this effect does not seem to 
depend on the presence of an extra copy of human chromosome 21. This 
conclusion further emphasizes the role of GATA-1s in the leukaemogenic 
process in DS, but needs to be evaluated taking into account the limited 
number of samples analysed. 
1.5. Mouse models of Down syndrome  
1.5.1. Partial trisomic models of Down syndrome 
 
 
The human chromosome 21 is homologous to mouse chromosomal regions 
that map to three different mouse chromosomes (MMU): MMU16, MMU17 and 
MMU10. As approximately 23 Mb of the HSA21 are syntenic to MMU16, the 
vast majority of mouse models of Down syndrome generated in the past years 
are trisomic for variable regions of mouse chromosome 16.  
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The first mouse model of DS, Ts16, contains three copies of the entire 
MMU16. Trisomy of the entire mouse chromosome 16 is lethal, and Ts16 mice 
die in utero at E15, this being very likely due to the presence on MMU16 of a 
large extra set of genes non syntenic to genes of HSA21. Ts16 chimeric 
foetuses generated with a pre-implantation trisomic-diploid aggregation 
technique (Cox et al., 1984) exhibit immunological and cardiac abnormalities 
typical of DS (Epstein et al., 1985). Because of the significant limitations of this 
model, segmental trisomic models were generated later on. 
To date, three segmental trisomy models of DS have been generated: 
Ts65Dn, Ts1Cje and Ms1Ts65. Each contains three copies of different regions 
of MMU16 (see Figure 1.7) and displays phenotypes of DS to various 
degrees.  
The Ts65Dn mouse model is trisomic for a region of approximately 16 Mb of 
HSA21 encoding 104 conserved genes (Davisson et al., 1990). Because the 
triplicated region does not include genes that are not homologous to genes on 
HSA21, the Ts65Dn is a viable and effective model for some aspects of Down 
syndrome. Ts65Dn present craniofacial abnormalities (Richtsmeier et al., 
2000), abnormal thymic functions (Paz-Miguel et al., 1999), male sterility and 
heart malformations (Moore, 2006), but their predominant phenotypes are 
confined to the nervous system. These mice exhibit profound defects in 
hippocampal-dependent spatial learning and memory (Reeves et al., 1995) 
and an age-dependent reduction of the number of cholinergic neurons in the 
basal forebrain (Granholm et al., 2000; Holtzman et al., 1996). Ts65Dn mice 
also have a significant reduction in cerebellar volume (Baxter et al., 2000) and 
a reduced number of granule cells. The postnatal viability of these mice, and 
the close resemblance of the spectrum of their phenotypes to the ones 
described in DS, make this model especially suitable for dissecting the role of 
candidate genes on HSA21 in the neuronal phenotypes of DS. This is 
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supported by the fact that after Ts65Dn were found to have a reduced number 
of cerebellar neurons, large cohorts of DS individuals were screened and 
found positive for this phenotype, which very likely accounts for the motor 
coordination disturbances in DS (Baxter et al., 2000).  
The Ts1Cje mouse model is trisomic for a smaller region of MMU16 (~12 Mb) 
than that present in three copies in the Ts65Dn, and this region contains 
approximately two-thirds of the genes triplicated in the Ts65Dn. This mouse 
model resulted from translocation of the distal end of chromosome 16 to 
chromosome 12 (Sago et al., 1998) and was derived during a gene-targeting 
event for the gene SOD1. The smaller size of the triplicated region might be 
responsible for the slightly less severe spectrum of phenotypes observed in 
the Ts1Cje compared to the Ts65Dn. Like the Ts65Dn, these mice survive to 
adulthood. They do not show morphological abnormalities in the brain and 
they have less severely impaired learning abilities than the Ts65Dn. Ts1Cje 
mice also present abnormalities in their cerebellum (Olson et al., 2004), 
although to a smaller extent than the Ts65Dn.  
In order to investigate the discrepancy in phenotypes between the Ts65Dn 
and the Ts1Cje models of DS, a third partial trisomy model for DS was 
generated. The Ms1Ts65 bears a third copy of the region that is triplicated in 
the Ts65Dn but is disomic in the Ts1Cje. These mice exhibit the least severe 
phenotypic defects of all the partial trisomic models (Sago et al., 2000). Their 
learning capacity is partially compromised and they have no changes in 
cerebellar volume, but present a slight reduction in the number of neurons of 
the cerebellar cortex (Olson et al., 2004).  
Despite the penetrance of the phenotypes in the partial trisomic models, which 
reflects that of phenotypes observed in the DS population, none of the DS 
mouse models are fully imbred. Therefore, the variations in phenotypes might 
be a consequence of genotypic background differences. 
  53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7. Synteny between human chromosome 21 and mouse chromosomes 16, 17 and 
10. MMU16 (depicted in blue) has the largest region of synteny with HSA21 (in pink) 
corresponding to 104 known genes on HSA21. MMU17 and MMU10 are syntenic with smaller 
distal portions of HSA21 (in green and red, respectively). Mouse models of trisomy 21 are 
shown on the right. The Ts65Dn, Ts1Cje and Ms1Ts65 mouse models are trisomic for different 
segmental regions of MMU16, with Ts65Dn being trisomic for the largest portion of MMU16. Tc1 
carry an extra copy of freely segregating HSA21 into a mouse euploid background. 
 
Nevertheless, these models have been extremely useful in studying nervous 
system and behavioural abnormalities and in validating the candidate region 
approach, whereby the gene dosage imbalance of a particular region of 
HSA21 is associated with a defined phenotype. 
Several transgenic models overexpressing single genes orthologous to 
HSA21 genes have also been developed. Examples include the TgSOD1 
mice, which exhibit learning defects, or the TgETS-2 and the TgDYRK1A 
(Dierssen et al., 2001) mice.  It is arguable that despite a proven utility in 
elucidating the contribution of individual genes to the DS phenotypes, these 
models are less relevant to the biology of DS because they do not recapitulate 
the 1.5 fold overexpression observed in DS, and only in some cases the 
expression of the transgene is under the control of endogenous regulators. 
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An alternative approach would be to generate mice carrying yeast artificial 
chromosomes (YACs) containing fragments of genomic DNA encoding for 
different genes of interests under the control of their endogenous regulatory 
sequences. Such mice have already been generated for some regions of the 
HSA21 (Smith et al., 1997), although the obvious size limitation (up to 2 MB) 
of the inserts YACs can carry makes this approach less than ideal to model 
trisomy in the mouse.  
1.5.2. Mice with a human chromosome 21: a novel model of Down 
syndrome 
 
 
The most significant drawback of the partial trisomic models described is that 
none of them contain a third copy all of the genes that are triplicated in human 
DS. This crucial point has been addressed by a novel approach, consisting of 
the introduction of the human chromosome 21, in its entirety, into a mouse 
euploid background (Hernandez et al., 1999). This was achieved by creating 
mouse ES cells engineered to carry an entire human chromosome through a 
technique known as irradiation microcell-mediated chromosome transfer 
(XMMCT, illustrated in Figure 1.8). XMMCT is a unique technique with respect 
to the large amounts of genetic material that it can introduce into cells. 
Microcells are defined as cell-like structures with a small nucleus 
(micronucleus) that contains one or a few chromosomes (Fournier and 
Ruddle, 1977). They have been shown to be very efficient vehicles for the 
transfer of whole chromosomes to a wide range of cells, including ES cells 
(Cuthbert et al., 1995; Tomizuka et al., 1997). 
The work from Hernandez et al. was initailly aimed to generate a human 
chromosome 21 targeted with a selectable marker (the neomycin resistant 
gene). This gene was inserted in the D21S55 (part of the DSCR region) in a 
human donor cell line. The human donor cell line with the targeted 
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chromosome 21 was then treated with colcemid, an inhibitor of the mitotic 
spindle, to induce the formation of microcells. After colcemid treatment, the 
chromosomes became partitioned into discrete subnuclear compartments 
termed micronuclei. Micronuclei were then centrifuged in the presence of 
cytochalasin B to prevent formation of actin filaments. The centrifugation step 
resulted in the formation of a thin cytoplasm and outer plasma membrane 
around individual micronuclei. The microcell layer was collected after 
centrifugation and irradiated to kill any remaining donor human cells. Irradiated 
microcells were then fused to the parental ES cell line D3 using polyethylene 
glycol (PEG), and colonies were selected in G418. Subsequently, colonies 
were screened with FISH analysis using human Cot1 DNA as a probe, and the 
colonies showing presence of a single freely-segregating human chromosome 
were further characterised by PCR and Southern Blotting using markers 
spaced approximately 1-2 Mb apart on HSA21. After this procedure, selected 
transchromosomic cell lines were also karyotyped to determine mouse 
chromosome number, and only the euploid ones were used for further studies. 
It is known that the irradiation process can cause chromosomal 
rearrangements, but no radiation breakage “hot spots” or rearrangements 
were detected at that stage, and the radiation dose used in the experiments 
was carefully titrated to avoid these effects. 
A panel of ES cells (Figure 1.9) carrying segments of HSA21 was generated, 
and one of them (named 47-1) appeared to contain the entire HSA21. Four 
different transchromosomic ES cell lines were then selected and injected into 
blastocysts to generate chimeric mice. Chimeric mice (as judged from the 
colour of the fur) were shown to contain human genomic DNA, but they 
exhibited deletions in the sequence of the human chromosome 21, most likely 
due to phenomena occurring during culture before the injection into 
blastocysts. 
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Fig. 1.8. A schematic view of the irradiation microcell-mediated chromosome transfer 
(XMMCT). Details of the procedure, which lead to the generation of chimeric mice, are 
described in the text. 
 
RT-PCR analysis showed that gene expression driven from human specific 
sequences was conserved and tissue-specific, suggesting that gene 
regulation was maintained in the transchromosomic system. Unfortunately, the 
chimeric mice from these experiments failed to reach germline transmission, 
possibly due to sex and genetic background limitations of the transmitting 
animals. A second attempt was carried out by the same group, leading this 
time to the generation of a mouse strain (named Tc1) bearing a freely 
segregating copy of HSA21 (O'Doherty et al., 2005). The ES cells used to 
generate the strain were named 91-1, and were generated by XMMCT on the 
mouse background of the MPI-VI ES cells (a parental cell line different from 
the one used for the previous attempt). 91-1 contained at least 42 Mb (90%) of 
the 46.9 Mb of the HSA21 and approximately 92% of all known HSA21 genes. 
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Among the genes mapping in the deleted region in the 91-1 cells are RUNX-1 
and DSCR-1; therefore these genes are not trisomic in the Tc1 model (F. 
Wiseman and E. Fisher, unpublished data). 
 
 
 
 
 
91-1 ES cells were injected into blastocysts and the resulting chimeras were 
mated to mice from the C57BL/6J strain. The progeny from this mating 
contained a freely segregating HSA21 with the same profile as the 91-1 cell 
Fig. 1.9. Map of the panel of transchromosomic ES cells generated from Hernandez et al. The red 
dot indicates the insertion of the neo-resistance gene. Filled bars indicate that that region of HSA21 is 
expressed in the ES cell line; open bar indicates that that region is absent. 47-1 (in green) contains the 
HSA21 in its entirety. (Reproduced from Hernandez et al, HMG, 1999). 
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line. Retention of the HSA21 in tissues from adult Tc1, measured by FISH and 
quantitative PCR, ranged from 66±7% in the brain to 49±5% in the spleen. 
Microarray, quantitative RT-PCR and western blot analysis all demonstrated 
specific expression of human genes in the transchromosomic mouse model. 
Tc1 mice show the most complete range of phenotypes of human DS 
reproduced in a mouse model. Behavioural tests have revealed that they have 
impaired learning abilities and synaptic plasticity, exhibiting short-term 
memory defects but not long-term memory alterations (Morice et al., 2008). 
Other neurological phenotypes include a decreased density of cerebellar 
neurons and disturbed motor coordination (Galante et al., 2009). Tc1 mice 
display a high penetrance of congenital heart defects, mimicking the 
abnormalities in septum formation observed in newborns with DS. CT scans 
measurements also showed that these mice have a smaller mandible than 
that of their wild type littermate, a phenotype that has been described in DS 
humans as well. 
The study of transchromosomic mice raises a series of issues. The first is that 
human genes may behave differently in a mouse context, possibly changing 
their pattern of spatial and temporal expression and their relative abundance. 
If a human protein works sub-optimally in the mouse, it will affect the gene 
dosage imbalance that these mice are trying to model. 
Secondly, it is unclear how expression of human genes in a cross-species 
context is regulated. Genetic and epigenetic mechanisms of regulation of 
transcription might be different for human genes in a heterologous context. 
Wilson et al. have recently addressed this matter utilising hepatocytes from 
Tc1 mice. The authors demonstrated that transcriptional regulation is largely 
dependent on the DNA sequence of the genes in question, whereas 
interspecies differences in epigenetic machinery, cellular environment, and 
transcription factors themselves play secondary roles. This means that the 
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expression of human genes in a cross-species system is driven predominantly 
by human DNA regulatory sequences rather than by the mouse cellular 
context (Wilson et al., 2008). 
The third issue concerns the stability of this system and the capacity of the 
animals to retain the human chromosome, which requires a thorough 
characterization and confirmation of the characteristics of the model itself 
before any experimental approach. 
Despite the limitations arising from working with a trans-species system, this is 
currently the most comprehensive mouse model DS, and the possibility of 
expressing genes from an entire chromosome under the control of their own 
regulatory sequences provided by this approach offers an extraordinary 
powerful tool to model DS and other aneuploidies in the mouse. 
 
1.5.3. Haematopoietic defects in mouse models of Down syndrome 
 
 
Ts65Dn and Ts1CjE mouse models of DS have both been recently 
characterised with respect to their haematopoietic system. 
Ts65Dn display macrocytic anaemia (humans with DS also display 
macrocytosis) and progressive thrombocytosis). Adult mice (14-15 months) 
develop a highly penetrant myeloproliferative-like disorder (MPD) with bone 
marrow fibrosis and hyperproliferation of the megakaryocytic lineage in the 
spleen and in the bone marrow.  Megakaryocytes infiltrating the spleen and 
the bone marrow in Ts65Dn express CD41 (a marker of mature 
megakaryocytes) but their ploidy profile is distorted, suggesting an abnormal 
maturation of this lineage. Additionally, the bone marrow of the Ts65Dn 
contains an increased number of c-KIT positive cells compared to the WT 
littermates, indicating an expansion of immature progenitor cells. In vitro 
colony forming assays to assess the number of haematopoietic progenitors in 
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Ts65Dn bone marrow and spleen showed a shift towards erythroid and 
megakaryocytic lineages in the spleen, and analysis of compartments in the 
bone marrow revealed an expansion of the LSK (lineage-Sca-1+c-KIT+) 
compartment, possibly reflecting deregulation of the haematopoietic stem cell 
pool. Long-term repopulating ability of Ts65Dn bone marrow cells was 
impaired and some of the characteristics of the adult MPD were also present 
in younger mice at the age of 4 months (Kirsammer et al., 2007). Interestingly, 
crossing the Ts65Dn with RUNX-1 heterozygous knockout mice to generate 
progeny trisomic for 103 genes of HSA21 but disomic for RUNX-1 did not 
attenuate the adult MPD phenotype, but somewhat influenced the 
megakaryocytic colony forming ability of the spleen derived cells. This result 
further highlights the complexity of mechanisms responsible for the phenotypic 
consequences of trisomy 21. 
Ts1Cje mice (which are trisomic for approximately two thirds of the triplicated 
genes in the Ts65Dn) also display macrocytosis in the peripheral blood and 
anaemia, but unlike Ts65Dn mice, they do not present any histological 
abnormality in the spleen or in the bone marrow. Foetal livers (FL) from 
Ts1Cje at E12.5 do not present alterations in the number of LSK cells, but 
they appear unable to reconstitute the haematopoietic system of lethally 
irradiated mice. In addition, the ability of FL haematopoietic progenitors from 
Ts1Cje mice to form colonies in vitro is impaired. The number of bone marrow 
HSCs is decreased in Ts1Cje, but their engrafting ability is not affected. An 
increase in the granulocyte-macrophage progenitor (GMPs) number with a 
concomitant decrease in the common myeloid progenitor (CMPs) fraction was 
also observed in Ts1Cje bone marrow, but the megakaryocytic-erythroid 
(MEPs) compartment was not altered.  Older mice did not develop any sign of 
MPD or acute leukaemia. These mice were then crossed to the GATA-1 Plt13/+ 
mice, which carry a mutation in the exon 2 of GATA-1 leading to the loss of 
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translation of the full length GATA-1 protein but not to the production of its 
short form. The crossing did not lead to any exacerbation of the observed 
phenotype, or to the development of MPD (Carmichael et al., 2009). The 
difference between the phenotypes observed in Ts1Cje and Ts65Dn might be 
due to the genetic background of the strain used to breed the colonies, or 
maybe to the specific effects of the region of HSA21 that is not triplicated in 
the Ts1CjE.  
       
          Phenotype 
 
 TsTs Ts65Dn 
    
 Ts1Cje 
   
   Tc1 
 
Macrocytosis and anaemia 
  
Yes 
 
      Yes  
 
Yes 
Thrombocytosis Yes        No No 
Foetal Liver- HPCs Not studied          Fewer colonies 
in semisolid 
medium, altered 
reconstitution 
potential  
NA 
 
 
Bone marrow HSCs and HPCs 
 
 
Expansion of 
HSCs in the 
bone marrow; 
fewer quiescent 
stem cells.  
 
Ske S  
Skewing of CMPs 
to GMPs 
 
 
NA 
 
Bone marrow fibrosis Yes No NA 
MKs infiltrating the spleen 
 
Yes No Yes 
MPD-like disease in adult mice  Yes No Yes 
Leukaemia No No No 
 
Table 1.3. A comparison between haematopoietic phenotypes in three mouse models of 
DS. Data for Ts65Dn and Ts1Cje are derived from Kirsammer et al. (Blood, 2009) and 
Carmichael et al. (Blood, 2009). At the moment K. Alford and V. Tybulewitcz are carrying out 
analysis of the haematopoietic system of the transchromosomic Tc1 mice. 
 
 
It is also worth noting that the lack of any abnormal/malignant haematological 
proliferation in the progeny resulting from the breeding of the Ts1CjE with the 
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GATA-1 Plt13/+ might have been influenced by the absence of the oncogenic 
effect of GATA-1s.  
Analysis of the haematopoietic system in the Tc1 mouse model of DS is 
currently under way. Preliminary observations suggest that these mice also 
develop an MPD-like phenotype in adult age, without the occurrence of an 
overt acute leukaemia (K. Alford and V. Tybulewitcz, unpublished data). 
Despite the relevance of some of the described phenotypes it is clear that 
there are peculiar differences between mouse models and humans with DS, 
which must be taken into account when trying to elucidate leukaemogenic 
mechanisms caused by the trisomy 21.  
 
1.6. ES cells as a model to study developmental processes   
The blastocyst stage of the mouse embryo is composed of three cell types: 
the trophectoderm, which gives rise to the placenta, the primitive endoderm, 
which leads to the visceral and parietal endoderm that lines the yolk sac 
cavity, and the inner cell mass (Evans and Kaufman, 1981; Martin, 1981). 
Embryonic Stem cells (ES) are derived from the inner cell mass (ICM) and 
they can be propagated in culture in an undifferentiated state (self-renewal) 
while retaining the capacity to generate any cell type in the body 
(pluripotency). Self-renewal requires that the ES cell genome maintains a 
cellular memory that specifies its pluripotent capacity while existing in an 
undifferentiated state. Additionally, the genome in pluripotent ES cells must be 
highly plastic to be able to enter any distinct differentiation pathway. Once 
differentiation starts, lineage specification is accomplished by the execution of 
gene expression programs, which are specific for each cell type. The tight 
balance between pluripotency and differentiation in ES cells is regulated by 
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the coordinated action of various regulatory mechanisms (Chen and Daley, 
2008).  
A very well studied mechanism involves the action of a network of pluripotency 
transcription factors such as OCT4, SOX-2 and NANOG (Nichols et al., 1998; 
Mitsui et al., 2003). These factors primarily act to regulate the expression of 
targets that are vital for differentiation and development, and are 
transcriptionally inactive at the undifferentiated stage, or are actively involved 
in maintaining pluripotency of the ES cells. Apart from regulating the 
expression of target genes through their DNA binding properties, these 
pluripotency TFs are extensively interconnected via protein-protein 
interactions (Wang et al., 2006) and are very likely to interact with chromatin 
remodelling factors and histone-modifying enzymes to modulate chromatin 
conformation. 
Given that the genome of ES cells is virtually identical to the one of somatic 
cells, it is likely that epigenetic regulation makes a major contribution to 
maintenance of pluripotency in ES cells. This is mainly achieved by silencing 
of genes whose up-regulation leads to differentiation through the action of 
repressive complexes known as Polycomb Group proteins (PcG) (Boyer et al., 
2006; Lee et al., 2006), but also through activation of developmental 
regulators during differentiation. The latter process requires the presence of 
genes which are “poised” for activation, and recent work has demonstrated 
that these genes harbour a characteristic chromatin signature known as a 
“bivalent” histone code (Bernstein et al., 2006; Azuara et al., 2006), with 
histones bearing both active and repressive methylation markers. The 
methylation status of CpG islands in promoters or regulatory regions of 
specific genes, as well as specific features of chromatin conformation are also 
key contributors to the epigenetic control of pluripotency in ES cells.  
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Further players in the control of pluripotency in ES cells have been recently 
identified with specific sets of micro-RNAs that are down-regulated as ES cell 
differentiation progresses (Houbaviy et al., 2003; Suh et al., 2004). 
Understanding the mechanisms underlying the molecular control of 
pluripotency is essential in order to direct ES cells differentiation into specific 
lineages and ultimately to exploit their full clinical potential for regenerative 
medicine.  
1.6.1. ES cells as a system to study haematopoiesis 
 
   
Haematopoietic stem cells (HSCs) are the best-characterised adult type of 
multipotent stem cells. Bone marrow transplantation has been the prototype of 
cellular therapy and is extensively employed for the treatment of a variety of 
bone marrow disorders. Unfortunately, it is very difficult to genetically 
manipulate HSCs and to expand them in vitro. ES cells offer an alternative, 
powerful source of HSCs.  Haematopoietic differentiation of ES cells harbours 
therefore an implicit therapeutic potential, while it enables basic investigation 
into genetic and epigenetic mechanisms of HSC specification and fate (Daley, 
2003). Mouse ES cells have been used as an invaluable tool for elucidating 
the mechanisms underlying normal and malignant haematopoiesis (Lensch 
and Daley, 2006). More than two decades of research into this field has 
provided researchers with a variety of protocols and experimental approaches 
to derive HSCs and blood cells of different lineages from mouse ES cells 
(Keller et al., 1993). The first demonstration that mouse ES cells can, under 
defined culture conditions, differentiate into at least four distinct 
haematopoietic lineages came in 1991 (Wiles and Keller, 1991). There are 
currently two in vitro approaches for the differentiation of the mES cells into 
the haematopoietic lineages. 
  65 
The first one is known as the “two-step” in vitro assay (Keller et al., 1993) and 
requires the culture of ES cells in semisolid medium containing 
methylcellulose. This method promotes ES differentiation into haematopoietic 
cells through the formation of embryoid bodies (EBs). EBs can then be 
harvested and replated in secondary methylcellulose cultures containing 
specific growth factors (e.g. Erythropoietin (EPO), IL-1, IL-3, Thrombopoietin 
(TPO)) in order to obtain differentiated haematopoietic cells. The advantages 
of the two-step system are that the differentiation through the EBs formation 
resembles the process in the early embryo, and that haematopoietic colonies 
can be recovered and used for morphological and molecular analysis. 
An alternative approach to obtain HSCs and blood cells from mES cells is a 
coculture system with stromal cells (Kitajima et al., 2003). Bone marrow 
stromal cells, foetal liver- and AGM-derived stromal cells have been 
successfully employed alone, or in combination with haematopoietic growth 
factors, to support HSC derivation from mouse and human ES cells (Weisel et 
al., 2006). This approach relies on the property of the supportive stromal 
population to reconstitute in vitro the haematopoietic niche that nurses HSCs 
during development. Unfortunately, the combination of cell surface associated 
molecules, soluble factors and extracellular matrix molecules expressed by 
the cells of the haematopoietic niche in vivo are not yet fully understood, 
making every attempt to recreate this situation in vitro less than optimal 
(Orlovskaya et al., 2008).  Despite these limitations, this approach is currently 
very well established to generate megakaryocytes and lymphoid cells from 
mES cells in vitro (Moore et al., 2006). 
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1.6.3. Transchromosomic ES cell lines and their potential use as a tool 
to investigate and map DS phenotypes   
                Transchromosic ES cell lines have been successfully used to model in vitro 
phenotypic aspects of Down syndrome. Indeed, they provide a solid model to 
explore the contribution of gene dosage imbalance caused by trisomy 21 to 
early developmental stages. Furthermore, it is possible to combine information 
from different cell lines carrying non-overlapping segments of HSA21 to 
identify a candidate gene for a given phenotype. RNAi technology and genetic 
manipulation can also be used in this model to restore a euploid state for a 
particular gene. Some care needs to be taken when evaluating results 
generated using a cross-species system. The effect of some human genes 
might be masked in a different species context by a variety of factors, 
including genetic and epigenetic regulation, or altered formation of protein 
complexes. Nevertheless, at least two examples have validated the utility of 
this model to explore pathogenetic mechanisms of DS. First, subcutaneous 
injection of pluripotent transchromosomic ES cells containing an entire copy of 
HSA21 into syngeneic mice gave rise to teratomas containing a significantly 
decreased percentage of neuroectodermal tissues compared to tumours 
derived from the control ES cells (Mensah et al., 2007). A comparison 
between genes present on HSA21 at the undifferentiated ES cells stage (at 
the time of the injection) and in the teratomas derived from transchromosomic 
ES cells allowed to identify a region on human chromosome 21 potentially 
responsible for the inhibition of neuroectodermal differentiation of the ES cells.  
Second, transchromosomic ES cells showed a significant reduction in the 
neuron-restrictive silencer factor (NSRE/REST), a key regulator of 
pluripotency and differentiation, and this alteration was reproducible across 
several DS models. Using partial trisomic ES cells and eQTL analysis, altered 
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expression of REST was shown to be caused by trisomy of DYRK1A, a 
tyrosine kinase on HSA21. DYRK1A was also demonstrated to contribute to a 
very early developmental skewing of compartments during embryoid bodies 
formation from transchromosomic ES cells, prompting the idea that the effect 
of trisomy 21 might be crucial at early developmental stages (Canzonetta et 
al., 2008). 
A further validation of the suitability of this model to explore pathological 
mechanisms of DS came from proteomic analysis of the transchromosomic 
ES cell lines. Mass spectrometry analysis identified approximately 50 proteins 
whose expression was significantly altered by the presence of an extra copy of 
HSA21 in comparison to the wild type ES cell control (Wang et al., 2009), 
suggesting that a perturbed dose of these proteins might contribute to DS 
phenotypes. 
Taken together, these results prompted us to use the transchromosomic 
model to explore mechanisms underlying physiological haematopoiesis and 
development of leukaemia in DS.  
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1.7. Aims of this thesis    
1) To derive megakaryocytes in vitro from the transchromosomic ES cells 
and to explore the effect of trisomy 21 on proliferation and differentiation of 
the megakaryocytic lineage. 
 
2) To generate a model of ES cells trisomic for genes on HSA21 and 
expressing GATA-1s as a tool to investigate the cooperation between 
HSA21 and GATA-1 mutations during leukaemic transformation in DS. 
 
3) To evaluate the effects of the gene dosage imbalance caused by the 
presence of an extra copy of HSA21 during the ontogenesis of 
haematopoietic stem cells from mesodermal precursors using 
transchromosomic ES cells. 
 
4) To dissect the contribution of individual HSA21 genes/regions to the 
measurable cellular phenotypes established in the aims above. 
 
5) To characterize the range and predict the consequences of acquired JAK3 
mutations in DS-TMD and DS-AMKL cases. 
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2. Materials and methods  
2.1. Cell culture  
2.1.1. Mouse ES cell culture 
 
 
The mouse embryonic stem (ES) cells D3 and 47-1 and mouse embryonic 
fibroblasts (MEFs) used for this study were provided by our collaborators (E. 
Fisher, Institute of Neurology, UCL, UK and V. Tybulewicz, NIMR, Mill Hill, 
UK). The wild type ES cell line D3 was originally established by Doetschman 
and colleagues from day 4 129/Sv blastocysts (Doetschman et al., 1985). The 
transchromosomic ES cell line 47-1 contains a freely segregating human 
chromosome 21 (HSA21) in the background of the diploid D3 mouse genome 
(Hernandez et al., 1999).  Other transchromosomic ES cells used in this study 
contained fragments of HSA21 and were also generated from the parental cell 
line D3. 
All ES cell lines were cultured using medium supplemented with 5x105 U/ml 
leukaemia inhibitory factor (LIF) in order to maintain them in an 
undifferentiated and pluripotent state. To optimally support their growth, ES 
cells were also cultured on a feeder layer of mouse embryonic fibroblasts 
(MEFs), mitotically inactivated by UV irradiation or treatment with mitomycin C. 
ES cell lines were grown on 25 cm2 tissue culture (TC) flasks. A 0.1% 
weight/volume gelatin solution was prepared by dissolving gelatin from porcine 
skin (Sigma G1890) in distilled water and sterilized by autoclaving. For coating 
of dishes with gelatin, 4 ml of the 0.1% gelatin solution was evenly dispensed 
onto the surface of the flasks. Flasks were left at room temperature for an hour 
in a laminar flow hood and then excess gelatin solution was aspirated. 4 ml of 
ES cells medium (450 ml DMEM, Sigma, D5796; 75 ml ES batch-tested FCS, 
PAA, A15208; 5 ml 200 mM L-Glutamine, Sigma G3126; 5 ml 100x MEM Non-
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Essential Amino Acids solution, Sigma, M71452; 5 ml 100x 
Penicillin/Streptomycin solution, Sigma, P4333; 3.5 µl β-mercaptoethanol, 
Sigma, M7522; 50 µl LIF-ESGRO®, Millipore, ESG1107) were subsequently 
added to gelatinised flasks to prevent the gelatin from drying out. Following 
this step, 2x106 MEFs were seeded onto each gelatinised flask. MEFs were 
left to attach from 1 hour to overnight at 37ºC in a humidified incubator with 
5% CO2. Medium was then changed and ES cells were seeded onto the 
feeder layer (MEFs). ES cells were passaged every two to three days by 
trypsinising and seeding onto fresh feeder or gelatin-coated flasks. Cells were 
typically split at ratios of 1:2 to 1:4 every two to three days, with the splitting 
ratio depending on their confluence. For splitting of cells, flasks were washed 
twice with sterile PBS, and then 1 ml of 0.25% trypsin-EDTA solution (Sigma 
T3924) was added and left on the cells for 1 – 2 minutes in a humidified, 37ºC, 
and 5% CO2 incubator. 4 ml of ES cell medium were added to neutralize the 
trypsin and cells were further dissociated by vigorous pipetting before seeding 
onto fresh feeder plates. 47-1 and other transchromosomic ES cells were 
maintained in ES cell medium supplemented with 500 µg/ml G418 (Sigma, 
G5013) in order to select for cells containing the neo tagged HSA21. One 
passage before starting the differentiation experiment, 47-1 ES cells were 
grown in the absence of G418.  
2.1.2. Adherent cell culture 
 
 
The ecotropic packaging cell line PLAT-E was a kind gift from Prof. T. 
Kitamura (Tokio, Japan) (Morita et al., 2000). Cells were maintained on TC-
treated 10 cm dishes in DMEM supplemented with 10% FCS, 5 ml 200 mM L-
Glutamine, 100U/ml penicillin and 100 U/ml streptomycin, 1 µg/ml puromycin 
(Sigma, P7255), and 10 µg/ml blastidicin (Sigma, 15205). Cells were split 
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every 2-3 days, when they reached approximately 80% confluency. For 
splitting, cells were detached from the plate by gentle pipetting using fresh 
medium without addition of trypsin. 
Puromycin-resistant primary mouse embryonic fibroblasts (used as feeder 
layers for culture of puromycin-resistant ES cells) were purchased from Stem 
Cell Technologies (Vancouver, Canada). Cells were grown on TC flasks in 
DMEM supplemented with 20% FCS, 5 ml 200 mM L-Glutamine, and 100 
U/ml penicillin and 100 µg/ml streptomycin. To inhibit cell proliferation, 
mitomycin C treatment was carried out as follows. Confluent flasks of 
fibroblasts were treated with culture medium supplemented with 7.5 µg/ml of 
mitomycin-C (Melford) for 2 hours. Cells were then washed thoroughly three 
times with PBS to avoid any potential residue of mitomycin-C. Fresh culture 
medium was then added and cells were incubated for 3 hours to overnight 
before being trypsinised, harvested and frozen down at the concentration of 2 
x 106 cells/vial. This amount of cells was enough to support ES cell growth in a 
small flask. 
The mouse fibroblast NIH3T3 cell line was obtained from ATCC, and cultured 
in DMEM supplemented with 10% FCS, 5 ml 200 mM L-Glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin, and split by trypsinization. Cells were 
typically split at ratios of 1:8 to 1:10 every three to four days, with the splitting 
ratio depending on their confluence. 
2.2. Haematopoietic differentiation of the ES cells 
 
Haematopoietic differentiation of the mouse ES cell line D3 and of the 
transchromosomic ES cells was performed using a coculture system based on 
the OP9 stromal cell line (Kitajima et al., 2003).  
OP9 cells were obtained from ATCC (CRL-2749). They were grown on TC 
flasks and kept in a medium prepared as follows: 4,028 g of MEM powder, 6.4 
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mg Phenol Red, and 8 ml sodium bicarbonate were dissolved in 450 ml of 
distilled water; medium was then sterilized by filtration and foetal bovine serum 
(ATCC, 30-2021) and L-glutamine were added to achieve a final concentration 
of 20% and 2 mM, respectively. OP9 cells were routinely passaged every 3 
days (at approximately 70–80% confluency) to avoid overgrowing. To passage 
OP9 cells, medium was removed, cells were washed once in PBS and 
incubated in 0.25% trypsin-EDTA at 37 ºC in a humidified incubator with 5% 
CO2 until they detached. Fresh medium was added, and after carefully 
pipetting to avoid clumps, one-third of the cells were dispensed into new 
flasks.       
Haematopoietic differentiation of mouse ES cells was carried out in 6-well 
plates (Era et al., 2000). A confluent layer of OP9 cells (2x105 cells/well) was 
seeded in 6-well plates 16 hours before starting the differentiation protocol. At 
day 0, each well of a 6-well plate covered with a confluent layer of OP9 cells 
was seeded with 5x104 ES cells using the OP9 medium. Half of the medium of 
each well was changed at day 3 of the differentiation protocol. At day 5, cells 
were trypsinised using 0.5 ml of trypsin-EDTA solution at 37 ºC in a humidified 
incubator with 5% CO2 until they detached. Fresh medium was added and 
cells from all the wells were harvested, pipetted vigorously to break clumps, 
and plated for 45 minutes into a T75 TC flask. This replating step was 
necessary to remove the stromal cells. The supernatant from this step 
contained the induced non-adherent fraction, which was used for further 
experiments. 
 
2.2.1. Flow cytometry analysis 
 
 
Day 5 HSCs/haematopoietic progenitors (HPs) derived from ES cells were 
washed once in PBS, centrifuged and resuspended in 100 µl of 10% FCS in 
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PBS containing anti-mouse CD41–FITC conjugated (BD Biosciences, 553848, 
clone MWReg30) and anti-mouse CD 117/c-KIT–APC conjugated (BD 
Biosciences, 553356, clone 2B8) at a dilution of 1:100, or the isotype controls 
rat IgG1 k-FITC conjugated (BD Biosciences, 553924) and rat IgG2b k-APC 
conjugated (BD Biosciences, 553991) at the same dilution. After 30 minutes of 
incubation at 4 ºC, cells were brought to the FACS facility for analysis. Data 
were collected on a LSRII instrument from BD Biosciences and analysed with 
the FlowJo software version 8.7.1. A minimum of 30,000 events was recorded 
per sample. A main gate was placed to exclude dead cells. Compensation for 
each fluorophore was performed using Becton Dickinson compensation beads 
with the FACSDiva software. The frequency of positive cells and the mean 
fluorescence intensity for FITC and APC within this subpopulation were then 
calculated. The same statistical analysis was applied to all the samples 
analysed, including the isotype controls. 
 
2.2.2. Assay for counting haematopoietic colonies derived from 
mesodermal precursors 
 
 
Induction of differentiation was carried out as in 2.2, and the cells were 
harvested by treatment with trypsin at day 5. Cells were then counted and 
replated onto a fresh OP9 feeder layer at a density of 5 x 102 cells/plate in a 
96-well plate. At day 12, wells were scored under a light microscope for the 
presence of haematopoietic colonies composed of round-shape cells loosely 
attached to the stromal cell layer.  
 
2.2.3. Colony forming assay 
 
 
At day 5 of the haematopoietic differentiation protocol, cells were harvested by 
treatment with trypsin, resuspended vigorously to a single cell suspension and 
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replated onto a fresh OP9 feeder layer. Three days later (day 8), cells were 
trypsinised again, pipetted up and down several times to break clumps, 
counted and plated into semisolid medium supplemented with cytokines 
(Methocult, M3434, Stem Cell Technologies, France) at a density of 1x 
105/dish in 35 mm dishes. Medium used for these experiments contained 
recombinant mouse IL-3, recombinant human IL-6 and recombinant human 
erythropoietin (EPO). Each culture was seeded in duplicate and left in a 
humidified incubator with 5% CO2 for 14 days. Scoring of the colonies was 
performed using a light microscope according to the manufacturer’s 
instructions.  
2.3. Megakaryocytic differentiation of the murine ES cell lines 
 
2.3.1. Megakaryocytic differentiation protocol  
 
 
Megakaryocytic differentiation (Figure 2.1) of mouse ES cell was induced 
using a coculture system based on the OP9 stromal cell line as described in 
2.2. At day 5 after the original seeding, induced cells (non-adherent fraction) 
were harvested and plated onto a fresh layer of OP9 in a 6-well plate at a 
concentration of 1x105 cells/well. 20 ng/mL of mouse recombinant 
thrombopoietin (TPO) was added to the medium. At day 8, cells were 
harvested again after a preplating step of 45 minutes and resuspended in 
fresh OP9 medium supplemented with TPO at a concentration of 10 ng/mL, 
recombinant murine IL-6 at a concentration of 10 ng/mL and recombinant 
human IL-11 at a concentration of 10 ng/mL. All cytokines were purchased 
from Peprotech, UK. Cells were kept in culture up to day 13. 
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2.3.2. Cytospin and AchE staining 
 
 
Day 13 megakaryocytes/megakaryocyte precursors were washed once in PBS 
and resuspended at a concentration of 1 x106 cells/ml. 100 µl were then spun 
onto poly-D-Lysine treated slides (VWR) in a Shandon Cytospin 3 centrifuge 
at 800 rpm for 5 minutes. Acetylcholinesterase (AchE) staining was performed 
on unfixed cells as described in 2.4.5.  
 
 
     
Fig. 2.1. Schematic view of the differentiation protocol used in this study to differentiate 
mES cells into megakaryocytes. The protocol is based on the presence of a stromal cell line 
(OP9) and the addition of cytokines with a known role in megakaryopoiesis. 
 
 
2.3.3. Surface antigen labelling and ploidy assay 
 
 
Day 13 ES-derived megakaryocytes were harvested and depleted of OP9 by a 
45 minutes preplating step (see 2.2). Cells were washed once in PBS, 
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Fresh OP9 monolayer 
+ 20 ng/ml TPO 
Day 8 
D3/47-1 on OP9 
 
ES medium +LIF 
OP9 medium -LIF 
D3/47-1 on OP9 
with TPO, IL-6 
and IL-11  
D3/47-1 on OP9 
with TPO, IL-6 and 
IL-11   
Day 0 
Day 5 
Day 13 
+ 10 ng/ml TPO 
   10 ng/ml IL-6 
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centrifuged and resuspended in 200 µl of 10% FCS in PBS containing anti-
mouse CD41–FITC conjugated (BD Biosciences, 553848, clone MWReg30) at 
a dilution of 1:100 or the isotype control Rat IgG1 k-FITC conjugated (BD 
Biosciences, 553924) at the same dilution. After 30 minutes of incubation on 
ice in the dark, cells were brought to the FACS facility for analysis. Data were 
collected on a LSRII (BD Biosciences) instrument and analysed with the 
FlowJo software version 8.7.1. The same number of events (30,000) was 
acquired for each sample, and the same acquisition parameters were applied 
to test tubes and isotype controls. A main gate was designed to exclude dead 
cells and applied to all samples. A positive subpopulation was then gated, and 
data obtained from this population were presented as histogram plots with 
overlay of curves of the isotype controls and test tube. Mean fluorescence 
intensity of the sample was plotted on the x-axis, and the number of events 
was plotted on the y-axis.  
Antibody labeling was performed as described above to perform sorting of 
CD41+ cells. Sorting was performed on a FACSAria platform (BD 
Biosciences). Cells were sorted in 10% FCS in PBS, washed once in PBS, 
then fixed in 70% ice-cold ethanol for 30 minutes on ice. After this step, cells 
were centrifuged at 1200 rpm for 5 minutes, washed once in PBS and 
centrifuged again. Cells were then incubated with 50 µL of RNase (100 mg/ml 
Sigma) for 15 minutes at 37 ºC. Before analyzing them on the FACS platform 
LSRII, 200 µL of propidium iodide (PI) solution (Sigma P4170, 50 mg/ml) were 
added to the cells. Data were acquired on the LSRII using the FACSDiva 
Software. The linear voltage on the 610/20 nm channel was adjusted so that a 
doublet discrimination gate was placed on the “Area versus Width” parameter. 
25,000 events were acquired per sample, and 2N, 4N, 8N and 16N classes 
were displayed on a linear scale.  
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2.3.4 TPO dependent colonies formation 
 
 
CFU-MK assay was performed using the MegaCult®-C kit (Stem Cell 
Technologies, 0496). At day 13 of the differentiation protocol, one tube of 
MegaCult®-C medium without cytokines was defrosted overnight at 4ºC and 
supplemented with 50 ng/mL of TPO, 100 U/ml penicillin and 100 µg/ml 
streptomycin. 1x105 cells for each slide were counted for each cell population 
using a Neubauer counting chamber and resuspended in 0.1 ml of Iscove’s 
MDM medium. Cells were then added to the MegaCult®-C medium and the 
tubes were vortexed. 1.2 ml of bovine collagen solution (StemCell 
Technologies, Europe), kept on ice, was then added to the tube containing 
cells and semisolid medium and vortexed again. 0.75 ml of the final culture 
was then dispensed into each of the two wells of a double chamber slide 
(StemCell Technologies, Europe) avoiding air bubbles formation. Slides were 
then placed in a covered 100 mm Petri dish containing 1 uncovered 35 mm 
dish with 3 ml of sterile water to ensure appropriate humidity, and transferred 
to a 37 ºC humidified incubator with 5% CO2. 
Slides were removed from the incubator after 10 days. At that point, the plastic 
walls and the rubber seal of the chamber slides were removed. A pre-cut 
spacer and a filter card were then placed onto the chamber slides and the 
liquid was allowed to soak the card. Slides were then fixed in ice-cold acetone 
for 5 minutes on ice, and then left to air dry. After that, a staining solution 
composed of 10 mg of acetylthiocholiniodide (Sigma, UK) in 15 ml of 0.1 M 
sodium phosphate buffer with the addition of 1 ml of 0.1 M sodium citrate, 2 ml 
of 30 mM copper sulfate and 2 ml of potassium ferricyanide was added to the 
slides, which were incubated in a humid chamber for 4 hours at room 
temperature in the dark. The staining solution was then removed and slides 
were fixed in 95% ethanol for 10 minutes and rinsed in water, counterstained 
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with Harris’ hematoxylin solution (Sigma) for 30 seconds, rinsed again and 
allowed to air dry. Scoring of the colonies was carried out by light microscopy 
using a 20x objective. Mouse megakaryocytes and early megakaryocytic 
progenitors appeared brown due to the copper ferricyanide in the cytoplasm 
resulting from the enzymatic reaction catalyzed by acetylcholinesterase. 
Colonies containing at least 3 brown cells were considered positive. Images 
from sequential fields of every slide were taken on a Leica Q5501W 
microscope. The Leica Qwin v3.2 software was used to determine the area of 
the colonies, in square pixels (pp2), by manually tracing the 20x magnification 
images, captured at a resolution of 37.79 pixels/cm. Colony size was classified 
in 3 categories (small: 2000-15,000 pp2, medium: 15,000-50,000 pp2 and 
large: > 50,000 pp2) and compared using the Pearson X-square test. 
CFU-MK assay was performed in slightly different conditions to address the 
effect of GATA-1s on the megakaryocytic lineage. MKs/MK progenitors were 
obtained by in vitro differentiation of D3 and 47-1 ES cells transduced with 
GATA-1s or the MSCV-PURO vector as described in 2.3.1. At day 13 of the 
differentiation protocol, 1x105 cells were counted and resuspended in 
Methocult semisolid medium (Stem Cell Technologies, M3231) 
supplemented with TPO at a concentration of 20 ng/mL, and recombinant 
murine IL-6, IL-3, and human IL-11 all at a concentration of 10 ng/mL. Medium 
was supplemented with puromycin at the concentration of 1 µg/mL to select 
for the growth of transduced cells only. Cytokines were purchased from 
Peprotech, UK. Each culture was seeded in two 35 mm dishes and left in a 
humidified incubator with 5% CO2 for 8 days. Scoring of the colonies was 
performed using a light microscope. 
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2.4. ES cells manipulation 
 
2.4.1 Human specific RNAi  
 
 
Human-specific, RNAi-mediated knockdown of RUNX-1 was achieved in 47-1 
ES cells by utilizing siRNA oligos targeting four different portions of the human 
RUNX-1 sequence. A pool of 4 different duplexes was purchased from 
Dharmacon (siGenome SMARTPool, M-003926-02-0005) and specificity of 
the targeted sequences was verified using the NCBI Basic Local Alignment 
Search Tool (BLAST). Target sequences are listed in Appendix 6.1. 100 
picomoles (pmol) of the oligo mixture were transfected into the mouse 
transchromosomic ES cell line 47-1 using 4 µg of the Lipofectamine 2000 
reagent (Invitrogen, 11668019) and the Opti-MEM® medium (Invitrogen, 
1058-021), according to standard manufacturer’s instructions for transfection 
of cells in suspension. Transfection was carried out in a 12-well plate; 5 x 105 
cells/well were transfected in suspension in a gelatinised plate without a 
feeder layer. Identical conditions were applied in parallel to the transfection of 
a control RNAi (targeting an irrelevant sequence of the mouse genome, see 
appendix 1.6). Opti-MEM® medium was replaced with fresh ES cell medium 5 
hours after transfection.  
 
2.4.2 Retroviral transduction 
 
 
To generate retroviral supernatant, 20 µg of the retroviral vectors MSCV-
PURO-GATA-1s and MSCV-PURO (details of the constructs are shown in 
Appendix I) were transfected into the ecotropic packaging cell line PLAT-E 
(stably expressing the viral components gag, pol and env) in a 10 cm dish 
format using the Lipofectamine 2000 reagent. Medium was replaced 24 
hours after the transfection and the retroviral supernatant was used at 48 and 
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72 hours. The retroviral supernatant was carefully collected from the plate, 
filtered through a 0.45 acetate cellulose filter and supplemented with 8 µg/ml 
Polybrene (Sigma, H9268). Medium containing the retroviral supernatant from 
8 plates per construct was pooled together and concentrated by centrifugation 
at 11,200 rpm for 2 hours at 4 ºC. The resulting viral pellet was resuspended 
in fresh ES medium (1/10 of the original volume) and used for the transduction 
procedure, derived with minor modifications from (Cherry et al., 2000). ES 
cells were washed, trypsinised and resuspended in retroviral containing 
medium; cells were then plated at the density of 8 x 105/well in a gelatinized 6-
well plate and centrifuged for 45 min at 2500 rpm at room temperature. The 
retroviral supernatant was then removed and replaced with fresh medium. 24 
hs after the “spinfection” procedure, ES medium was aspirated and replaced 
with freshly collected retroviral supernatant prepared as the day before. Cells 
were then incubated overnight with the retroviral supernatant, and the morning 
after medium was replaced by fresh medium. 48 hours after the infection, cells 
were trypsinised, plated on puromycin-resistant feeder cells, and puromycin at 
the concentration of 1 µg/mL was added. Selection was carried out for at least 
10 days before sampling the cells for verification of the integration and 
expression of the retroviral construct by PCR on genomic and complementary 
DNA. 
For optimizing the protocol of infection, production of retroviruses was also 
carried out by triple transfection of 293T cells with the retroviral vector MSCV-
IRES-GFP (MIG) and plasmids encoding the viral components gag, pol and 
env. Details of these plasmids are provided in Appendix 6.1. The efficiency of 
the transduction protocol was tested by infecting NIH3T3 with retroviral 
supernatant produced by transfection of the PLAT-E packaging cell line or by 
triple transfection of the 293T cell line using the MIG vector. The level of GFP 
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expression was monitored by FACS analysis. The MIG vector was also 
utilized to test the transduction protocol on ES cells. 
2.5. Immunohistochemical analysis  
 
2.5.1. Immunohistochemistry protocol on paraffin-embedded tissues 
 
 
Archived material was obtained from the autopsy collection of specimens at 
the Department of Pathology, University of Split Medical School. All archived 
material was consented for use in research, and the project was covered by 
ethical approval from the North East London Health Authority. 
To dissolve the paraffin, 5 µm thick sections were incubated twice in fresh 
xylene (Fluka, 95673) for 5 minutes. Slides were then incubated twice for 5 
minutes in 100% ethanol, once for 5 minutes in 95% and 70% ethanol 
solutions, and then subjected to two rehydration steps of 5 minutes each in 
distilled water. Antigen retrieval was performed by incubating the sections for 
20 minutes in citrate buffer (10 mM Na-citrate, 0.05% Tween20, pH6.0) pre-
heated to 95°C in a boiling water bath. For staining with the anti-CD34 
antibody, the citrate buffer was replaced by an EDTA Buffer (1 mM EDTA, 
0.05% Tween 20, pH 8.0). Endogenous peroxidase activity was blocked 
incubating slides for 10 minutes with a 3% H2O2 solution in methanol. After this 
step, blocking solution (10% donkey or horse serum in PBS) was added to the 
sections, which were then incubated for an hour at room temperature in a 
humidified chamber. After a wash with agitation in PBS for 5 minutes, slides 
were incubated with the primary antibody solution (antibody in 2% serum in 
PBS) from an hour to overnight. A list of primary antibodies used for staining 
and their dilutions is provided in table 2.1.  
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Antibody Species Dilution Manufacturer 
Anti CD41 Goat Polyclonal 1:500 Santa Cruz 
Anti CD34 Mouse Monoclonal  1:50 Dako 
Anti von Willebrand Rabbit Polyclonal 1:400 Dako 
 
Table 2.1. Antibodies used for immunohistochemical analysis. List of primary antibodies, 
species they were derived from, and manufacturers. Working dilution in 2% serum in PBS is 
also indicated.  
 
The incubation with primary antibody was followed by 3 x 10 minute washes in 
0.05% Tween-20 in PBS. Slides were then incubated with the secondary 
antibody solution (antibody in 1% serum in PBS) for 1 hour at room 
temperature. Secondary antibodies used were: biotinylated horse anti-goat 
IgG; biotinylated donkey anti-mouse IgG; biotinylated goat anti-rabbit IgG. All 
secondary antibodies were used at a dilution of 1:1000. Immunoreactivity was 
developed with the Vectastain Elite ABC Kit (VectorLabs, UK). Following 
incubation with secondary antibodies, sections were washed twice in 0.05% 
Tween-20 in PBS for 10 minutes; in the meantime, two drops of solution A and 
B from the kit were mixed in 5 ml PBS (ABC-HRP solution) and incubated at 
room temperature for 30 minutes before use. The ABC-HRP solution was then 
added to the slides and left to act for 30 minutes. After extensive washes in 
0.05% Tween-20 in PBS, diaminobenzidine (DAB) liquid substrate solution 
(Sigma, D6815) prepared according to the manufacturer instructions was 
added to the sections for 30 seconds-5 minutes. Slides were washed in 
distilled water twice for 5 minutes, stained for 10 minutes at RT with Harris 
Haematoxylin solution (Sigma, H3136), flooded for 15 seconds in a 1% acid 
alcohol solution (1 ml of concentrated HCl in 100 ml of 70% Ethanol) and 
washed again twice in distilled water for 5 minutes. Tissues were finally 
dehydrated through sequential steps in 70%, 95%, 100% Ethanol, equilibrated 
for 10 minutes in xylene and sealed with a few drops of DPX mounting 
medium (Sigma) and a coverslip. Slides not incubated with the primary 
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antibody served as negative controls. Sections were analysed with the Leica 
Application Suite software on a Leica Q5501W Microscope.  
2.6. Western Blotting 
 
2.6.1 Nuclear extracts preparation 
 
 
Nuclear extracts from cells transfected with hRUNX-1 RNAi oligos and control 
RNAi oligos were prepared by Dr. Frederic Delom with the Qproteome Nuclear 
Protein Kit (Qiagen) according to the manufacturer’s instructions.  
 
2.6.2. Western Blotting 
 
 
Proteins were separated by SDS-PAGE. The separating and stacking gels for 
two minigels (BioRad system) were prepared as described below: 
Separating gel (12%): 
 H2O 1.78 ml 
Buffer A (0.75 M Tris pH 8.8, 0.2% SDS) 6.75 ml 
Acrylamide/Bisacrilamyde (30%) 5.4   ml 
TEMED 37.5 µl 
APS 10% 95    µl 
  
Table 2.2. Components of the separating gel for SDS page. 7 ml of this solution were 
poured into each Bio-Rad MiniPROTEAN® casting frame and used as a separating gel. 
 
Stacking gel:  
H2O 1.64 ml 
Buffer A (0.25 M Tris pH 6.8, 0.2% SDS) 2.5   ml 
Acrylamide/Bisacrilamyde (30%) 660  µl 
TEMED 10    µl 
APS 10% 25    µl 
  
Table 2.3. Components of the stacking gel. 3 ml of a 4% gel were used as stacking gel. 
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The SDS-PAGE running buffer was composed of Tris-glycine (30 g Tris-HCl, 
144 g glycine in deionized water up to 1 L) plus 0.1% SDS. The stacking gel 
was electrophorised at 20 mA until the dye front reached the separating gel, 
then the current was increased to 40 mA. Proteins were then transferred to 
nitrocellulose membranes by wet blotting in transfer buffer (1.8 L Tris-glycine 
plus 0.2 L methanol) with a Bio-Rad mini Trans-Blot apparatus. The transfer 
was allowed to proceed for one hour at a current of 160 mA. The blotting 
sandwich was disassembled and the membrane was rinsed in TBST buffer 
(20 mM Tris, 150 mM NaCl, 0.1% Tween 20), and then blocked for 1 h at 
room temperature in 5% dry milk in TBST buffer. After blocking, the 
membrane was cut into strips to separate proteins with different molecular 
weight, and the strips were probed with individual primary antibodies at 4°C 
overnight. Primary antibodies used in this study are reported in table 2.4.  The 
membrane was then rinsed 3 times, washed 5 times x 5 minutes with TBST 
and then incubated for 1 hr at room temperature with the secondary antibody 
(anti mouse or rabbit IgG HRP-conjugated at a concentration of 1:5000 in 5% 
dry milk in TBST). Finally, membranes were washed 3 x 5 minutes in TBST 
and proteins were visualized using the ECL (enhanced chemiluminescence) 
detection system (Amersham).  
Antibody Species Dilution Manufacturer 
Anti RUNX-1 Mouse Monoclonal 1:500 Abcam 
Anti-EXH2 Rabbit Polyclonal 1:1000 Abcam 
 
Table 2.4. Primary antibodies used for western blot analysis in this study. 
2.7. gDNA analysis 
 
2.7.1. gDNA extraction from formalin archived material 
 
Formalin fixed tissue was extensively washed overnight at 4°C in PBS, then 
washed three times for 30 minutes each in TE buffer (10 mM TRIS, 1 mM 
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EDTA, pH 8.0). After removal of excess liquid, the sample was snap frozen in 
liquid nitrogen and ground into a fine powder. The powder was then 
resuspended in 500 µL of genomic DNA lysis buffer (10 mM Tris (pH 8); 100 
mM NaCl; 100 mM EDTA and 0.5% SDS). 5 µl of Proteinase K (20 mg/mL, 
Qiagen, 19131) were added and the sample was incubated overnight at 55 ºC. 
After the incubation, 500 µl of phenol were added to the samples, and after 
vigorous shaking for 3 minutes to mix phases completely, the tube was 
centrifuged at maximum speed for 3 minutes to separate the phases. The 
aqueous phase was then transferred to a new microfuge tube, 500 µl of 
phenol/chloroform (1:1) were added, and the sample was shaken vigorously 
for 2 minutes and centrifuged again at maximum speed for 2 minutes. The 
aqueous phase was removed and transferred to a clean microfuge tube. After 
adding 50 µl of 3 M sodium acetate (NaOAc pH 6) and 500 µl of 100% ethanol 
(EtOH) at room temperature (RT) to the tube, the DNA precipitate was 
pelleted, and the ethanol supernatant was removed.  The DNA pellet was 
washed in 1 ml of 70% Ethanol at RT, and then air-dried and resuspended in 
30-50 µl of TE buffer. Details of alternative methods to extract gDNA from 
archived material are provided in chapter III.1. The heat/alkaline lysis antigen-
retrieval method was derived from Shi et al (Shi et al., 2004). 
 
2.7.2. gDNA extraction from fixed TPO-dependent colonies 
 
 
After fixation and Ache staining of megakaryocytic colonies, gDNA was 
extracted from selected large colonies with the following procedure. Selected 
colonies were scratched with a G18 needle from double chamber slides and 
resuspended in 50 µL of 1x Amplitaq Gold PCR buffer (Applied Biosystems). 
The buffer containing the fixed cells was then transferred to a well of a 96-well 
plate and supplemented with 1 µl of Proteinase K (20 mg/mL, Qiagen). The 
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96-well plate was then wrapped in cling film and incubated in a hybridisation 
oven at 55 ºC overnight. The plate was then placed on a heating block at 100 
ºC for 10 mins to avoid carryover of the proteinase K in the PCR reaction. 5 µl 
of this solution were used as a template in the PCR reaction to amplify and 
sequence GATA-1 exon 2.  
 
2.7.3. PCR and sequencing analysis of mouse and human GATA-1 
 
 
PCR amplification was performed in a thermal cycler with the following 
conditions: 7.5 mins at 95 ºC; 35 cycles of 30 seconds at 95 ºC, 30 seconds at 
56 ºC and 1 min at 72 ºC; followed by 10 mins at 72 ºC. Reaction components 
were as follows: 
PCR component Volume (µl) Final Concentration 
10x Gold Buffer 2.5 1X 
10 mM dNTPs  1  0.4 mM 
25 mM MgCl2  2.5 2.5 mM 
5 mM FWD/REV primer 0.5 of each 500 nM of each 
Amplitaq Gold (5 U/µl)   0.2   1 U 
gDNA    1-2   - 
H2O Up to 25     - 
 
Table 2.5. Reaction components for PCR analysis of genomic DNA. PCR reactions were 
performed in a final volume of 25 µl. 
 
Human GATA-1 I1 Forward GGATTTCTGTGTCTGAGGAC 
Human GATA-1 I2 Reverse CCAACAGCACTCAGCCAATG 
Mouse GATA-1 I1 Forward CACAACCCTTTCTGTTCCTC 
Mouse GATA-1 I2 Reverse CGGTACACCTATCCACAGAG 
 
Table 2.6. Primers used for amplification of human and mouse GATA-1. Primers were 
designed in intron 1 (forward primer) and intron 2 (reverse primer) to amplify the entire exon 2 of 
both mouse and human GATA-1. 
 
Primers used in PCR amplifications of gDNA extracted from mouse colonies 
or archived material are listed in table 2.6. They were designed to span GATA-
1 exon 2 in both species. Primers were 18-22 bases in length, melting 
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temperatures were between 55 ºC and 62 ºC and CG content was between 
35% and 60%. Agarose gel electrophoresis was performed using 1.2% 
agarose gels in 0.5% TAE (Tris-Acetate-EDTA) buffer. Amplified fragments 
were run next to a 100 bp DNA ladder (Promega). After the run, agarose gels 
were stained with ethidium bromide. Stained gels were analysed under a UV 
analyser (Alpha Innotech Corporation). Amplified DNA products were purified 
for sequencing analysis using ExoSap-IT, (USB, GE Amersham). 2 µl of 
Exosap-IT were added to 5 µl of PCR product and incubated in a thermal 
cycler at 37 ºC for 45 mins, then 80 ºC for 15 mins to inactivate the enzyme. 
Cycle sequencing was performed with an ABI BigDye terminator V3.1 using 
an ABI3130XL automated sequencer (Applied Biosystems). Components of 
the sequencing reaction were as follows: 
Sequencing reaction component Volume (µ l) 
PCR purified product 1-4 
Primer (Forward or Reverse 0.8 nM each) 2 
BigDye Buffer 5x 2 
BigDye terminator V3. 1  2 
H2O Up to 10  
 
Table 2.7.  Sequencing reaction components. Sequencing reaction was carried out in a final 
volume of 10 µL. 
 
Sequencing reactions were performed in a thermal cycler with the following 
conditions: 25 cycles of 10 seconds at 96 ºC; 5 seconds at 50 ºC, 4 minutes at 
60 ºC. After sequencing cycles, 1 µl of NaOAc 3M (pH 5.2) and 25 µl of ice-
cold ethanol were added; samples were incubated for 10 minutes on ice and 
centrifuged for 20 minutes at maximum speed. The ethanol supernatant was 
then removed, and after a wash in 1 ml of 70% Ethanol at RT, DNA pellets 
were dried carefully and resuspended in 10 µl of formamide. Samples were 
then subjected to capillary electrophoresis in the ABI3130XL automated 
  88 
sequencer and sequences were analysed using the Chromaslite201 software, 
Technelysium Pty. 
 
2.7.4. Verification of integration of retroviral constructs in ES cells 
 
 
gDNA was extracted from undifferentiated ES cells grown under puromycin 
selection for at least 10 days. Cells were trypsinised, washed once in PBS and 
centrifuged to obtain a compact pellet. After removal of the supernatant, the 
cell pellet was resuspended in 250 µl of genomic lysis buffer and 5 µl of 
Proteinase K, and then incubated at 55 ºC for 2 hours. Samples were then 
subjected to a standard phenol/chloroform extraction and the gDNA was 
precipitated with EtOH (see 2.7.1). gDNA was resuspended in 20 µl of TE 
buffer, and 2 µl were used as a template for PCR analysis. PCR was 
performed using the same conditions and the same reagents described in 
2.7.2, but with primers listed below. 
Mouse GATA-1 EXON 5 Forward ATGAGGAAAGATGGAATCCAGAC 
FLAG Reverse ATCGTCGTCATCCTTGTAATC 
 
Table 2.8. Primers used for verification and expression of the GATA-1s-MSCV-PURO 
vector in transduced ES cells. 
 
Primers were designed to amplify a fragment of 374 bp. Because the forward 
primer was designed in the GATA-1s insert and the reverse in the FLAG-tag, a 
PCR product would result only from gDNA where the GATA-1s construct is 
integrated. 
2.8. RNA analysis 
 
2.8.1. Total RNA extraction from frozen tissues 
 
 
Total RNA was extracted from frozen tissues using the Trizol® reagent 
(Invitrogen, 15596-026), a solution containing phenol and guanidine 
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thiocyanate. RNaseZap wipes (Ambion) were used to remove RNases from 
work surfaces and equipment. Individual frozen tissues were ground into 
powder using a DEPC-treated pestle and mortar (a different pestle and mortar 
was used for each sample). Liquid nitrogen was added to samples during 
grinding to maintain a low temperature. Ground material was then added to a 
2 ml RNase-free Eppendorf tube containing 1 ml of Trizol® reagent. RNA was 
then chloroform extracted, isopropanol precipitated and washed with 75% 
ethanol in accordance with the manufacturer’s instructions. For RNA 
solubilisation, each air-dried RNA pellet was dissolved in DEPC-treated H2O. 
To ensure full dissolution of RNA, RNA solutions were pipetted several times 
and then incubated in a 55 ºC heat-block for 10 minutes. The volume of DEPC 
H2O used for dissolving RNA ranged from 50 µl to 200 µl, depending on the 
amount of tissue from which the RNA was extracted. If not being used 
immediately, RNA solutions were stored at -80 ºC. 
For determining the purity and concentration of RNA solutions, 
spectrophotometric analysis of diluted RNA solutions was carried out in a 
Biophotometer (Eppendorf). For assessing RNA purity, 1 µl of each RNA 
solution was diluted 1:60 in 10 mM Tris-HCl solution, pH 7.5. The A260/A280 
ratio of the diluted RNA sample was used to determine its purity. A260/A280 
ratios of 1.8 and above were considered to indicate adequate RNA purity. For 
the determination of RNA concentration, 1 µl of each RNA solution was diluted 
1:60 in DEPC-treated H2O before being spectrophotometrically analysed. The 
following formula was used to calculate the concentration of each RNA 
sample: A260 of diluted RNA x 60 (dilution factor) x 40 (extinction coefficient of 
absorbance of RNA, µg/ml). 
All RNA samples were DNase treated before being used in RT-PCR reactions. 
For DNase treatment of RNA, up to 5 µg of RNA solution was added to a 
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reaction mixture containing a final concentration of 1X DNase buffer and 1 
U/µg of RNase free DNase (Promega). Samples were incubated for 30 
minutes at 37 ºC. Each reaction was terminated by adding 1 µl of RQ1 DNase 
Stop Solution and further incubated at 65°C for 10 minutes to inactivate the 
DNase. 
 
2.8.2. RNA extraction from cells 
 
 
RNA from cell lines was extracted using RNeasy mini kit (Qiagen) with the 
gDNA eliminator columns step, according to the manufacturer’s instructions. 
The volume of RNase-free H2O used for eluting RNA ranged from 30 µl to 50 
µl, depending on the amount of cells from which the RNA was extracted. 
Purity and concentration of RNA solutions were determined as in 2.8.1. 
 
2.8.3. cDNA synthesis  
 
 
Up to 5 µg of RNA were reverse-transcribed using 200 U of the Superscript II 
enzyme (Invitrogen) in a total volume of 20 µl, with 10 µM DTT, 100 ng 
random hexamers, 0.5 mM dNTPs and 40 U RNase OUT (all from Invitrogen, 
Paisley, UK). Details of the reaction are shown below: 
 
Reaction component  Volume (µl) 
100 ng random hexamers 1 
5 µg RNA (max 10 µl) 
10 mM dNTP mix 1 
RNase-free water up to 12 µl 
 
Table 2.9. Components of the reverse-transcription reaction (1).  
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Initially, all reaction components listed in table 2.8 were incubated at 65 ºC for 
5 minutes. Reaction tubes were then cooled on ice before the addition of the 
following components to the reaction: 
 
Reaction component Volume (µl) 
5x buffer (First Strand Buffer for Invitrogen Superscript II RT) 4 
RNaseOUT  (40 U/µl) 1 
Superscript II RT 1 
DTT 0.1 M 1 
 
Table 2.10. Components of the reverse-transcription reaction (2). Final volume of the 
reverse transcription reaction was 20 µL. 
 
This final reaction mixture was incubated in a thermal cycler at 25 ºC for 10 
minutes, at 42 °C for 50 minutes, at 70 °C for 15 minutes and then cooled 
down to 4 °C. A reaction without reverse transcriptase served as a negative 
control (RT- control). The final volume was adjusted to 50 µl with DEPC-
treated water. Reverse transcription products were used immediately in PCR 
reactions or stored at –20ºC until required. 
 
2.8.4. RT-PCR analysis 
 
 
Human-specific RT-PCR was performed on cDNA derived from the 47-1 ES 
cells using human-specific primers. Primers were designed to flank a large 
intron in the sequence of the gene analysed to minimize amplification of 
contaminant gDNA. The sequence of the primers was aligned to the mouse 
genome using the NCBI BLAST tool to avoid interspecies amplification. 
Primers used for RT-PCR experiments are shown in table 2.11. PCR 
conditions and components of the reaction mix were as indicated in 2.7.2; the 
number of PCR cycles was between 32 and 37 for all of the amplicons. 
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Mutational analysis of GATA-1 exon 2 was carried out on cDNA derived from 
human foetal liver tissues amplified with the primers GATA-1 exon 2 Forward 
(TAATCCCCAGAGGCTCCATG) and GATA-1 exon 2 Reverse 
(CTGGGGAGTGTCTGTAGGCC). Sequencing analysis of GATA-1 exon 2 
was performed as in 2.7.2. 
Human DYRK1A Forward ATGACCTTGCCATTGATATGTG 
Human DYRK1A Reverse GAATACCCAGAACTTCCACTAT 
Human RUNX-1 Forward GATGGCACTCTGGTCACTGT 
Human RUNX-1 Reverse CTTTTCCCTCTTCCACTTCG 
Mouse RUNX-1 Forward GGTGGAGGTACTAGCTGACCA 
Mouse RUNX-1 Reverse AGTGCCACCACCTTGAAAGC 
Mouse GAPDH Forward TCACCACCATGGAGAAGGC 
Mouse GAPDH Reverse GCTAAGCAGTTGGTGGTGCA 
 
           Table 2.11. Primers used for human-specific RT-PCR analysis. 
 
2.8.5. Verification of expression of retroviral constructs in ES cells and 
MKs 
 
 
RNA was extracted from undifferentiated ES cells grown under puromycin 
selection for at least 10 days and from megakaryocytes derived from in vitro 
differentiation of the ES cells. Cells were harvested, washed once in PBS and 
centrifuged to obtain a compact pellet. RNA was extracted using the RNeasy 
mini kit from Qiagen and eluted in 30 µl of RNAse-free water. 2 µg of RNA was 
reverse transcribed as in 2.8.3 and 1 µl was used as a template for RT-PCR 
analysis. PCR was performed using the same conditions, reagents and 
primers described in 2.7.2. An RT- control was included for samples 
transduced with the MSCV-PURO-GATA-1s vector to exclude that the 
presence of a specific product was due to amplification of residues of 
contaminant gDNA. A positive control PCR was performed on the same 
amount of cDNA with β-actin primers (FWD- 
CTAAGGCCAACCGTGAAAAGTGAT; REV-CACAGCCTGGATGGCTACGT).  
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2.9. Gene expression analysis by qRT-PCR 
 
Quantitative RT-PCR (qRT-PCR) experiments were carried out in the ABI 
PRISM 7500 Sequence Detection System (Applied Biosystems). 
 
2.9.1. qRT-PCR reaction conditions 
 
 
Experiments described in this study were performed using both the Taqman® 
and the SYBR Green detection systems from Applied Biosystems, UK. 
The Taqman® probe-based chemistry employs a probe with a reporter 
fluorescent dye bound at the 5’ end and a quencher dye at the 3’ end. When 
bound to the target sequence, the probe (which anneals between primer sites) 
gets cleaved by the Taq polymerase present in the Master Mix, and the 
fluorescent signal from the reporter dye (previously reduced by the proximity 
with the quencher dye) greatly increases. Because an increased number of 
dyes are cleaved with each cycle, there is an increase in fluorescence 
intensity, which is proportional to the amount of amplicons produced during 
the PCR. This detection strategy is highly specific, and quick, because primers 
and probes are pre-designed. Assays chosen for the work described in this 
thesis produced amplicons of a size ranging between 60 and 150 nucleotides. 
Assay-on-demand® primers and probes used in this study are listed in table 
2.11. 
Gene   Assay ID 
Mouse GATA-1 Mm00484678_m1 
Mouse ETS-1 Mm01175817_m1 
Mouse Integrin alpha2b (CD41) Mm00439768_m1 
Mouse Pouf51 (Oct4) Mm00658129_gH 
Mouse GAPDH 4352932E 
Human GATA-1 At02279226_g1 
Human CD41 Hs00166246_m1 
Human GAPDH Hs99999905_m1 
 
Table 2.12. Taqman Assay-on-Demand  primers and probes used in this study. 
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Details of the qRT-PCR reaction performed with Assays-on-Demand kits are 
provided in the table below: 
Reaction component     Volume (µl) Final concentration 
2X TaqMan PCR Mix1 12.5 1X 
20X Assays-on-Demand Mix2   1.25 1X 
cDNA in sterile H2O Up to 25  - 
 
Table 2.13. Components of the Taqman qRT-PCR reactions.   1TaqMan PCR mix contains 
Amplitaq Gold polymerase, Gold Buffer, MgCl2 and dNTPs. 2Assays-on-Demand mix contains 
primers and a FAM-labelled probe at optimised concentrations. 
 
Thermal cycling conditions for qPCRs were: 95 ºC for 10 minutes, followed by 
40 cycles of 95 ºC for 15 seconds and 60 ºC for 1 min. 
The SYBR® Green dye binds to all double-stranded DNA; hence the 
fluorescent signal increases proportionally to the amount of double-stranded 
PCR products. Even if SYBR Green based detection is a cost effective 
approach, its major limitation is the presence of non-specific binding to 
unwanted PCR products, i.e. primer dimers or residual genomic DNA, when 
performing gene expression analysis. When using this platform, non-specific 
product formation needs to be checked to avoid false positives. Primers for 
experiments performed using the SYBR green detection system in this thesis 
were designed spanning large introns to avoid amplification of genomic DNA 
contamination. CG content of the primers was between 50 and 60%; 
sequences were chosen to avoid secondary structure formation. Melting 
temperature of the primers ranged between 58 °C and 63 °C and amplicon 
size was between 100 and 150 nucleotides. A list of the primers used in this 
study is given in table 2.15. Before being used in qRT-PCR reactions, primers 
were tested for their ability to amplify specific target sequences on control 
cDNA. Reaction setup and cycling conditions for RT-PCRs to test primers 
were as described in section 2.8.4.  
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Reaction components of the SYBR Green based qRT- PCRs were as follows: 
Component  Volume (µ l) Final concentration 
2X SYBR Green PCR Mix1 10 1X 
5 mM FWD/REV primers  
2.5 mM FWD/REV primers  
1.2 
1.2 
300 nM/300 nM 
150 nM/150 nM 
cDNA in sterile H2O Up to 20 µl  - 
 
Table 2.14. Components of SYBR Green qRT-PCR reactions. 1SYBR Green PCR mix 
contains Amplitaq Gold polymerase, Gold Buffer, MgCl2, dNTPs and SYBR Green dye. 
 
Mouse GATA2 Forward ACCACACTTGTTGCACAGC 
Mouse GATA2 Reverse GGGTGCTCCAGCAGCTGAG 
Mouse c-KIT Forward CTCACATAGCAGGGAGCACA 
Mouse c-KIT Reverse ACAACTCACCCACACGCATA 
Mouse FLK-1 Forward CTGAATGGCACCATGTTTTC   
Mouse FLK-1 Reverse CTGTTTGACCAGGCAATGTC 
Mouse SCL Forward  CAGCCTGATGCTAAGGCAAG   
Mouse SCL Reverse AGCCAACCTACCATGCACAC 
Mouse TIE-2 Forward GAAGTCGAGAGGCGATCCC 
Mouse TIE-2 Reverse GTTGACTCTAGCTCGGACTGT 
Mouse PECAM Forward AGAGACGGTCTTGTCGCAGT 
Mouse PECAM Reverse TACTGGGCTTCGAGAGCATT 
Mouse VEGF Forward CATAGAGAGAATGAGCTTCCTACAGC 
Mouse VEGF Reverse TGCTTTCTCCGCTCTGAACAAGG 
Mouse RUNX-1 Forward GGTGGAGGTACTAGCTGACCA 
Mouse RUNX-1 Reverse AGTGCCACCACCTTGAAAGC 
Mouse GAPDH Forward TCACCACCATGGAGAAGGC 
Mouse GAPDH Reverse GCTAAGCAGTTGGTGGTGCA 
Human GATA2 Forward CTGGCTCCCACCTTTTCG 
Human GATA2 Reverse CGTCCTTGTCCTCTCCTCG 
Human RUNX-1 Forward GATGGCACTCTGGTCACTGT 
Human RUNX-1 Reverse CTTTTCCCTCTTCCACTTCG 
Human c-KIT Forward TGACTTACGACAGGCTCGTG 
Human c-KIT Reverse AAATGCTTTCAGGTGCCATC 
Human GAPDH Forward GGTCATCCATGACAACTTTG 
Human GAPDH Reverse GCCATCACGCCACAGTTTC 
 
Table 2.15. Primers used for SYBR Green qRT-PCRs. 
 
Thermal cycling conditions for SYBR Green qPCRs were: 95 ºC for 10 mins, 
followed by 40 cycles of 95 ºC for 15 secs and 60 ºC for 1 min.  A dissociation 
stage was performed at the end of each run. Conditions used were: 95 °C for 
15 s, 60 °C for 30 s, then temperature was ramped up from 60 °C to 95 °C (at 
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the rate of 0.03 °C/s), and fluorescence intensity data were collected 
continuously over the ramping stage for 20 min.  
For all qRT-PCRs carried out, cDNA templates were diluted 1:5 in sterile H2O. 
10-fold serially diluted cDNA expressing the gene of interest were used as 
standards. 5 standards ranging in concentration from 100 (neat cDNA) to 0.1 
arbitrary units were set up for each primer pair. A non-template control (NTC) 
was always added and both standards and unknown samples were run in 
duplicates. The level of every gene of interest was normalized to an 
endogenous housekeeping control (usually GAPDH). An RT- control was 
added to each GAPDH run. An absence of amplification in the RT- control 
indicated absence of contaminant genomic DNA in the cDNA synthesized for 
that particular experiment. 
 
2.9.2. qRT-PCR data analysis 
 
 
Gene expression data were obtained in this thesis using the method of the 
absolute quantification with a standard curve. Data were analysed with the 
Software SDS version 2.1 (Applied Biosystems). 
A typical amplification plot of fluorescence signal versus cycle number 
obtained from a run is represented in Figure 2.2. 
In this plot, the threshold cycle (Ct) is the PCR cycle at which the fluorescence 
generated in a reaction exceeds the threshold. Therefore, it reflects a 
statistically significant accumulation of amplicons above the baseline, in a 
particular reaction well. Two manual adjustments were required in the 
amplification plot before analysis. These were an adjustment of the baseline 
fluorescence level (the background signal generated during the initial cycles of 
PCR before significant accumulation of the target amplicon has occurred) and 
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a manual positioning of the threshold bar at the beginning of the exponential 
region of PCR amplification. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. A typical output obtained by the ABI PRISM 7500 Sequence Detection System 
(Applied Biosystems). Amplification plot shows number of cycles on the x-axis and 
fluorescence intensity on the y-axis. Ct (cycle threshold) value is defined as the number of 
cycles required for the fluorescent signal to cross the threshold (or background fluorescence 
level). Using the Ct value for each unknown and parameters deduced by the equation of the 
standard curve, the SDS software calculates the amount of target mRNA/cDNA present in each 
‘unknown’ sample. 
 
The standard curve plot was then visualized to ensure that all of the Ct values 
for “unknowns” fell within the boundaries of the standard curve. The equation 
for the standard curve was: y  = mx + b, where b denotes the y intercept of 
the standard curve line, and m represents the slope of the standard curve. b 
and m were then used by the software to calculate the amount of target 
mRNA/cDNA present in each ‘unknown’ sample as follows: 
1. [Ct value of ‘unknown’ – b] / m = log input amount of the target mRNA/cDNA 
2. 10^[log input amount] = input amount of the target mRNA/cDNA 
3. Sum of input amounts for ‘unknown A’/ number of replicates for ‘unknown A’  
= average input amount of target mRNA/cDNA in ‘unknown A’ 
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The average input amount of the mRNA/cDNA of interest for each ‘unknown’ 
was then divided by the average input amount of the endogenous control 
(GAPDH) for that ‘unknown’ sample. This gave the normalised amount of the 
mRNA/cDNA of interest present in each ‘unknown’ sample.  
Melting curve analysis was performed according to the dissociation stage data 
and only reactions with a single peak at expected melting temperature (Tm) 
were considered for further analysis. This allowed to determine the specificity 
of an amplification product and to distinguish specific PCR products from 
primer dimer products (which have a comparatively lower Tm than the 
amplicons). 
2.10. JAK3 mutational analysis on primary samples 
 
 
2.10.1. Patient samples 
 
 
The sequencing project on DS-AMKL and DS-TMD patients was approved by 
the North East London Health Authority’s Ethical Committee. Samples were 
surplus clinical or archived material collected by the tissue bank of the Italian 
National Association for Pediatric Haematology-Oncology and the Italian 
National Down’s Syndrome Association (samples kept by the team of Galliera 
Genetic Bank, http://ggb.galliera.it/). The tissue banks obtained informed 
written consent for all subjects included in this study. Details about the 
patients are presented in Chapter IV.2. Every patient included in the study had 
constitutional trisomy 21, and all had acquired mutations in GATA-1. 
 
2.10.2. JAK3 mutational analysis 
 
 
 
RT-PCR was performed with 1 µl of random primed cDNA using 5 pairs of 
overlapping primers, spanning the JAK3 coding sequence (table 2.16). 
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cDNA Forward Primer cDNA Reverse Primer 
C1F-CGCCCTTCGAAAGTCCAGG  C1R-CCAGGTCCATGATGTACTTG 
C2F-TGATCCAGGGCCTGAGCTTC C2R-CAGGAAGTGAGGGTCACTGC 
C3F-CCACAGGAACCTTCCTTCTG C3R-CCCACTTGTCAGCTTCCAAG 
C4F-CTGTGTTAAGCCTGGAGATG C4R-CGAGGAATAGAGAAGGAGGC 
C5F-GTCATGGAGTACCTGCCCAG C5R-GTAGAGGACCCTCATAAGGC 
 
Table 2.16. Primers used for JAK3 cDNA sequencing. Primers were designed to span the 
entire coding sequence of JAK3. 
 
Amplification of the 24 exons of JAK3 was performed by PCR with 5-10 ng of 
gDNA using 15 pairs of primers as indicated in the following table: 
 
Exon  
 
Forward Primer 
 
Reverse Primer 
 
1 ACTTTCGGTAAATGACAGTGG AGCCTTTGCCCTGGCAGCAC 
2 and 3 CCCTGCTCAGAAGTCCAATC TGGGCACCTCGAAATGCAAG 
4 and 5 ATAATGTCACTCCTACTGAGG GAAAGCTTGCAGGAGAACTC 
6 CAGCTAAAAGGCCTGTGGG CCCACTTCCCCAAGTCTTTC 
7 and 8 CCACTTCGGTACTCCCCCTC AGGGCTCCTGGAAGGTGAG 
9 GAGGTACCTGAATTTGAGCC CAGGAACCAAATGCTGACTG 
10 TGTCTGTCGCTCAGTCCCAC ACTTGCCACCCACACAGGAG 
11 and 12 CTCAAACTAAGGCATGAGTTAG ATTTCTCTGCATCCACGACC 
13 GGGCCAAAGGTGACCTGTG TATAGCGGCTCAGAACAGAG 
14 CAGGGTGTTGGCAGAACCTC CTCCTATGCATACTACAGAGC 
15, 16 and 17 GATGCTGGAGCATGTCTGAG GCTGCAAACCACGCTCCTTC 
18 and 19 TGCACAGCAAGTCAACTCAG TTCCCAGCCTACCTAAAGTG 
20 and 21 TCGAGAGGGACACAAGGTCC GCTAAGGCTGGGGAGCAAAG 
22 and 23 GACCAGTTCCCCATTCCAAG TCAGTACAGAGACTCAGGCG 
24 CGCTGAATGGGAGTTGTGTC CTACATGAATGTCCCCATTG 
 
Table 2.17. Primers used for JAK3 genomic sequencing.  Primers were designed to cover 
the 24 exons of the human JAK3 gene. 23 of these exons are coding. 
 
PCR conditions were: 7.5 mins at 95 ºC; 35 cycles of 30 seconds at 95 ºC, 30 
seconds at 58 ºC, and 1 min at 72 ºC; followed by 10 min at 72 ºC. DNA 
preparation before sequencing and sequencing analysis were performed as in 
2.7.2. Sequences were analysed using the Chromaslite201 software, 
Technelysium Pty, LTD. 
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Selected PCR products were cloned into the pCR-TOPO 2.1 vector using the 
TOPO-TA cloning kit (Invitrogen, K2000-01). Ligation reaction and 
tranformation of the One Shot competent cells were performed according to 
the manufacturer’s instructions. Ten light blue colonies per plate were 
screened by PCR to check for the presence of the insert. PCR products of the 
right size were then sequenced to identify the nature of the mutation cloned.  
2.11. Statistical analysis   
Statistical analysis on parametric data was performed in this thesis using the 
Student’s t-test function of Excel, Microsoft. T-tests carried out were unpaired 
tests, with a two-tailed distribution.  
Differences in the level of expression of haematopoietic genes in primary 
samples were assessed using the two-sided Wilcoxon's signed ranks test. For 
determining the correlation between certain measured variables (see Chapter 
III.2), Pearson correlation coefficients (r values) were calculated using the 
StatsDirect software. Directional and non-directional probability values for the 
statistical significance of r were given by the analysis tool. The non-directional 
probability was used in this thesis as it allows for the significance of either a 
positive or a negative correlation to be assessed, and is more stringent than 
the directional probability.  
Fisher's exact test was used to assess statistical significance of categorical 
data. A 2x2 contingency table was built and a Fisher two-sided test was 
performed using the StatsDirect (StatsDirect, Ltd) software. 
For every type of statistical analysis, probability values (p values) of 0.05 or 
less (<0.05) were considered to be statistically significant. In graphs of this 
thesis, p values between 0.05 and 0.01 are denoted with *, p values between 
0.01 and 0.001 with **, p values = or < 0.001 with ***.  
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2.12. Declaration of individual contribution and authenticity 
of the work presented in this thesis   
The work presented in this thesis was entirely carried out by the author at the 
ICMS, Queen Mary University of London, England, with the following 
exceptions. Flow-cytometry experiments and analysis of data were performed 
under the supervision of Dr. Gary Warnes at the Flow Cytometry Facility of the 
ICMS, QMUL, London. Dr. Gary Warnes and Miss Sandra Martin performed 
cell sorting for experiments presented in 3.I.3 at the FACS facility of the ICMS, 
using a FACSAria (BD Biosciences) instrument. Dr. Frederic Delom performed 
nuclear extracts preparation for the western blot experiment presented in 
Figure II.9C. Constructs used for retroviral transduction of ES cells were 
cloned by Dr. Jurgen Groet. Strategy for the cloning and information about the 
vectors are included in Appendix I. Dr. Groet also analysed CGH array data 
for the panel of transchromosomic ES cells included in the experiments 
showed in II.4.  
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3. Results  
I. Effects of trisomy 21 on megakaryocytic 
differentiation of ES cells   
In vitro production of blood cells of different lineages from both mouse and 
human ES cells has been successfully achieved using the EBs formation 
system, as well as employing a coculture approach with stromal cell lines 
(Olsen et al., 2006).  
Differentiation of mouse ES cells with either of these two approaches leads to 
the production of a relatively homogenous population of blood cells of different 
lineages upon addition of lineage-specific cytokines.  
The data shown in this chapter were generated adopting an established 
system to obtain a population of megakaryocytes/megakaryocytic precursors 
from mouse ES cells (Era et al., 2000; Eto et al., 2003). The experimental 
approach I used has been previously employed to study the formation of 
platelets and the biology of megakaryocytes (Eto et al., 2002), and is based on 
the coculture of ES cells with the mouse stromal cell line OP9. OP9 cells are 
derived from the op-/op- mice. Due to a mutation in the coding region of the 
macrophage colony-stimulating factor (M-CSF) gene, these mice are defective 
in osteoclast formation, resulting in bones that lack the bone marrow cavity. 
When stromal cell lines other than the OP9 are used, differentiation of mouse 
ES cells is drastically shifted toward macrophages, with an inhibition of other 
haematopoietic lineages (Borzillo et al., 1990). In contrast, OP9 stromal cells 
support efficient production of blood cells of all different lineages. 
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Previous studies have demonstrated that upon withdrawal of LIF, mouse ES 
cells seeded onto OP9 stromal cells form mesodermal colonies containing 
HSCs/immature haematopoietic precursors within five days (Nakano et al., 
1994). If left on the same stromal layer, differentiating ES cells tend to get 
buried underneath the feeder layer. After a trypinization step and replating 
onto fresh OP9, cells within the mesodermal colonies become less firmly 
attached to the stromal layer and more circularly shaped. At this stage, without 
the addition of any cytokines, the colonies almost exclusively consist of HSCs. 
Upon addition of lineage-specific recombinant cytokines, generation of blood 
cells of specific lineages is greatly enhanced. Differentiated cells of the 
desired lineage appear to detach from the feeder layer and can be collected 
and used for further analysis. 
The established cocktail of cytokines to obtain megakaryocytes from mouse 
ES cells seeded onto OP9 cells include mouse recombinant thrombopoietin 
(TPO), which acts through the Mpl receptor and stimulates late differentiation 
of megakaryocytes and production of platelets, and mouse IL-6 and human IL-
11, which both have pro-survival effect on the differentiating cells (the use of a 
human cytokine is based on the high inter-species homology of these 
glycoproteins and on previous studies testing its effects on differentiating 
mouse ES cells). The addition of the IL-6 and IL-11 has been shown to be 
dispensable for obtaining a good in vitro differentiation of the mouse ES cells, 
but it promotes the survival of the cells and was included in all of my 
differentiation experiments (Eto et al., 2003).  
Because of the megakaryoblastic nature of DS-TMD and AMKL, I decided to 
investigate developmental phenomena associated with megakaryocytic 
differentiation of mouse ES cells containing an extra copy of HSA21. Several 
genes present on HSA21 (most notably RUNX-1, but also ERG and ETS-2) 
have a specific effect on proliferation/differentiation of megakaryocytes (as 
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discussed in 1.4.5). I therefore aimed to investigate whether trisomy 21 would 
cause abnormalities in the megakaryocytic compartment using the 
transchromosomic model. The working hypothesis was that an extra copy of 
HSA21 causes an abnormal proliferation of the megakaryocytic lineage, which 
underlies the differentiation arrest caused by GATA-1 mutations in DS-
leukaemia. To test this hypothesis, I compared megakaryocytic differentiation 
of the transchromosomic ES cells 47-1 (which previous data have shown to 
contain virtually the entire chromosome 21, see (Hernandez et al., 1999; 
Mensah et al., 2007; Canzonetta et al., 2008)) to the parental ES cell line D3 
from which the 47-1 were derived. 
Taking into account the peculiar cooperation between trisomy 21 and GATA-
1s in the malignant transformation of DS-leukaemia, I also wanted to establish 
an in vitro model to study this interplay. Experimental evidence to address 
these points is presented in this chapter.  
I.1. Terminal megakaryocytic differentiation is not impaired 
by the presence of an extra copy of HSA21  
 
Several factors can influence mouse ES cells behaviour in culture, such as the 
type of reagents employed, the use of a supportive feeder layer, and the 
maintenance of the ES cells at an ideal, constant confluence.  
All of the experiments described in this thesis were performed using serum 
that was batch-tested for ES cells. Batches of foetal calf serum were routinely 
screened in our laboratory for their capacity to maintain ES cells in a 
pluripotent state, as judged by morphological appearance of the cells and by 
transcriptional levels of at least one pluripotency factor (routinely OCT-4). 
Several batches of serum were also tested for their capacity to support optimal 
growth of OP9 stromal cells and to induce ES cell differentiation into 
mesodermal colonies.  
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 A preliminary assessment of the efficiency of the differentiation protocol used 
for the set of experiments described in this chapter was obtained by 
performing acetylcholinesterase (AchE) staining on the cells. Figure I.1 
represents morphology of the undifferentiated ES cells under standard culture 
conditions and AchE staining performed on megakaryocytic 
precursors/megakaryocytes derived from ES cells after 13 days of culture on 
the OP9 cells with the addition of recombinant TPO and other cytokines. 
Mouse megakaryocytes or precursors that express AchE have brown granular 
deposits of copper ferricyanide in the cytoplasm resulting from the enzymatic 
reaction, and they appear brown. 
 
 
 
 
 
 
 
 
Fig. I.1.  Morphology of undifferentiated ES cells (A) and megakaryocytes (B, C) obtained 
from in vitro differentiation of mouse ES cells stained with Acetylcholinesterase staining. 
Pictures were taken at 20x magnification. C shows a large megakaryocyte (stained brown) with 
multiple lobules in the nucleus and ferrous deposits in the cytoplasm. Picture was taken at 40x 
magnification. 
 
I.1.1. CD41 expression and ploidy of MKs are not altered by the 
presence of an extra copy of HSA21 
 
In order to quantify the efficiency of the differentiation protocol, a fluorescence-
activated cell sorting (FACS) staining for the megakaryocyte-specific surface 
marker CD41 was performed on MKs at day 13 of the protocol. The number of 
CD41 positive cells in three independent differentiation experiments did not 
show a significant difference between D3 and 47-1. 
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Fig. I.2. CD41 expression in MKs/MK progenitors derived from D3 and 47-1. A. Histogram 
plots of the FACS measurement of CD41-FITC in MKs/MK progenitors derived from D3 and 47-
1 at day 13 of the differentiation protocol. Black lines indicate the isotype control, red lines the 
FITC-CD41 expression. Data were collected on a LSRII FACS instrument (BD Biosciences); 
results were analysed with the FlowJo software version 8.1. One representative experiment is 
shown for each cell line. B. Average percentage of cells expressing CD41-FITC within the gated 
population (main gate was placed to exclude death cells) in three independent experiments. 
Error bars indicate s.e.m.  
 
An example of the FACS staining for each cell line and a bar graph showing 
the mean percentage of CD41 positive cells are showed in Figure I.2 
In addition to the expression of specific surface markers (such as CD41, CD42 
and CD61), before releasing platelets MKs become increasingly bigger and 
undergo several rounds of DNA replication without cell division. This 
phenomenon, called endomitosis, is responsible for the increased DNA 
content (ploidy) of these cells (Ravid et al., 2002). To investigate the nature of 
the cells derived from the differentiation protocol, I performed an analysis of 
the DNA content of the in vitro derived CD41 positive MKs. CD41+ sorted cells 
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were fixed and stained with a nuclear dye (propidium iodide) to determine their 
DNA content. The average percentage of endomitotic cells, as judged by the 
number of cells with a DNA content of 8n and 16n, was comparable between 
the populations derived from the D3 and the 47-1 cells, as shown in Figure I.3. 
MKs isolated from mouse or human bone marrow usually display even higher 
classes of ploidy (32n, 64n and sometimes even up to 128n), however in this 
set of experiments the population analysed contained cells at non-
synchronous stages of maturation and OP9 stromal cells derived from 
previous steps of the protocol, making it difficult to detect the low number of 
cells with higher classes of ploidy. Maintaining the differentiating cells in 
culture for longer might have been a way to address if more immature 
progenitors would have eventually reached higher classes of ploidy, but the 
viability of the cultures tends to decrease after 13 days. 
The conclusion from these experiments is that in vitro generation of MKs is 
generally unaffected by the presence of an extra copy of human chromosome 
21, and proceeds at the same rate in transchromosomic and WT cells. 
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Fig. I.3. DNA content analysis in CD41 positive cells derived from D3 (pink bars) and 47-1 
(green bars).  A, Histogram plots of the DNA content in the two populations. Propidium iodide 
staining intensity is represented on the x-axis; number of events acquired is plotted on the y-
axis. The bar graph in B represents the mean percentage frequency of cells with a DNA content 
of 8n or 16n in three independent experiments. Error bars indicate s.e.m. No significant 
differences were detected in the distribution of ploidy of MKs/MK progenitors derived from D3 
and 47-1 at day 13 of the differentiation protocol. 
 
 
I.1.2. Effect of trisomy 21 on the molecular signature of megakaryocytic 
differentiation of ES cells 
 
To identify the molecular differences, if any, between the 47-1 
transchromosomic cells and the D3 parental cells during megakaryocytic 
differentiation, I took advantage of the differentiation protocol based on the 
OP9 stromal cell line, which allows for the harvesting of cells at different 
stages of megakaryocyte development. I then analysed the expression levels 
of various markers to uncover any differences between 47-1 and D3 cells at 
specific time points along the megakaryocytic differentiation program.  
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Fig. I.4. A molecular signature of megakaryocytic differentiation in D3 and 47-1. Mean 
mRNA levels of OCT4, CD41 and ETS-1 relative to GAPDH are indicated in this figure. No 
significant differences were detected between levels of the analysed markers during 
megakaryocytic differentiation (at day 5, day 8, and day 13 after initial seeding of the ES cells 
on the OP9 stromal cells) in D3 (red) and 47-1 (blue) derived populations. Levels of OCT4 (a 
pluripotency marker) are expressed as fold change of levels at day 0 (undifferentiated ES cells), 
whereas other markers are normalized to day 5, when their expression becomes detectable. 
Bar graphs show the average fold change of mRNA levels divided by GAPDH in 4 independent 
experiments. Error bars indicate s.e.m. 
 
Markers analysed in this set of experiments included: ETS-1, a transcription 
factor known to activate megakaryocyte-specific gene expression programs 
(Jackers et al., 2004; Pang et al., 2006), CD41, a megakaryocyte and platelet-
specific surface antigen, and OCT4, a pluripotency transcription factor whose 
expression declines upon in vitro differentiation of mouse ES cells. Gene 
expression analysis was performed using the Taqman chemistry and 
primers and probes from Applied Biosystems. Expression levels of mOCT4, 
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mETS-1, and mGPIIB (CD41) in the 47-1 transchromosomic ES cell line and 
in the D3 parental line are shown in Figure I.4. Details of qRT-PCR analysis 
performed with the SDS software version 2.1 by Applied Biosystems are 
discussed in 2.9. The average quantity of mRNA for each gene of interest in 
duplicate samples was divided by the level of mRNA of the housekeeping 
gene GAPDH for each time point. Results in the bar graphs are expressed as 
fold change of the average level of these values above a baseline (day of 
differentiation in which the expression of the gene of interest becomes 
detectable) set as 1. For OCT-4, data are presented as fold change relative to 
day 0, where the expression of this pluripotency marker is the highest. Graphs 
report the results from four independent experiments. Error bars indicate 
standard error of the mean (s.e.m). Data presented here indicate that by day 
13 of the differentiation protocol, both D3 and 47-1 (transchromosomic ES 
cells) derived populations lost pluripotency (as indicated by the reduction in 
mRNA levels of OCT4), and achieved an efficient megakaryocytic 
differentiation (as indicated by the progressive expression of ETS1 and 
CD41). No significant differences were observed between the two populations 
in the levels of the MK specific genes CD41 and ETS-1, confirming that, at a 
molecular level, programs specifying megakaryocytic differentiation are not 
perturbed by the presence of an extra copy of HSA21. 
 
I.1.3. Human specific gene expression during megakaryocytic 
differentiation of the transchromosomic ES cells 
 
 
Retention of the human chromosome in the mouse ES cell system was 
confirmed in the 47-1 ES cells used in this study by FISH analysis and human 
specific PCRs on genomic DNA or cDNA performed by Hernandez et al. 
(Hernandez et al., 1999). Unpublished data from Jurgen Groet et al. have also 
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provided a fine map of the content of these ES cells based on high resolution 
CGH array analysis. In the experiments described in this thesis, 
undifferentiated 47-1 ES cells were cultured under continuous selection with 
G418 to ensure retention of human chromosome 21. Furthermore, cells were 
defrosted right before starting an experiment, avoiding prolonged maintenance 
in culture. Previous data have showed that chromosome 21 is maintained in 
the undifferentiated mouse ES cell lines for up to 6 passages, even without 
selection (Afua Mensah, PhD Thesis, University of London).  
To investigate if human specific genes were expressed in the 
transchromosomic model during megakaryocytic differentiation, I performed 
an RT-PCR analysis using human-specific primers. Primers were chosen in 
non-conserved regions to specifically amplify the human mRNA for RUNX-1 
and DYRK1A. Both genes are expressed during megakaryocyte differentiation 
(Kyttala et al., 2009; Huang et al., 2009a), therefore I postulated that (if the 
chromosome was properly retained) their expression was likely to be driven 
from the human chromosome during megakaryocytic differentiation of the 
transchromosomic system.  
Figure I.5 shows that the primers used for this analysis were human specific, 
and that both hRUNX-1 and hDYRK1A mRNA were transcribed from the 
human chromosome throughout megakaryocytic differentiation. The presence 
of at least two human-specific mRNAs during megakaryocytic differentiation of 
the transchromosomic system is indicative of a good retention of the 
chromosome despite the absence of selection during the differentiation 
protocol. It is also a proof of principle that human genes are expressed in the 
mouse background and might exert their influence as supernumerary copies 
during the megakaryocytic differentiation process, mimicking the presence of 
the third copy of genes on HSA21 seen in Down syndrome. 
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Fig.I.5. Human-specific gene expression during megakaryocytic differentiation of the 
transchromosomic system. Human-specific primers do not show cross-amplification with 
cDNA from the mouse erythroleukaemia cell line MEL, but specifically amplify the human 
RUNX-1 in cDNA derived from the human cell line K562 (upper panel), Lower panels show 
human RUNX-1 and human DYRK1A expression during megakaryocytic differentiation of the 
transchromosomic ES cells. NTC indicates non-template control Human-specific primers were 
designed to span two exons to minimize risk of amplifying contaminant gDNA. PCR products 
were run on a 2% agarose gel and visualized by ethidium bromide staining. 
 
I.1.4. GATA-1 mRNA levels are increased in transchromosomic ES cells 
compared to the euploid control during megakaryocytic differentiation 
 
Because GATA-1 is a master regulator of megakaryocytic differentiation, and 
mutations of this gene leading to the exclusive production of GATA-1s are 
associated with the development of TMD/AMKL in DS, I sought to analyse 
GATA-1 levels during megakaryocytic differentiation of the 47-1 ES cells. 
Levels of GATA-1 mRNA were quantified using the Taqman chemistry and 
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primers and probes from Applied Biosystems. Results are presented as in 
I.1.2.  Figure I.6A shows that levels of GATA-1 are increased during 
megakaryocytic differentiation in the transchromosomic system compared to 
the parental cell lines. This increase is statistically significant at day 8 
(unpaired t-test, p-value = 0 .007); a near significant trend is also observed at 
day 13 (unpaired t-test, p-value = 0.06). Next, I asked whether the increase in 
GATA-1 mRNA levels in 47-1 was due to the presence of a shorter transcript 
(GATA-1s) or to the exclusive presence of the GATA-1 full-length transcript. 
Panel B of Figure I.6 shows that in both D3 and 47-1 cells GATA-1 mRNA is 
only present as a full-length transcript during megakaryocytic differentiation. 
These data suggest that the presence of one (or more than one) gene on 
HSA21 might trigger an abnormal expression of GATA-1 during 
megakaryocytic differentiation of the transchromosomic system. 
 
Fig. I.6. GATA-1 mRNA levels during megakaryocytic differentiation of D3 and 47-1 cells. 
Panel A represents fold change of mean GATA-1 mRNA normalized to the housekeeping gene 
GAPDH, relative to day 5, as detected by qRT-PCR on D3 (red) and 47-1 (blue) cells during 
megakaryocytic differentiation. Graph bar represent average fold change of mRNAs levels 
divided by GAPDH in 3 independent experiments. Error bars indicate s.e.m. Panel B shows RT-
PCR products on a 1.2% agarose gel visualized by ethidium bromide staining. Primers used for 
RT-PCR analysis flank GATA-1 exon 2, therefore they would detect the presence of the short 
transcript (GATA-1s) arising as a consequence of splicing events affecting exon 2, which are a 
frequent finding in human DS-TMD and AMKL samples. Insertions or deletions in the genomic 
sequence of GATA-1 exon 2 would result in an altered size of the amplicon generated by these 
primers.  
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GATA-1 specifies megakaryocyte identity, but the increased levels of GATA-1 
mRNA did not translate into an increased number of MKs (CD41+ cells in 
Figure I.2) derived from the trisomic cells, suggesting that the observed 
phenotype might reflect cell-intrinsic mechanisms, rather then being the 
consequence of an increased number of cells expressing GATA-1. 
I.2. MKs and MK progenitors derived from transchromosomic 
ES cells generate a bigger number of large TPO-dependent 
colonies than parental ES cells 
 
The clonogenic potential of MK progenitors/megakaryocytes derived from 47-1 
transchromosomic ES cells and the D3 parental cell line was assessed using 
a collagen-based colony-forming assay (colony forming unit megakaryocytes, 
CFU-MK). An equal number of progenitors/MKs was seeded into semisolid 
medium supplemented with recombinant TPO (50 ng/ml) and collagen and 
colonies were scored after 10 days. Addition of collagen to the semisolid 
medium allows for the fixing of cells and staining with AchE (a megakaryocyte-
specific staining), making morphology of the colonies and of individual cells 
within colonies more easily recognisable. A positive colony was judged by the 
presence of at least 3 cells stained for AchE (brown). The number of positive 
colonies formed by an equal number of progenitors (1x105 cells) derived from 
47-1 transchromosomic cells and the D3 parental cells was not significantly 
different in four independent experiments, each performed in duplicate slides 
(Figure I.7A). Despite the fact that the size of the colonies was extremely 
variable, even within a single chamber, there was a clear tendency of the 
colonies derived from 47-1 cells to be larger and to contain fewer AchE-
positive cells than D3-derived colonies. Figure I.7B shows representative 
pictures of colonies derived from D3 and 47-1.  
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Fig. I.7. CFU-MK assay for D3 and 47-1 derived progenitors. A. Average number of AchE 
positive colonies/100,000 cells in 4 independent experiments. Error bars indicate s.e.m. 
Colonies were scored 10 days after initial seeding. B. Representative images of colonies 
derived from D3 and 47-1. Pictures were taken at 20x magnification. 
 
To quantify the observed phenotype, colony size was calculated using images 
of sequential fields spanning the entire slide captured at 20x magnification, 
and examined using the Leica QWin Software. Manual tracing of the perimeter 
of each positive colony was performed, and the area of individual colonies was 
automatically calculated by the software in square pixels (pp2). The average 
area of the colonies is shown in Figure I.8A.  To examine the distribution of the 
size of the colonies, data were organized into three arbitrary categories: small 
colonies (2000-15,000 pp2), medium colonies (15,000-50,000 pp2) and large 
colonies (>50,000 pp2).  
The probability of forming large rather than small colonies was significantly 
higher for the MKs derived from 47-1 than for the D3 derived ones (Pearson 
X-square test, p value = 0.002487). Figure I.8.C shows a dot plot of the size of 
the large colonies derived from D3 and 47-1 cells in four independent 
experiments each performed in duplicate.  The average number of large 
colonies derived from each of the two populations in 4 independent 
experiments is indicated in bar graph I.8B. Error bars represent s.e.m. of 4 
experiments. 
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Fig. I.8. CFU-MK assay for D3 and 47-1 derived progenitors. Panel A indicates the average 
size of all of the colonies formed from D3 and 47-1 derived MK progenitors/MKs in 4 
independent experiments, each performed in duplicate. Area of the colonies was quantified 
using the Leica QWin software and is indicated in pp2. Error bars indicate s.e.m. Panel B shows 
the average number of large colonies in 4 independent experiments. Error bars indicate s.e.m. 
The average number of large colonies was significantly higher in 47-1 compared to D3 
(unpaired t-test, p-value=0.02).  Panel C is a dot plot showing the number and the size of the 
large colonies (size > 50,000 pp2) in 4 independent experiments. 
 
 
These results indicate that the presence of an additional copy of HSA21 in 
megakaryocytes derived from mES cells confers the potential to form larger 
colonies upon TPO-dependent growth conditions. 
 
 
I.2.1. Large colonies derived from transchromosomic ES cells do not 
harbour GATA-1 mutations 
 
Transchromosomic-derived MKs or MK progenitors form bigger colonies 
containing fewer AchE-positive cells than the control colonies. This 
phenomenon is suggestive of an abnormal tendency of the MKs and MK 
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progenitors derived from 47-1 to proliferate rather than to differentiate after 
day 13 of the differentiation protocol. Li et al. (Li et al., 2005) described a 
similar phenotype in a knock-in mouse model bearing a GATA-1Δe2 allele, 
which exclusively expresses the GATA-1s protein. Foetal liver progenitors and 
differentiating ES cells from this model cultured with TPO produced 
hyperproliferative MK colonies compared to the wild type GATA-1 expressing 
controls.  To exclude that the phenotype observed in the 47-1 derived colonies 
was caused by acquired mutations of GATA-1, leading to the expression of 
GATA-1s, gDNA extraction and sequencing analysis of GATA-1 exon 2 was 
performed on 10 large (“hyperproliferative”) colonies derived from 47-1 cells 
and 10 colonies derived from the D3 parental cells (as a control). 
Due to the limited amount of material available for gDNA extraction, and the 
nature of the material itself (colonies had been fixed and stained with AchE), 
this procedure required a few optimisation steps. Several gDNA extraction 
methods were tested, including phenol-chloroform based methods and 
commercially available kits, but none of them yielded amplifiable gDNA. 
Ultimately, a mechanical lysis of the colonies scraped off the slide directly in 
PCR buffer, followed by treatment with proteinase K, gave an amplifiable 
product. Once an extraction method was established on test samples, PCR 
and sequencing analysis were performed on 10 large colonies from 47-1 cells 
and on 10 control colonies derived from D3 cells using primers spanning 
GATA-1 exon 2 (Figure I.9A, 1.9B). None of the colonies showed mutations in 
the GATA-1 exon 2, suggesting that the phenotype observed in the large 
colonies derived from 47-1 cells was entirely independent from the production 
of GATA-1s, and most likely caused by a gene dosage imbalance due to the 
presence of an extra copy of HSA21 in the transchromosomic system. 
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Fig. I.9. gDNA extraction and GATA-1 sequencing analysis from hyperproliferative 
colonies. gDNA was extracted (after fixing and staining with AchE) from hyperproliferative 
colonies using a direct lysis in PCR buffer. Panel A shows efficient amplification obtained from 
colonies of 50-100 cells using GATA-1 exon 2 primers. PCR products were run on an on a 1.2% 
agarose gel and visualized by ethidium bromide staining. Panel B shows an example of 
electropherogram obtained from GATA-1 exon 2 sequencing of D3 and 47-1 colonies. No 
mutations were detected in GATA-1 exon 2 in either the 47-1 transchromosomic derived 
colonies or the D3 derived controls. 
 
I.3. Investigating the effect of GATA-1s on megakaryocytes 
derived from the transchromosomic system 
 
After having established that 1) transchromosomic ES cells can differentiate 
into megakaryocytes in vitro, 2) terminal megakaryocytic differentiation is not 
impaired by the presence of an extra copy of human chromosome 21, and 3) 
transchromosomic ES cells form “hyperproliferative” megakaryocytic colonies 
independently of overt GATA-1 mutations, I sought a way to investigate the 
oncogenic cooperation between GATA-1s and trisomy 21.  
I therefore decided to genetically manipulate the transchromosomic ES cells 
and the parental control to force the expression of GATA-1s. The purpose of 
the experiments described in this subchapter was to investigate whether the 
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known hyperproliferative effect of GATA-1s overexpression during 
megakaryocytic differentiation (Li et al., 2005) was exacerbated by the 
presence of an extra copy of chromosome 21 in the transchromosomic model. 
Due to the nature and the length of the differentiation protocol, I needed to 
generate a stable system capable of ensuring expression of GATA-1s from the 
undifferentiated stage throughout the entire process of generation of MKs/MK 
precursors. To achieve this, I chose to adopt a well-established system of 
gene transfer, retroviral transduction. Retroviruses are a powerful vehicle of 
gene delivery into dividing mammalian cells, and they can achieve high levels 
of expression through the stable integration of their genome into the one of the 
target cell (Yang et al., 1999).  Efficiency of the transduction, which is 
mediated by an interaction of the viruses with specific receptors on the cell 
surface, is essential to achieve stable integration and subsequent expression.  
Despite the advantage of using this system, certain cell types are notoriously 
less susceptible to infection with retroviruses. ES cells, in particular, are quite 
difficult to infect. Furthermore, even after integration, ES cells tend to 
transcriptionally silence integrated viral DNAs (Wolf and Goff, 2009). 
Therefore, the choice of a retroviral vector that contains a promoter that will 
not be repressed after integration is crucial for achieving an efficient 
expression of the gene of interest. This is the reason why (for this set of 
experiments) I utilised the retroviral vector MSCV, which contains a 5’ LTR 
(Long Terminal Repeat) promoter that enhances transcriptional activation and 
prevents transcriptional repression in ES cells. GATA-1s-FLAG tagged cDNA 
was cloned into the MSCV-PURO backbone (Clontech), and the MSCV-PURO 
was used as a control. Full details of the vectors used in this chapter can be 
found in Appendix 6.1.  
Retroviral particles to be used for transduction of target cells not only need the 
viral genome, but also the viral-specific proteins (gag, pol and env) to ensure 
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the appropriate infection, reverse transcription and integration of the viral 
genome into the DNA of the host cell. The most common way of producing 
retroviruses is by transient transfection of a retroviral vector and of the viral 
components gag, pol and env into the 293T cell line. This cell line is very easy 
to transfect by standard lipid-based methods and can produce high virus titers 
after transfection. To optimise the efficiency of infection of the ES cells, I 
tested different conditions to produce retroviruses to transduce readily 
infectable target cells (NIH3T3, a mouse fibroblast cell line). All the 
optimisation experiments (see Figure I.10 for a schematic view of the 
conditions tried) were carried out using a retroviral vector (MIG) containing no 
insert, but carrying a green fluorescent protein (GFP) tag. 
The first approach I used was based on a triple transfection of the viral 
components (gag-pol and env vectors) and the MSCV-IRES-GFP (MIG) 
retroviral vector into 293T cells. Details of the constructs are provided in 
Appendix 6.1. Infection was carried out by overnight incubation of the retroviral 
supernatant, generated by transfection of a confluent 10 cm dish of 293T cells, 
with adherent NIH3T3 in exponential growth phase. Polybrene at the 
concentration of 4 µg/ml was added to enhance infection. Fortyeight hours 
after the infection, cells were analysed by FACS for GFP expression. Only 
15% of the NIH3T3 analysed were positive (Figure I.11A). I therefore decided 
to employ an alternative approach, based on the use of a “packaging” cell line. 
The vast majority of packaging cell lines has been generated by stable 
transfection of plasmids containing viral elements (gag-pol and env) into 293T 
cells. 
The packaging cell line (“PLAT-E”) I used in this study was a kind gift from T. 
Kitamura (Morita et al., 2000). Compared to other packaging cell lines, PLAT-
E express viral structural proteins at high levels because of the substitution in 
the viral packaging constructs of the MMuLV-LTR promoter with EF1α, which 
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is almost 10 fold stronger than MMuLV-LTR in 293T cells. Furthermore, I 
chose to utilize the PLAT-E for safety reasons, as they produce ecotropic 
viruses capable of infecting mouse cells only. Upon transient transfection of 
the MIG vector into a confluent 10 cm dish of PLAT-E cells, and infection 
performed in the same conditions as described above, the percentage of GFP-
positive cells was still 18% (Figure I.11B). Because of the equivalent results 
given by the two described methods, I decided to use the packaging cell line 
PLAT-E, and to further optimise the conditions of infection. 
The conditions that gave the highest percentage of infection for the NIH3T3 
cells utilised virus-containing supernatant from a 10 cm dish collected 48 
hours after the transfection of the MIG vector into PLAT-E cells. Supernatant 
containing viral particles was centrifuged at room temperature for 45 minutes, 
together with NIH3T3 cells in a six-well plate (“spinfection”). Twenty-four hours 
later, fresh supernatant collected from PLAT-E cells (i.e., at 72 hours after the 
original transfection) was added to the NIH3T3 that had been “spinfected” the 
day before. This procedure gave a percentage of 98% GFP-positive NIH3T3 
(Figure I.11C). The same conditions were therefore applied to the infection of 
ES cells. The preparation of retroviral particles and infection procedure 
(spinfection plus an extra round of infection) were repeated as for NIH3T3 
cells but reducing the number of target cells from 1x106 to 8x105. Under these 
conditions, 30.4% of D3 ES cells were GFP positive (Figure I.11D). 
I then used the optimised infection protocol to transduce both D3 and 47-1 
(transchromosomic ES cells) with a retroviral vector expressing GATA-1s 
(MSCV-PURO-GATA-1s) or with the empty vector control (MSCV-PURO) for 
further experiments. 
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Fig. I.10. Schematic view of the optimisation steps for the retroviral transduction protocol 
of ES cells. Two ways of producing viruses were tested: the triple transfection method, based 
on the simultaneous transfection of viral components (gag-pol and env plasmids) and retroviral 
construct (MIG) into the 293T cells (A), and the transfection of the retroviral construct into a 
packaging cell line (PLAT-E) stably expressing the viral components (gag-pol and env) (B). The 
packaging cell line method was selected because of simplicity and safety reasons. Conditions 
tested for optimal transduction included the overnight incubation of target cells with viral-
containing supernatant with the addition of polybrene (C), and a combination of spinfection 
(centrifugation of viruses and cells in the presence of polybrene) and overnight incubation with 
fresh virus-containing medium after 24 hours (D). 
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Fig. I.11. GFP expression in cells infected with the MIG retroviral vector. Panels A and B 
show the percentage of NIH3T3 cells expressing GFP 48 hours after infection. Retroviruses 
were prepared by (A) transient transfection of 293T with the packaging plasmids gag-pol and 
env and the retroviral vector MIG or (B) transfecting the MIG vector into the packaging cell line 
PLAT-E. Infection in A and B was performed by overnight incubation of target cells with virus-
containing medium. Infection in B-D was performed with a combination of spinfection and 
subsequent overnight incubation with fresh retroviral containing supernatant. Panel C shows the 
efficiency of transduction of NIH3T3 cells, and panel D shows the efficiency of transduction of 
D3 ES cells. In all histogram plots, GFP fluorescence intensity on a logarithmic scale is plotted 
on the x-axis, number of cells is plotted on the y-axis. Numbers indicate the percentage of 
positive cells. Black line in panels C and D indicate basal background fluorescence of the 
untransduced cells. 
 
For further studies, PURO-MSCV retroviral vector was preferred to the MIG 
used for the optimisation of the protocol because the expression of the 
puromycin resistance cassette in this vector allows for antibiotic selection of 
the infected cells. 
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I.3.1. Generation of ES cell lines overexpressing GATA-1s 
 
 
After transduction of the D3 and 47-1 ES cells with the MSCV-PURO-GATA-
1s or the MSCV-PURO vector, infected cells were grown under puromycin 
selection for at least 10 days. By day 10, untransduced cells treated with 
puromycin at the same concentration of the transduced ones had all been 
killed by the antibiotic. Once a puromycin-resistant population was obtained, 
verification of the integration and expression of the viral constructs was carried 
out by PCR analysis on gDNA and RT-PCR on cDNA extracted from the 
transduced ES cells, respectively (Figure I.12). PCR was performed on gDNA 
using a forward primer in the GATA-1 insert and a reverse primer in the FLAG 
tag (cloned in frame with the GATA-1s cDNA in the retroviral vector). No 
amplification was detected in the D3 and 47-1 cells infected with the MSCV-
PURO vector, whereas a specific product of 374 bp was detected in the gDNA 
extracted from the cells transduced with the MSCV-PURO-GATA-1s vector. 
Likewise, a specific band of the same size was detected in RT-PCR using the 
same pairs of primers as for the PCR on gDNA, but there was no amplification 
in the MSCV-PURO controls or in the samples without reverse transcriptase 
(RT- controls). 
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Fig. I.12. Integration and expression of GATA-1s-FLAG in D3 and 47-1 undifferentiated ES 
cells. Panel A shows agarose gel electrophoresis of DNA fragments obtained by PCR 
amplification of gDNA extracted from D3 and 47-1 transduced with GATA-1s and MSCV control. 
PCR was performed with a GATA-1 exon 5 forward primer and a FLAG-tag reverse primer. 
Amplicon size was 374 bp. A mouse genomic DNA was included in the PCR as a negative 
control. Positive control PCR was performed with Keratin 19 primers (amplicon size 266bp). 
PCR products were visualized on a 1.2% agarose gel stained with Ethidium bromide. Panel B 
shows RT-PCR analysis performed on cDNA synthesized from RNA extracted from 
undifferentiated D3 and 47-1 transduced with GATA-1s or MSCV control. RT- controls were 
included in the PCR to ensure that amplification was driven by mRNA in the samples, rather 
than from contaminant gDNA. Bottom panel in B shows a positive control RT-PCR performed 
with β-actin primers on the same samples used for PCR in upper panel. Amplicon size for β-
actin PCR was 90 bp. 
 
 
3.3.2 Clonogenic potential of the GATA-1s expressing cells 
 
 
Once a system to overexpress GATA-1s in the transchromosomic ES cells 
and in the parental control was established, I aimed to assess the effect of 
GATA-1s expression on the megakaryocytic lineage in the trisomic context. 
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The first point to address was whether GATA-1s was still expressed 
throughout MK differentiation of both D3 and 47-1 (even in absence of 
selection). To examine this, RT-PCR analysis was performed on MKs/MK 
progenitors derived in vitro from D3 and 47-1 infected with GATA-1s and the 
control vector. (Figure I.13). 
 
 
Fig. I.13. Expression of GATA-1s-FLAG in D3 and 47-1 derived MKs/MK progenitors. RT-
PCR analysis was performed on MKs/MK progenitors derived from D3 and 47-1 transduced 
with GATA-1s and MSCV control. An RT- control was included for the GATA-1s transduced 
samples to ensure that amplification was driven by the presence of cDNA in samples, not from 
contaminant gDNA. RT-PCR analysis was performed with the GATA-1 forward primer and the 
FLAG reverse primer used in I.12. Amplicon size was 374 bp. A control RT-PCR was performed 
with primers for β-actin using the same amount of template cDNA used for the GATA-1s PCR. 
Amplicon size of the β-actin PCR was 90 bp. 
. 
 
At day 13, both D3 and 47-1 cells transduced with MSCV-PURO-GATA-1s 
expressed GATA-1s, as shown by amplification of a specific product of 374 
bp. No product was detected in the MSCV-PURO controls or in the controls 
without reverse transcriptase. Absence of amplification from contaminant 
gDNA in the RT- control proved that the construct was not only integrated, but 
also expressed in the transduced cells. 
Once continuous expression of GATA-1s was verified during megakaryocytic 
differentiation, I assessed the clonogenic potential of the D3 and 47-1 derived 
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MKs/MK progenitors expressing this truncated “oncogenic” form of GATA-1 
protein. A CFU-MK assay was performed, comparing D3 and 47-1 cells 
transduced with GATA-1s or the empty retroviral vector. Because AchE 
staining was not performed to identify these colonies, a selective cocktail of 
cytokines was used to supplement the semisolid medium employed in these 
experiments. 
Murine recombinant interleukin 3 
was added to TPO, IL-6 and IL-11 
to create stringent megakaryocytic 
growth conditions. Under the 
same culture conditions, Salek-
Ardakani et al. recently 
demonstrated the cooperating 
effect of overexpression of ERG 
(a candidate megakaryocytic 
oncogene on HSA21) with GATA-
1s in foetal liver progenitors 
{Salek-Ardakani, 2009 #293}. 
  
 
Fig. I.14. Number of megakaryocytic colonies derived from D3 and 47-1 infected with 
GATA-1s and MSCV control. Colonies derived from MK/MK progenitors infected with GATA-1 
or MSCV control were scored 8 days after the initial seeding (the number of progenitor cells was 
1x 105/dish; every culture was seeded in duplicate dishes). Colonies were grown in a selective 
semisolid medium supplemented with IL-3, IL-6, IL-11 and TPO. Puromycin (1 µg/ ml) was also 
added to maintain selection pressure.  The number of colonies in GATA-1s-transduced D3 and 
47-1 cultures was higher than MSCV-transduced cultures. This difference was statistically 
significant when comparing 47-1 infected with MSCV to 47-1 infected with GATA-1s (unpaired t-
test, p value = 0.008). D3-GATA-1s derived colonies were also increased in number compared 
to colonies derived from D3 transduced with the control vector, but the difference was not 
statistically significant between these two groups (unpaired t-test, p value = 0.1). The difference 
between D3-GATA-1s and 47-1-GATA-1s was also not statistically significant (unpaired t-test, p 
value = 0.2). 
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Eight days after the initial seeding of an equal number of MK/MK progenitors 
transduced with the GATA-1s or the control vector, the number of colonies 
generated under puromycin selection was assessed. The average number of 
colonies in three independent experiments - each performed in duplicate - was 
increased in both D3 and 47-1 derived MKs transduced with GATA-1s 
compared to the MSCV control. 
The fold increase in the number of megakaryocytic colonies relative to the 
control caused by the ectopic expression of GATA-1s was about 1.15 for D3 
cells and 1.8 for 47-1 cells. The difference between colonies derived from cells 
transduced with MSCV-PURO-GATA-1s versus control vector reached a 
statistical significance using an unpaired t-test only in the 47-1 
transchromosomic cells (p-value = 0.008), suggesting that the effect of the 
ectopic expression of GATA-1s, although present in the D3 cells as well, is 
further exacerbated by the trisomy 21. Data are represented in Figure I.14. 
I.4. Final remarks   
AMKL and TMD arise in DS through pathological perturbation of the balance 
between proliferation and differentiation of the megakaryocytic lineage. New 
evidence suggests that abnormalities of the MEP compartments are present in 
DS human foetal livers and are caused by the dosage imbalance of one (or 
possibly more) gene(s) on HSA21, which have yet to be identified (Chou et al., 
2008; Tunstall-Pedoe et al., 2008).  
In this chapter, I have presented a comprehensive analysis, with respect to 
megakaryocytic differentiation, of an innovative model of Down syndrome 
generated by introducing an extra copy of a freely segregating HSA21 on a 
mouse euploid background. The transchromosomic system is a powerful tool 
to dissect the contribution of trisomy 21 to the development of 
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megakaryoblastic leukaemia in DS because it provides the most 
comprehensive model of DS generated so far. All of the genes trisomic in DS 
are present in a third, human copy in the cell line (47-1) used in this study. 
Furthermore, their level of expression mimics closely the situation of DS, 
avoiding the artificial overexpression observed in other transgenic models. 
Despite the presence of an extra copy of HSA21, transchromosomic ES cells 
(47-1) can efficiently generate MKs/MK progenitors in vitro. The population of 
MKs/MK progenitors derived from the in vitro differentiation of the 
transchromosomic ES cells does not exhibit any abnormalities in quantity (as 
demonstrated by the percentage of CD41 positive cells) or quality (as shown 
by the ploidy assay) when compared to the ones derived from the wild type. 
However, on the molecular level, MKs derived from 47-1 cells express higher 
levels of GATA-1 mRNA. It is known that GATA-1 levels tightly regulate the 
balance between proliferation and terminal differentiation of erythroid cells 
through a direct effect on the cell cycle machinery (Whyatt et al., 1997; Whyatt 
et al., 2000; Kadri et al., 2009), and it is intriguing to speculate that this effect 
might apply to the megakaryocytic lineage as well. Muntean et al. have 
recently demonstrated that GATA-1 directly regulates proliferation of 
megakaryocytes by controlling their entry in the cell cycle through 
mechanisms that are specific for this lineage and not shared with erythroid 
cells (Muntean et al., 2007). The increased levels of GATA-1 during the 
megakaryocytic differentiation of the transchromosomic cells might therefore 
account for an imbalance between proliferation and differentiation at late 
stages of the in vitro generation of megakaryocytes (day 8 and 13 of the OP9 
protocol). Megakaryocytes generated by the ES cells containing an extra copy 
of HSA21 form the same number of colonies as the ones derived from the 
control, parental ES cells (D3). The colonies generated by the 47-1 
transchromosomic cells show remarkable morphological differences compared 
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to the controls; they are larger (i.e., contain more cells) and contain fewer cells 
positively staining for AchE (compared to the total number of cells forming an 
individual colony). This phenotype suggests a reduction in the number of 
terminally differentiated MKs per colony and an increased tendency of the 
more immature progenitors derived from the 47-1 ES cells to proliferate. The 
data presented in this chapter supports the hypothesis that this effect is 
independent from the presence of overt GATA-1 mutations, and is induced by 
the set of extra genes present in a third copy in the 47-1 cells. Whether this 
phenotype is linked to the imbalance in GATA-1 levels observed at day 8 and 
13 of the differentiation protocol needs to be determined. 
Ectopic expression of GATA-1s in the transchromosomic system gives rise to 
a higher number of colonies compared to the empty vector. Despite the fact 
that the short form of GATA-1 exerts a positive effect on the clonogenic 
potential of the megakaryocytic lineage even in the wild type (D3) context 
(which is in agreement with previously published data (Li et al., 2005)), this 
effect is more pronounced in the trisomic (47-1) model. Of note, the 
“oncogenic” effect of GATA-1s might be attenuated in the 47-1 experimental 
system by the presence of full length GATA-1, as opposed to the human 
situation of DS-AMKL where only GATA-1s is produced in the 
megakaryoblasts. 
Taken together, the data presented in this chapter suggest that trisomy 21 
shifts the balance between proliferation and differentiation during 
megakaryocyte development. Ectopic expression of GATA-1s, as shown by 
the increase in the clonogenic potential of the transchromosomic-derived 
colonies, exacerbates this phenomenon. In the future, it will be important to 
expand these observations by testing the contribution of individual genes to 
the described phenotypes by human-specific RNAi silencing. This approach, 
combined with data obtained by ES cell lines carrying partial fragments of the 
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HSA21, is likely to define a more specific role for trisomy in the observed 
phenotypes and to provide further support for the observations carried out so 
far.  
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II. Effects of trisomy 21 on the ontogenesis of HSCs 
from mesodermal precursors cells  
II.1. Identifying developmental stages of haematopoietic 
differentiation in the OP9 based system 
 
 
Canzonetta et al. recently described a disturbance of all embryonic lineages in 
the transchromosomic model used in this study (Canzonetta et al., 2008). The 
authors of this paper have shown that trisomy for the kinase DYRK1A (which 
is encoded on HSA21) causes a disturbance in the levels of some 
pluripotency regulators, which results in the premature expression of 
transcription factors that drive early endodermal and mesodermal 
differentiation. Given that this disturbance is present in the undifferentiated ES 
cells, I wanted to investigate whether trisomy 21 would cause any further 
effects during the mesodermal commitment and the generation of HSCs from 
the transchromosomic ES cells.  
After the removal of LIF and 
seeding on a confluent layer of 
OP9 cells, the first step of 
haematopoietic differentiation 
of ES cells is the formation of 
colonies containing the 
precursors of the major 
derivatives of mesodermal 
tissues, including 
haematopoietic progenitors 
(Figure II.1). 
 
Fig. II.1. A mesodermal colony generated 
from D3 ES cells upon removal of LIF and 5 
days of culture on the OP9 stromal cell line. 
Picture was taken at a 20x magnification. 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Initially, I aimed to dissect the early stages of the haematopoietic 
differentiation and to define the composition of mesodermal colonies at day 5. 
Although mesodermal colonies arise from ES cells within 2.5-3 days, day 5 
was chosen as a time point of analysis because the commitment of 
differentiation towards the haematopoietic lineage requires a longer exposure 
to the OP9 feeder cells (Zhang et al., 2005). In the first set of experiments that 
I performed, a molecular signature for the day 5 colonies was established by 
qRT-PCR analysis.  
 
 
          Gene 
 
 Marker of: 
 
    Expression 
 
SCL 
 
   HSC, CMP  
              
            ++ 
GATA-2 
C-MYB 
   HSC, CMP 
   HSC, CMP 
            +++ 
            +++ 
C-MPL    MEP              - 
NF-E2    CMP, MEP              - 
GATA-1    MEP            +/- 
EPO-R    MEP            +/-  
PU.1    CMP, GMP            +/- 
C/EBPα    GMP            +/- 
 
Table 3.1. Definition of the composition of mesodermal colonies generated 
from ES cells after 5 days on OP9 cells. Differentiating ES cells (both D3 and 47-1) 
were harvested at day 5 after a preplating step of 45 minutes. Total RNA was extracted, cDNA 
synthesised and expression of indicated markers was assessed by qRT-PCR analysis. +++ 
indicates that the target was abundant (Ct values between 18 and 25); ++ denotes that the 
target was present at moderate quantities (Ct values between 26 and 30); +/- indicates low to 
very low expression (Ct values between 30 and 38), whereas - indicates that the marker was 
undetectable. HSC stands for haematopoietic stem cells, CMP for common myeloid progenitors, 
GMP for granulocyte-macrophage progenitors, MEP for megakaryocyte-erythroid progenitors. 
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Day 5 colonies were analysed for the expression of several markers of the 
haematopoietic stem cell compartment (HSCs) and of the lineage progenitors, 
such as the common myeloid progenitors (CMP), the granulocyte-macrophage 
progenitors (GMP) and the megakaryocyte-erythroid progenitors (MEP). A 
seminal paper in the field from Akashi et al. guided the choice of markers 
analysed (Akashi et al., 2000). Results from this analysis are summarized in 
table 3.1. Assessment of the transcriptional profile of the mesodermal colonies 
at day 5 suggested that the predominant haematopoietic population within the 
colonies was comprised of HSCs and lineage non-restricted cells. A detailed 
analysis and characterization of the effect of trisomy 21 on these initial steps 
of haematopoietic commitment is presented in this chapter. 
 
II.2. Transcriptional levels of markers of the haemogenic 
endothelium and HSCs compartments are increased 
during differentiation of trisomic ES cells   
Generation of HSCs from ES cells in vitro proceeds through a mesodermal 
commitment (characterised by the onset of an FLK-1 positive population of 
cells), followed by the appearance of a transient common precursor of the 
endothelial cells and haematopoietic cells. This precursor, named the 
haemangioblast, has been identified in vivo and during the embryoid bodies 
stage of the in vitro differentiation of both mouse and human ES cells (Jaffredo 
et al., 2005; Park et al., 2005; Jezierski et al., 2007). The haemangioblast is a 
bipotent cell, capable of generating both endothelial and haematopoietic cells 
in vivo. In vitro, this transitory precursor gives rise to blast colonies with both 
endothelial and haematopoietic components. Using ES in vitro differentiation, 
a recent paper has proposed that HSCs derive from early mesodermal 
progenitors through the formation of an intermediate specialised haemogenic 
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endothelium, which expresses high levels of TIE-2 and c-KIT and is CD41 
negative (Lancrin et al., 2009). I reasoned that, besides HSCs and immature 
haematopoietic progenitors, the in vitro colonies should contain populations of 
cells at different stages of mesodermal development, and decided to test a 
variety of markers associated with each stage (see Figure II.2). GATA-2, c-KIT 
and SCL were chosen as markers of HSCs. Levels of FLK-1 (a marker of early 
mesodermal precursors), TIE-2 (also known as TEK), and the endothelial 
markers PECAM and VEGF were compared between the colonies formed by 
the 47-1 transchromosomic cells and the D3 parental cells.  
 
Fig. II.2. From ES cells to HSCs. Schematic diagram showing the development of HSCs from 
mouse ES cells. In vitro generation of HSCs proceeds through the formation of a mesodermal 
precursor (marked by the expression of the receptor FLK-1, known in humans as KDR) followed 
by the generation of the haemangioblast, a common precursor for endothelial cells and HSCs. 
Recent findings indicate that HSCs derive from a transitory intermediate (haemogenic 
endothelium), which is a specialized subset of cells of endothelial nature with haematopoietic 
potential. The haemogenic endothelium expresses high levels of TIE-2 and c-KIT and is CD41 
negative. Markers of HSCs and immature haematopoietic progenitors include GATA-2, c-KIT 
and SCL. Markers of endothelial cells include PECAM, VEGF and VE-cadherin.  
Figure II.2 summarizes the development of haematopoietic stem cells and 
endothelial cells from mouse ES cells, and the markers associated with each 
stage of this process. No morphological or numerical differences were 
detected between the mesodermal colonies derived from D3 and 47-1 starting 
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at day 0 from the same number of pluripotent undifferentiated ES cells. Figure 
II.3 shows a comparison of mRNA levels for FLK-1, TIE-2, VEGF and PECAM 
in transchromosomic 47-1 cells and the parental D3 cells.  
 
 
Fig. II.3. A comparison between D3 and 47-1 of mRNA levels of markers of the 
haemangioblast and the haemogenic endothelium. Total RNA was extracted from D3 and 
47-1 at day 5 of the haematopoietic differentiation protocol, cDNA synthesised and qRT-PCR 
analysis performed. Mean mRNA levels of the gene of interest relative to the housekeeping 
gene GAPDH are expressed as fold changes of levels in D3 cells. There was no significant 
difference in the levels of FLK-1 (marker of mesodermal specification), or PECAM and VEGF 
(endothelial markers) between D3 and 47-1. mRNA levels of TIE-2 were significantly increased 
(unpaired t-test; p-value = 0.02) in the 47-1 (transchromosomic ES cells) compared with D3 
(parental ES cells). Data from three to six independent experiments are shown. Error bars 
indicate the standard error of the mean  (s.e.m.). 
 
The expression level of each marker was analysed by qRT-PCR using cDNA 
synthesised from day 5 mesodermal colonies after a preplating step of 45 
minutes necessary to eliminate the OP9 stromal cells. Results in the bar 
graphs are expressed as fold change of the average mRNA level in the 
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parental D3 cells. The data used for the graphs in Figure II.3 are from three to 
six independent experiments. Error bars indicate standard error of the mean 
(s.e.m.). No significant difference was observed in the levels of mRNA of FLK-
1, PECAM and VEGF between mesodermal colonies derived from D3 and 47-
1. However, a statistically significant increase was observed in the mRNA 
levels of TIE-2 in the 47-1 colonies compared to D3 (unpaired t-test; p-value = 
0.02). Absolute levels of FLK-1 were quite low in this set of samples (Ct values 
= 28-30), suggesting that the mesodermal precursors had already evolved to 
further stages of development by day 5. 
 
Fig. II.4. A comparison between D3 and 47-1 of mRNA levels of markers of the 
haematopoietic stem cell compartment/immature haematopoietic precursors. Total RNA 
was extracted from D3 and 47-1 at day 5 of the haematopoietic differentiation protocol, cDNA 
synthesised and qRT-PCR analysis performed. Mean mRNA levels of the gene of interest 
relative to the housekeeping gene GAPDH are expressed as fold change of levels in D3. There 
was no significant difference in the levels of SCL between D3 and 47-1. mRNA levels of GATA-
2 and c-KIT were significantly increased in the 47-1 (transchromosomic ES cells) compared to 
D3 cells (unpaired t-test; p-value = 0.03 and 0.009, respectively). Data shown are from six 
independent experiments. Error bars indicate standard error of the mean (s.e.m.). 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Expression analysis of markers of the haematopoietic stem cell 
compartment/immature haematopoietic precursors is shown in Figure II.4. No 
significant differences were detected when comparing SCL mRNA levels 
between D3 and 47-1. However, levels of mRNA for GATA-2 were significantly 
increased in the 47-1 compared to D3 (unpaired t-test; p-value = 0.03). Levels 
of mRNA for c-KIT also showed a significant increase in the DS model 
(unpaired t-test; p-value = 0.009). Results in the Figure II.4 are expressed as 
fold change of the average D3 mRNA levels. Error bars indicate standard error 
of the mean (s.e.m.) of six independent experiments.  
 
II.2.1. Trisomic ES cells produce an increased number of 
haemogenic endothelial cells 
 
 
To define whether the increase observed in the mRNA levels of 
haematopoietic markers in trisomic cells reflected an increase in a specific 
population of cells, I performed a FACS analysis of CD41 and c-KIT 
expression.  
In addition to being used as a marker for mature megakaryocytes and 
platelets, CD41 has recently been associated with the early onset of 
haematopoiesis in the mouse (Ferkowicz et al., 2003; Mikkola et al., 2003). c-
KIT is a marker of HSCs and immature haematopoietic progenitors. High 
levels of c-KIT, in combination with the absence of CD41 and the expression 
of TIE-2, define a specific subset of cells within the mesodermal colonies 
capable of giving rise to the haematopoietic stem cells (i.e., the haemogenic 
endothelium) (Lancrin et al., 2009). 
Double staining for c-KIT and CD41 revealed an increase in the percentage of 
c-KIT+CD41- cells in 47-1 compared to D3 (unpaired t-test; p value = 0.04). 
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There was no significant difference in the percentage of c-KIT+CD41+ cells in 
the two populations analysed (Figure II.5).  
 
 
Fig. II.5. FACS analysis of the expression of CD41 and c-KIT in mesodermal colonies at 
day 5 of the differentiation protocol. Cells differentiated for 5 days on OP9 stromal cells were 
subjected to FACS staining with an anti CD41-FITC antibody at a 1:100 dilution and anti-c-KIT-
APC at the same dilution. Data were collected on a LSRII instrument and analysed with FlowJo 
software version 8.1. Panel A shows two-colour fluorescence dot plots for D3 and 47-1. 
Quadrant circled in blue contains the CD41-c-kit+ population; quadrant circled in purple contains 
the CD41+c-kit+ population. Panel B shows the quantification of the two different populations 
highlighted in A. Chart in purple indicates the percentage of cells positive for CD41 and c-KIT in 
both D3 and 47-1 (minus the isotype control); chart in blue shows the percentage of c-KIT 
positive CD41 negative cells (minus the isotype control). Data shown in both charts represents 
the average percentage of three independent experiments. Error bars indicate s.e.m. The 
percentage of cells positive for c-KIT and negative for CD41 was significantly higher in the 
trisomic cells than in the control (unpaired t-test, p value = 0.04). 
 
The data presented in this sub-chapter indicate that mesodermal colonies 
derived from 47-1 transchromosomic ES cells contain a higher percentage of 
CD41-c-KIT+ cells and express higher levels of TIE-2 and GATA-2 than 
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colonies derived from D3 parental ES cells. Assuming that the observed 
increase in TIE-2 expression in 47-1 is associated with the increase in the 
number of CD41-c-KIT+ cells, it is logical to postulate that the mesodermal 
colonies derived from 47-1 cells contain more intermediate precursors with 
haematopoietic potential than the control colonies.  
GATA-2 is a master regulator of haematopoiesis. GATA-2 null ES cells and 
chimeric mice generated from GATA-2-/- ES cells display a profound deficit in 
haematopoietic stem cells or progenitor cells (Tsai et al., 1994). Accordingly, 
conditional expression of GATA-2 from a tetracycline-inducible promoter 
enhances the production of hematopoietic progenitors from murine embryonic 
stem cells (Kitajima et al., 2002). Given that GATA-2 mRNA levels are 
increased in 47-1 cells compared with D3 cells, I next asked whether 
haematopoietic specification from the intermediate progenitors is boosted in 
trisomic cells compared to the control.  
II.3. Functional analysis of haematopoietic progenitors 
derived from the transchromosomic ES cells   
II.3.1. Quantifying the number of haematopoietic progenitors derived 
from ES cells 
 
 
To assess whether the increased expression of GATA-2 translates into the 
generation of more haematopoietic progenitors from the mesodermal colonies 
derived from trisomic ES cells on OP9 stromal cells, a limited dilution assay 
was performed. Mesodermal colonies at day 5 of the differentiation protocol 
were trypsinised and cells were dissociated and replated at a density of 500 
cells/well in a 96-well plate containing a fresh layer of OP9 cells. The 
prolonged contact with stromal cells allows for the generation of colonies 
containing haematopoietic precursors that are capable of generating colonies 
of all haematopoietic lineages in semisolid medium (see II.3.2). The low 
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density of cells seeded allows for easy scoring of the positive wells. The 
number of haematopoietic colonies generated from D3 cells and 47-1 cells 
under these conditions was assessed after 7 days; the experiment was 
performed starting from five independent cultures for each cell line, each 
seeded in duplicate for a total of ten 96-well plates for each ES cell line 
(Figure II.6). 
 
 
 
 
           
Fig. II.6. Assay for counting cells producing haematopoietic colonies. Mesodermal 
colonies at day 5 of the differentiation protocol were trypsinised and cells were dissociated, 
counted and replated at a density of 500 cells/ plate in a 96-well plate containing a fresh layer of 
OP9 cells. Number of haematopoietic colonies generated from D3 cells and 47-1 cells under 
these conditions was assessed at day 12. The bar graph represents the average number of 47-
1 colonies relative to the average number of D3 colonies in ten 96-well plates (5 independent 
cultures each seeded in duplicate). Error bars indicate s.e.m.  The number of haematopoietic 
colonies formed by transchromosomic cells (47-1) was higher than the euploid control (D3) 
(unpaired t-test p value = 0.03).  
 
Data in Figure II.6 are presented as fold change of the average number of 47-
1-derived colonies relative to D3-derived colonies. Error bars indicate s.e.m. 
The number of colonies varied broadly between plates, however despite this 
variation, the number of haematopoietic colonies formed by transchromosomic 
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cells (47-1) was significantly higher than the control (D3) (unpaired t-test, p 
value = 0.03).  
 
II.3.2. Clonal analysis of haematopoietic progenitors derived from ES 
cells 
 
 
A well-established in vitro assay to test the identity and the functional 
properties of HSCs and haematopoietic progenitors from the bone marrow is 
the colony-forming cell (CFC) assay. In this assay, under appropriate culture 
conditions (a selected cocktail of cytokines and a supporting matrix of 
methylcellulose), HSCs/haematopoietic progenitors can give rise to a variety 
of colonies of all blood lineages. Despite the utility of the CFC assay, the most 
stringent assays to measure HSC number and their functional potential are: 1) 
the long-term in vivo competitive repopulation assay, which tests the capacity 
of a particular set of HSCs to repopulate the bone marrow of irradiated host 
mice compared to a set number of HSCs (usually derived from bone marrow 
of congenic wild-type mice), and 2) serial transplantation assays, which 
assess the ability of HSCs to sustain haematopoiesis by presumptive self-
renewing divisions (Purton and Scadden, 2007). To date, it has not been 
possible to generate from ES cells HSCs that are capable of reconstitution of 
the bone marrow of an irradiated host mouse, with the well-known exceptions 
of murine ES cells transduced with HOXB4 (Helgason et al., 1996; Kyba et al., 
2002), BCR/ABL (Peters et al., 2001) or STAT-5 (Schuringa et al., 2004). It is 
therefore necessary to utilise surrogate in vitro assays (i.e., CFC assay) to test 
the ability of the immature precursors derived in vitro from ES cells to give rise 
to all blood lineages. 
A colony-forming cell assay was performed with haematopoietic progenitors 
derived from 47-1 trisomic ES cells and the D3 parental cell line to compare 
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their ability to form colonies of different blood lineages. The system utilised for 
this set of experiments is commercially available from Stem Cell Technologies 
and it does not assess the potential of haematopoietic progenitors to form B 
and T lymphocytes. However, it allows for the scoring of colonies of three 
different types: erythroid (BFU-E), granulocyte-macrophages (CFU-GM), and 
mixed (CFU-GEMM), which are composed of at least two different lineages 
and reflect the number of immature progenitors. 
D3 and 47-1 cells were differentiated for 5 days on a layer of OP9 cells without 
LIF, and then trypsinised and replated onto a fresh layer of OP9 cells for three 
more days. At day 8, cells were counted and seeded at the density of 1x105/35 
mm dish and grown in a humidified incubator with 5% CO2 for 14 days. 
Colonies were then evaluated using a light microscope with a 20x objective 
and classified based on morphology according to the manufacturer’s 
instructions.  
 
 
 
 
 
 
 
 
 
 
Fig. II.7. Morphology of colonies generated from haematopoietic progenitors in semisolid 
medium supplemented with IL-3, IL-6 and EPO. Figure shows the three types of colonies 
scored at day 14 after seeding in semisolid medium. CFU-GM (myeloid) colonies have a dense 
core surrounded by cells and are composed of at least 30 cells. Individual cells of a CFU-GM 
colony are easily distinguishable, especially at the periphery of the colony. BFU-E (erythroid) 
colonies are composed of a minimum of 30 cells; they do not usually have a dense core and the 
clusters are relatively scattered. CFU-GEMM (mixed) colonies are generally large and contain 
cells of different lineages. Pictures were taken on a light microscope using a 20x objective. 
 
Results from these experiments are shown in Figure II.8. Bar charts represent 
the average number of total colonies, as well as the average number of 
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myeloid, erythroid and mixed colonies in three independent experiments, each 
performed in duplicate. Error bars indicate the s.e.m. 
 
 
Fig. II.8. Quantification of colonies derived from haematopoietic progenitors in semisolid 
medium supplemented with IL-3, IL-6 and EPO. ES cells were seeded onto a confluent layer 
of OP9 cells. On day 5, differentiated ES cells were harvested and seeded onto a new OP9 
layer. On day 8, haematopoietic cells developing on the OP9 layers were harvested and plated 
in methylcellulose-based medium supplemented with IL-3, IL-6 and EPO. Fourteen days later, 
colonies were counted and classified according to morphology. Shown are bar charts indicating 
the average number of total colonies, myeloid colonies, erythroid colonies and mixed colonies in 
three independent experiments, each performed in duplicate. Error bars indicate s.e.m. No 
significant differences were detected between control cells and trisomic cells in the total number 
of colonies or in the number of erythroid and myeloid colonies. However, a highly significant 
(unpaired t-test, p value<0.001) increase was detected in the number of mixed colonies (a 
measure of the number of more immature progenitors) derived from 47-1 cells compared to the 
control. 
 
The ability of the trisomic haematopoietic progenitors to form erythroid and 
myeloid colonies did not significantly differ from the control D3 progenitors. 
However the number of mixed colonies, which reflects the most immature 
(multipotent) progenitors (Broxmeyer et al., 2003) was dramatically increased 
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in 47-1 compared to the control (unpaired t-test, p value < 0.001). Together 
with the increase observed in 47-1 cells in the limited dilution experiment (see 
Figure II.6), these findings strongly argue that trisomy 21 increases the 
number of immature haematopoietic precursors generated in vitro from ES 
cells. 
II.4. Alteration of HSC ontogenesis in transchromosomic ES 
cells is caused by trisomy of specific HSA21 genes/regions 
 
Transchromosomic ES cells generate a higher number of specialized cells 
with haematopoietic potential (i.e., haemogenic endothelium) and a higher 
number of immature haematopoietic progenitors than the wild type ES cells. 
One of the major players in the generation of the haematopoietic cells from the 
mesoderm and the haemangioblast is a gene on HSA-21, RUNX-1. 
A recent study has provided evidence for the role of RUNX-1 in this 
developmental process (Lancrin et al., 2009). Authors of this study 
demonstrated that the TIE-2+c-KIT+CD41- haemogenic endothelial cell 
population is generated in absence of RUNX-1, but that RUNX-1 is 
indispensable for the generation of definitive haematopoietic cells from this 
population. 
Using conditional gene expression in ES cells, Sakai et al. have also recently 
suggested that RUNX-1 increases the number of haematopoietic progenitors 
and suppresses endothelial gene expression during in vitro ES differentiation, 
without affecting number of haemogenic cells (Sakai et al., 2009). The 
involvement of RUNX-1 in the phenotypes described during in vitro 
differentiation of trisomic ES cells was therefore tested. In order to do so, I 
undertook two separate approaches, which are described in II.4.1 and 2. 
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II.4.1. Silencing the third copy of RUNX-1 by human-specific RNAi 
 
The first approach I employed took advantage of a peculiar feature of the 
transchromosomic system, which is the possibility of restoring the diploid dose 
of a gene on HSA21 by specifically silencing its third human copy.  
Low levels of the mouse RUNX-1 mRNA transcript were detected in 
undifferentiated ES cells, as previously reported in the literature (Fujita et al., 
2001). Human RUNX-1 was also found to be expressed in the undifferentiated 
transchromosomic ES cells (see I.1.3, Figure I.5). Human-specific knockdown 
of RUNX-1 was accomplished by transient transfection of the undifferentiated 
ES cells with a pool of human-specific oligos (designed and produced by 
Dharmacon, Belgium). Species-specificity of the human RNAi was screened 
by aligning the target sequences of the oligos with both mouse and human 
mRNA sequences of RUNX-1 using the BLAST feature of the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences targeted by the oligos were 
found to be human-specific. To test the efficiency of the knockdown of the 
human RUNX-1, and its specificity against the human form of the gene, RT-
PCR and western blot analysis were performed. 
In all RNAi experiments, a transfection with oligos targeting an irrelevant 
sequence of the genome was performed as a control. Figure II.9 shows that 
the human-specific RNAi was efficient in knocking down the human RUNX-1 
gene (panel A; primers used for this RT-PCR were the same as the primers 
used for RT-PCR shown in Figure I.5, and they were previously shown to be 
human-specific) and did not affect the mouse gene, as demonstrated by RT-
PCR analysis with mouse specific primers shown in panel B.  
Panel C shows that human RUNX-1 protein was efficiently reduced by 72 
hours after siRNA transfection. No effects on human RUNX-1 were observed 
in the control RNAi samples both at the mRNA and at the protein level. 
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Fig. II.9. Human-specific RNAi in undifferentiated transchromosomic ES cells. Panel A 
shows RT-PCR analysis performed on cDNA extracted from untreated 47-1 transchromosomic 
cells, 47-1 transfected with oligos targeting human RUNX-1 or with non-targeting oligos. RT-
PCR was performed on the same samples with primers specific for human RUNX-1 (as shown 
in Figure I.5) and primers for mouse GAPDH as a positive control. Cells were harvested for total 
RNA extraction at the indicated time points after transfection. Panel B shows RT-PCR 
performed on the same samples used for RT-PCR shown in panel A, but with primers specific 
for mouse RUNX-1. A positive control (cDNA from mouse bone marrow) and a negative control 
(cDNA from the human leukaemic cell line K562), labelled ‘Mouse p.c.’ and ‘Human n.c’, 
respectively, were included to show specificity of the primers used in this experiment. Panel C 
shows western blot analysis performed on untreated 47-1, 47-1 transfected with oligos targeting 
hRUNX-1 and non-targeting oligos. Nuclear extracts were generated from cells harvested 72 
hours after transfection. The membrane was probed with a mouse monoclonal antibody anti-
human RUNX-1, which detects a band of approximately 49 KDa, and with a rabbit polyclonal 
against the human and mouse nuclear protein EZH2, which recognizes a band of approximately 
85 KDa, to serve as a loading control.  
 
 
After having established that the knockdown for RUNX-1 was efficient and 
human-specific, I used this experimental tool to investigate the molecular 
changes caused by an increased dosage of RUNX-1 during the early stages 
of the haematopoietic differentiation of the transchromosomic system. In order 
to do so, undifferentiated ES cells were transfected with human specific oligos 
targeting RUNX-1 or with non-targeting oligos and seeded onto a confluent 
layer of OP9 cells twelve hours after transfection.  
  148 
 
Fig. II.10. Effect of hRUNX-1 RNAi on the expression of haematopoietic markers during 
differentiation of transchromosomic ES cells. Twelve hours after transfection with oligos 
targeting human RUNX-1 or non-targeting oligos, transchromosomic ES cells were seeded onto 
a confluent layer of OP9 cells. After 5 days, mesodermal colonies were harvested, total RNA 
extracted and cDNA synthesised. qRT-PCR analysis was performed to quantify the levels of 
mRNA for TIE-2, GATA-2 and c-KIT. Bar charts represent the mean mRNA levels divided by 
GAPDH of 5 independent experiments. Error bars indicate s.e.m. There was a significant 
reduction (unpaired t-test, p value = 0.01) of the levels of GATA-2 in the hRUNX-1 RNAi 
compared to the control, suggesting that GATA-2 levels are sensitive to the gene dosage of 
RUNX-1. 
 
Haematopoietic differentiation was carried out for 5 days, at which time the 
cells were harvested, total RNA extracted and cDNA synthesised. Quantitative 
RT-PCR analysis was performed to assess levels of markers that previously 
showed an alteration in the transchromosomic system. As shown in Figure 
II.9, no significant difference was observed in levels of mRNA for TIE-2 and c-
KIT between the hRUNX-1 RNAi and the control RNAi, indicating that RUNX-1 
is not required for the increased formation of the haemogenic endothelium 
during in vitro differentiation of the ES cells. In contrast, a significant reduction 
of the levels of mRNA for GATA-2 was detected in the hRUNX-1 RNAi 
compared to control RNAi (unpaired t-test, p value = 0.01), suggesting that 
haematopoietic specification from the haemogenic endothelium was sensitive 
to the gene dosage of RUNX-1. 
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These results support a recent study, which demonstrated that conditional 
overexpression of RUNX-1 in ES cells promotes an increase in immature 
haematopoietic cells without affecting the number of haemogenic cells (Sakai 
et al., 2009). These data also reinforce the crucial findings from the study of 
Lancrin et al. that the haemogenic endothelium is generated in the absence of 
RUNX-1, but that RUNX-1 is necessary for the generation of definitive 
haematopoietic cells from this population (Lancrin et al., 2009). For the first 
time, these data suggest that the described effect might be accomplished by 
RUNX-1 through up-regulation of GATA-2. 
 
II.4.2. Reproducing the observed phenotypes in partial trisomic ES cells 
 
During the experimental procedure required to generate a murine ES cell line 
carrying a freely segregating copy of HSA21, Hernandez et al. generated a 
panel of at least 21 ES cell lines containing partial fragments of HSA21 
(Hernandez et al., 1999). These cell lines have morphological characteristics 
of the parental D3 cell line from which they were derived, and they all carry 
partial stretches of HSA21 extending proximally or distally from the D21S55 
locus, where the G418 selection marker is inserted. 
Hernandez et al. grossly characterised the panel of partial trisomic ES cells. A 
more detailed analysis of the genomic content of these cells is being carried 
out by Jurgen Groet et al. using high-resolution comparative genomic 
hybridization (CGH) array (HG-18-CHR21 tiling oligo arrays from NimbleGen 
at 70 bp resolution). Preliminary unpublished data from this analysis, together 
with more conventional mapping data, were integrated to choose partial 
trisomic ES cell lines with a defined content to address the following points: 1) 
the molecular changes observed in 47-1 are not an artefact of this particular 
cell line, but are reproducible across a range of trisomic ES cells; 2) it is 
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possible to combine information derived from different transchromosomic ES 
cells in order to pinpoint a role for a candidate gene on HSA21 (in this case 
RUNX-1) in DS-related phenotypes. 
Data from the RUNX-1 RNAi experiment suggest that RUNX-1 gene dosage 
does not affect the formation of the intermediate haemogenic endothelium, but 
has an effect on the generation of immature haematopoietic progenitors during 
in vitro differentiation of transchromosomic ES cells through regulation of 
GATA-2 levels. To provide further evidence in support of these data, I 
performed a molecular analysis of markers related to haematopoietic 
differentiation in partial trisomic ES cells, chosen according to RUNX-1 
presence and expression. Figure II.11 shows RT-PCR analysis performed on 
a variety of ES cell lines from the panel of transchromosomic ES cells with 
primers specific for human RUNX-1. 
I included in this PCR the   
parental cell line D3 from which 
the transchromosomic cells 
were derived, a positive 
(human leukaemic cell line 
K562) and a negative (mouse 
bone marrow) control. Data 
from this experiment were then 
compared to the original 
mapping data published from 
Hernandez et al.  
Surprisingly, 43-Q ES cells, which were shown by Hernandez et al. to carry a 
deletion encompassing the RUNX-1 gene, expressed hRUNX-1 at the 
undifferentiated stage (see Figure II.12). This might be due to rearrangements 
or amplification of portions of the human chromosome carried by the murine 
Fig. II.11. RT-PCR analysis performed with 
human-specific RUNX-1 primers on a variety of 
transchromosomic ES cell lines.  
Total RNA was extracted from undifferentiated 
transchromosomic ES cells cultured under G418 
selection. cDNA was synthetized and RT-PCR 
performed with human-specific RUNX-1 perimers. 
ES cells included in this experiment were chosen 
according to their availability in the lab and their 
growth properties.    
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ES cells, or to contamination from clones derived from a different panel of ES 
cells due to extensive handling in tissue culture. The presence of the human 
RUNX-1 gene was also confirmed at the gDNA level. Due to this discrepancy 
with Hernandez et al., 43-Q cells were excluded from further analysis. These 
data show the necessity of verifying expression of individual candidate genes 
in the panel of ES cells and to use the most comprehensive approach possible 
in determining genomic content of cells carrying distinct fragments of HSA21 
when performing experiments aimed to pinpoint genes causing phenotypes 
associated to DS in this system. 
Figure II.13 shows mRNA levels of TIE-2, c-KIT and GATA-2 in partial trisomic 
ES cells. In agreement with the hRUNX-1RNAi data, results from the partial 
trisomic ES cell lines highlight different requirements for distinct fragments of 
HSA21 in the regulation of mRNA levels of genes regulating the formation of 
the haemogenic endothelium and the generation of HSCs during in vitro 
differentiation of ES cells. 
47-14 ES cells contain a large proportion of the genes on HSA21, including 
RUNX-1, but they harbour at least two deletions, one of which affects a region 
of at least 11.65 Mbs (from D21516 to APP). 47-14 cells show a molecular 
signature that is nearly indistinguishable from 47-1 cells, with levels of mRNA 
for TIE-2, c-KIT and GATA-2 significantly increased compared to the parental 
D3 control (unpaired t-test p values = 0.006, 0.006 and 0.03, respectively). 
These data demonstrate that alteration of the levels of mRNA for the markers 
analysed is not an artefact of the 47-1 cell line and is reproducible in at least 
another ES cell line with a defined HSA21 content (47-14).  
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Fig. II.12. Characterisation of HSA21 content of transchromosomic ES cell lines used for 
experiments described in this chapter. Figure summarises the original data published from 
Hernandez et al. (Hum Mol Gen, 1999) integrated with available results from HR-CGH array 
(from J. Groet). D21S55 (where the neomycin resistance marker is integrated) is indicated by a 
red dot, and is present in every transchromosomic ES cell line. Light grey bars indicate that a 
given gene on HSA21 is present in the ES cell line; white bars indicate that that gene is absent. 
According to data from Hernandez et al., 43-Q cells have a deletion encompassing RUNX-1. 
However, RT-PCR analysis revealed expression of hRUNX-1 in the undifferentiated 43-Q ES 
cells; hence these cells were excluded from further analysis. Although RUNX-1 was present in 
both 39-5 and 47-14 ES cell lines, HSA21 genomic content of these two cell lines was not 
overlapping. Of the HSA21 genes with a potential role in haematopoiesis/leukaemogenesis, 
ERG and DSCR-1 were present in both 39-5 and 47-14, and so was DYRK1A, whereas ETS-2 
and BACH-1 were absent in 39-5 but present in 47-14. 47-1 ES cells contain the entire HSA21. 
 
In this set of experiments I also included an additional trisomic cell line (39-5), 
with a HSA21 genomic content different from both 47-1 and 47-14. In 39-5, 
mRNA for GATA-2 was up-regulated compared to D3 parental cells, as seen 
to a similar extent in 47-1 and 47-14. However mRNA levels for TIE-2 and c-
KIT did not show a significant difference when compared to the parental cell 
line D3. These data, in agreement with the RNAi results shown in II.4.1 
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suggest that whereas RUNX-1 might be responsible for regulation of 
expression of GATA-2, its presence does not influence levels of TIE-2 and c-
KIT. 
 
 
 
Fig. II.13. Comparison of the molecular changes observed in 47-1 across a panel of 
partially trisomic ES cells. TIE-2, c-KIT and GATA-2 mRNA levels were tested in two 
additional transchromosomic ES cell lines, 47-14 and 39-5, and compared with 47-1 cells and 
D3 parental cells. Bar charts show the average mRNA levels of 3 independent experiments. 
Error bars indicate s.e.m. All p values were calculated using the unpaired two-tailed t-test. 
Levels of GATA-2 mRNA were significantly increased in both 47-14 and 39-5 compared to the 
D3 euploid control (unpaired t-test, p value = 0.003 and 0.001, respectively). Levels of TIE-2 
and c-KIT were significantly up-regulated in 47-14 compared to the D3 control (p value = 0.006), 
but not in 39-5. Data are represented as fold change relative to levels in D3 parental cells.  
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These data also indicate that one or more genes, which are present in 47-1 
and 47-14 but absent in 39-5, are required for regulating levels of TIE-2 and c-
KIT. Interestingly, among the genes that fit this genetic criterion are the 
transcription factors ETS-2, which has a known role in haematopoiesis, and 
BACH1. Finer mapping of the HSA21 content for 39-5 is ongoing and will very 
likely guide the identification of potential candidates responsible for the 
regulation of TIE-2 and c-KIT mRNA levels. 
Very recently, a study from Korbel et al. has attempted to identify the regions 
on HSA21 involved in several DS phenotypes by high-resolution analysis of 
samples from patients with segmental trisomies (Korbel et al., 2009). Three of 
the 30 patients included in this study had TMD (2) or AMKL (1). Based on this 
approach, the authors found a critical leukaemia-predisposing region on 
HSA21 of 8.35 Mb (35-43.35). Despite the limited number of patients 
analysed, it is striking that the region identified in this study includes RUNX-1, 
ERG and ETS-2, but not BACH-1 or TIAM-1. The authors also suggested that 
a deletion in the short arm of HSA21 common to all three of the patients 
analysed might contribute to the phenotype. Besides leading to the same 
direction as my study, results from Korbel et al. also prompt a deeper 
investigation on the genomic content of the short arm of HSA21.  
II.5. Final remarks 
 
In this chapter, analyses of the early stages of haematopoietic differentiation in 
the transchromosomic system are described.  
It is quite difficult to unequivocally define separate stages of the 
developmental process that leads to the in vitro generation of haematopoietic 
cells from mesodermal precursors. One reason for this is the appearance of 
transient populations at intermediate developmental stages, which often share 
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expression of surface markers and TFs with previous or subsequent stages. 
Furthermore, new findings often challenge previous theories in the field, and 
there is a lot of open debate regarding the nature of this developmental 
process. The aim of the experiments described in this chapter was to apply 
the most recent knowledge in the field to characterise the effect of trisomy 21 
on early haematopoietic development from embryonic stem cells. 
A combination of FACS staining and gene expression analysis revealed that 
trisomic ES cells generate a larger number of CD41-c-KIT+ cells, and express 
higher levels of mRNA for TIE-2, GATA-2 and c-KIT than the parental D3 
control during haematopoietic development. These data indicate that direct 
precursors of the haematopoietic stem cells (haemogenic endothelial cells, 
CD41-c-KIT+TIE-2+) are generated at a higher rate in the transchromosomic 
system.  
GATA-2 is crucial for the maintenance, proliferation, and/or survival of 
immature hematopoietic progenitors (Tsai and Orkin, 1997). In vivo data 
support the hypothesis that GATA-2 plays a role in haemogenic precursor 
formation in the AGM region. Transgenic embryos with a GFP marker under 
the control of GATA-2 transcriptional regulatory sequences show high levels of 
GATA-2 expression in CD45- AGM cells with haemogenic potential, and there 
is a significant decrease in the percentage of CD45+ cells (HSCs) in AGM 
regions from GATA-2+/- mice (Minegishi et al., 2003). Moreover, GATA-2 is 
expressed in the endothelial cells lining the dorsal aorta and some underlying 
mesenchymal cells at the time of the first induction of HSCs, during 
midgestation. Hence, high GATA-2 expression in haemogenic cells of the 
AGM suggests that GATA-2 is acting on the cells just prior to the induction of 
HSCs (Ling et al., 2004). Recent data from Lugus et al. suggest that GATA-2 
might play multiple roles in haemangioblast development and differentiation, 
including acting as a proliferative signal to primitive erythroid progenitors 
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(Lugus et al., 2007). In my analysis, GATA-2 expression was used as a 
marker of haematopoietic commitment during the differentiation of ES cells. 
Because mRNA levels were higher in the transchromosomic ES cells 
compared to the D3, I set out to test whether there was an increased 
production of haematopoietic progenitors in the transchromosomic system. An 
assay designed to count the number of haematopoietic progenitors showed 
that the number of haematopoietic colonies derived from the 
transchromosomic ES cells was higher than the ones formed by the D3 
control, and I also observed a significant increase in the number of immature 
haematopoietic colonies derived from the trisomic cells in a colony formation 
assay.  
Reducing RUNX-1 to the disomic stage using human-specific RNAi decreased 
mRNA levels for GATA-2 in transchromosomic ES cells, without affecting 
levels of mRNA for TIE-2 and c-KIT. The data obtained from the RNAi studies 
showed that the copy number of RUNX-1 does not influence the formation of 
the haemogenic endothelium, but might affect generation of haematopoietic 
stem cells through up-regulation of GATA-2. Data generated from a panel of 
ES cells containing different fragments of HSA21 support this conclusion, 
underlining a requirement for RUNX-1 in the regulation of mRNA levels of 
GATA-2 but not of TIE-2 and c-KIT. A previous study has demonstrated that 
during HSCs ontogenesis, GATA-2 transcriptionally regulates RUNX-1 by 
binding to the haematopoietic-specific +23 enhancer element (Nottingham et 
al., 2007). Furthermore, Pimanda et al. have demonstrated that key stages of 
mouse HSC specification in the AGM region and in the midgestation foetal 
liver are regulated by the three specific haematopoietic enhancers GATA-2 -3, 
FLI-1 +12 and SCL +19, each bound by the TFs GATA-2, FLI-1 and SCL to 
form a fully connected kernel operating during mammalian development 
(Pimanda et al., 2007). These types of regulatory circuits are emerging as key 
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controllers of HSC development, and it is possible that a regulatory network 
controlling the development of HSCs includes the reciprocal regulation of 
RUNX-1 and GATA-2. In silico analysis that I performed with the TFSEARCH 
software (Yutaka Akiyama: "TFSEARCH: Searching Transcription Factor 
Binding Sites", http://www.rwcp.or.jp/papia) has revealed that the 1 kb region 
upstream the TSS of the murine GATA-2 contains at least 2 consensus 
binding sites for RUNX-1, giving rise to the possibility that GATA-2 might be a 
direct target of RUNX-1. Further studies are therefore required to establish the 
mechanisms by which RUNX-1 can control GATA-2 levels, contributing to 
HSC formation in vitro and in vivo. 
A model for the effect of trisomy 21 during early stages of haematopoietic 
development based on the data presented in this chapter is shown in Figure 
II.14. 
 
Fig. II.14. Effect of trisomy 21 on in vitro haematopoietic development from 
transchromosomic ES cells. ES cells containing an extra copy of HSA21 express higher 
levels of markers associated with the transient haemogenic endothelium compared to normal 
euploid mouse ES cells. This effect is not dependent on an increased dosage of RUNX-1, but it 
is very likely caused by trisomy of another gene (or genes) on HSA21. However, copy number 
of RUNX-1 affects the specification of a haematopoietic programme during development, very 
likely by regulating levels of GATA-2. The combined effect of these two phenomena is that the 
number of immature haematopoietic progenitors generated by the transchromosomic ES cells is 
higher than the control. 
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According to this model, one or more unidentified gene(s) on HSA21 are 
responsible for an increased formation of specialised haemogenic endothelial 
cells, but RUNX-1 is not required for this phenomenon. However, an increased 
gene dosage for RUNX-1 is associated with increased mRNA levels of GATA-
2, a key regulator of HSC ontogenesis and specification. The overall 
consequence of trisomy 21 on the haematopoietic differentiation of ES cells is 
the formation of an increased number of immature haematopoietic precursors. 
It is intriguing to speculate that this larger pool of progenitors might be 
dysfunctionally regulated in vivo, constituting the substrate allowing for the 
acquisition of mutations such as GATA-1 or JAK-2, and ultimately accounting 
for the increased incidence of acute leukaemias of both lymphoid and myeloid 
lineages in DS.   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III. Haematopoietic defects in DS: insights from 
primary samples 
 
Megakaryocytic leukaemia in DS is characterized by the presence of acquired 
mutations of the erythroid-megakaryocytic transcription factor GATA-1, and by 
the presence of a supernumerary chromosome 21 in the blast cells. Factors 
that predispose 10% of DS children to develop megakaryocytic leukaemia, 
and additional events that are necessary for progression from TMD to AMKL, 
are largely unknown (Hitzler and Zipursky, 2005). GATA-1 mutations leading 
to the exclusive production of GATA-1s (a truncated, “oncogenic” form of the 
protein) are acquired in utero (Ahmed et al., 2004) and can be detected in 
genomic DNA from foetal livers at 18–23 weeks of gestational age (Taub et 
al., 2004). To date, acquired GATA-1 mutations have never been reported in 
blast cells that did not also carry a trisomy 21 (either as constitutional DS, or in 
individuals mosaic for trisomy 21). The role of trisomy 21 in the pathogenesis 
of DS leukaemia remains to be fully clarified. In chapter I, I have presented 
experimental evidence supporting the hypothesis that trisomy 21 provides a 
proliferative advantage to the megakaryocytic lineage, creating conditions 
favorable to the block of differentiation caused by GATA-1s. The possible 
contribution of trisomy 21 (through one or more genes on HSA21) to the 
increased risk of occurrence of GATA-1 mutations is an additional possible 
mechanism to explain the laeukaemogenic process in DS. 
In the first part of this chapter, I describe an intriguing case of a perinatal 
hydrops foetalis (HF) in DS, with hyperproliferation of megakaryocytes in both 
foetal liver and spleen, without a detectable GATA1 mutation. This case gives 
further substance to the theory that abnormalities of the megakaryocytic 
compartment might occur in DS independently from mutations of GATA-1. The 
second part of this chapter describes a gene expression analysis performed 
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on matched DS and euploid human foetal liver samples.  
III.1. Hyperproliferation of the megakaryocytic lineage in the 
liver of a DS foetus  
III.1.1. Immunohistochemical analysis on archived tissues 
 
Clinical records of the Pathology Department of the University of Split Medical 
School showed that a preterm female was delivered at 29 gestational weeks 
with slight dysmorphic facial features resembling DS, and lived for less than 
one hour before dying with severe hydrops foetalis (HF). Standard karyotype 
analysis revealed trisomy 21 (47, XX+21). Histopathological analysis of liver 
and spleen biopsies showed numerous clusters of large, polyploid cells with 
megakaryocytic morphology in the parenchyma of the two organs. Deposits of 
haemosiderin and a mild degree of fibrosis were also observed in liver and 
spleen of the foetus. 
Paraffin-embedded archived tissue from the liver and spleen biopsy 
specimens were obtained from the Pathology Department of the University of 
Split to perform a characterisation of the nature of the cells infiltrating the 
organs. 
Haematoxylin/Eosin staining performed on 5 µm thick sections from the liver 
and the spleen of the case confirmed an evident infiltration of polyploid cells, 
resembling mature megakaryocytes (Figure III.1 and III.3). Figure III.1 shows a 
comparison between a section of the liver of the HF case and a control 
archived foetal liver biopsy of a therapeutically terminated DS matched for sex 
and gestational age. Both liver and spleen sections from the case revealed 
numerous and widespread islands of apparent hyperproliferation of large cells, 
containing multiple nuclei. In contrast, no such islands were visible in the 
gestational age-matched DS foetal liver. 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Analysis of phenotypic markers associated with the megakaryocytic markers 
CD41 and von Willebrand factor (vWF) was then performed on sections from 
the liver of the case, and the infiltrating cells showed strong positive staining 
for both markers (Figure III.1 and III.2). Approximately 93% of DS-TMD and 
50% of DS-AMKL cases express the surface antigen CD34 on their blasts 
(Langebrake et al., 2005), so this marker was also tested on the liver sections 
from the case. Cells infiltrating liver and spleen were negative for CD34 
expression, revealing their mature megakaryocytic nature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. III.1 Morphological features of the megakaryocytic hyperproliferation in the liver of a 
Down syndrome case prematurely born with hydrops foetalis (1). Panels on the left show 
H/E staining of the DS case and of a DS control matched for sex and gestational age. Upper 
panel on the right shows cells infiltrating the parenchyma stained with a goat polyclonal anti-
CD41. Lower right panel display a control slide incubated with secondary antibody only. 
Pictures were taken on a Leica Q5501W microscope at 20x magnification. 
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Fig. III.2 Morphological features of the megakaryocytic hyperproliferation in the liver of at 
Down syndrome case prematurely born with hydrops foetalis (2). Upper panel on the left 
shows cells infiltrating the liver parenchyma stained with a mouse monoclonal anti-CD34. Upper 
panel on the right shows staining with a rabbit polyclonal anti-von Willebrand antibody. Lower 
panel display control slides incubated with secondary antibody only. Pictures were taken on a 
Leica Q5501W microscope at 20x magnification. 
 
Figure III.3 shows staining results for the sections taken from the spleen of the 
case. Infiltrating cells were less numerous in this tissue, but had the same 
features (CD41 positive, vWF positive, CD34 negative) of the cells infiltrating 
the liver. Taken together, data from histochemical analysis distinguished this 
case from the majority of DS-TMD cases, which typically show a proliferation 
of immature megakaryoblasts, rarely multinucleated, usually vWF- and CD34+. 
 
 
 
 
 
  163 
 
 
 
 
 
 
 
 
 
Fig. III.3 Morphological features of the megakaryocytic hyperproliferation in the spleen of 
a Down syndrome case prematurely born with hydrops foetalis. Figure shows that cells 
infiltrating the spleen, although less numerous, displayed the same features of the ones 
infiltrating the liver, as they were strongly positive for both CD41 and vWF expression. Pictures 
were taken on a Leica Q5501W microscope at 20x magnification. 
 
III.1.2. GATA-1 sequencing analysis on archived material 
 
After having established that the cells infiltrating the liver and the spleen of the 
patient were mature megakaryocytes, I wanted to assess whether this 
abnormal proliferation was associated with the mutations in the GATA-1 gene 
pathognomonic of DS-TMD and AMKL. Therefore, GATA-1 mutational 
analysis was performed on formalin-fixed, paraffin-embedded tissues from the 
liver and spleen of the patient. 
The challenge of this approach is that treatment with formalin induces 
chemical modification of DNA, making it difficult to extract gDNA of PCR-
amplifiable grade from fixed archived tissues (Shi et al., 2004).  A summary of 
different protocols tested is provided in Figure III.4.  
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Fig. III.4. Experimental conditions tried to extract gDNA of PCR-amplifiable quality from 
archived material. Several extraction methods were performed, starting from sections cut from 
the paraffin block or from bigger pieces of tissue from both the paraffin block and the formalin-
fixed tissue.  
 
To facilitate amplification, PCR was performed on gDNA extracted with each 
of the experimental conditions listed in Figure III.4 using a very short amplicon. 
Figure III.5 shows an agarose gel electrophoresis analysis of fragments 
amplified with test primers from gDNA extracted from archived tissue using 
conditions 4 to 8 of Figure III.4. 
Only conditions 6 and 7, listed in red in Figure III.4, gave an amplifiable 
product in the test PCRs.  
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Fig. III.5. PCR analysis performed on gDNA extracted from archived material using test 
primers. gDNA extracted according to methods from 4 to 8 listed in Figure III.4 was tested by 
PCR with primers spanning an intron of GATA-1. Amplicon size was very short (65 bp) to 
facilitate amplification. Figure shows agarose gel electrophoresis of DNA fragments performed 
on a 1.8% gel stained with ethidium bromide. The only two conditions of extraction that gave 
amplifiable products were the ones performed with a piece of tissue cut out of the formalin-fixed 
tissue (not paraffin embedded) regardless of the extraction method. However, the number and 
length of washes performed before starting the extraction influenced the quality of extracted 
gDNA (compare lanes 6-8). 
 
Both of the amplifiable gDNA samples were extracted from formalin-fixed 
tissue. Both a kit-based and a standard phenol/chloroform extraction 
procedure gave an amplifiable product. However, the number and length of 
the washes performed before starting the extraction, to eliminate the fixative, 
highly influenced quality of gDNA extracted.   
Once the quality of extracted gDNA was tested, the same material was used 
as a template in a GATA-1 specific PCR. Primers used in this PCR allowed 
amplification of the entire exon 2 of GATA-1, which was then sequenced to 
screen for mutations that would lead to the production of GATA-1s. 
Figure III.6 shows an agarose gel electrophoresis analysis of the DNA 
fragment amplified from the formalin-fixed liver tissue of the HF case and a 
positive control (human genomic DNA from unfixed tissue) using primers 
specific for GATA-1 exon 2. Panel B of Figure III.6 shows a portion of the 
electropherogram obtained by sequencing GATA-1 exon 2 in the DS case. 
The amplified product of GATA1 exon 2 was the correct length, with a wild 
type sequence that showed no signs of mutation. 
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Fig. III.6. GATA-1 sequencing analysis performed on gDNA extracted from foetal liver 
archived material. Panel A shows agarose gel electrophoresis of DNA fragments amplified 
with primers for GATA-1 exon 2. PCR was performed on fixed tissue from the foetal liver of a 
DS preterm with severe hydrops foetalis and on a human genomic DNA control.  Panel B shows 
electropherogram of the sequencing analysis performed on the gDNA from the case with both 
the forward and the reverse primer used for the ampification of GATA-1 exon 2. No mutations in 
GATA-1 were detected in gDNA from the DS foetal liver. 
 
These data suggest that hyperproliferation of megakaryocytic cells can occur 
in DS foetal liver in the absence of GATA-1 mutations. The hyperproliferation 
described in this case is distinct from a typical TMD, because it is not 
associated with GATA-1 mutations and the proliferative cells appear to have a 
more mature phenotype. Nevertheless, it is an intriguing possibility that 
unknown events different from GATA-1 mutations (likely related to the gene 
dosage imbalance caused by trisomy 21) may initiate an abnormal 
megakaryocytic hyperproliferation. This shift toward megakaryopoiesis in a 
fraction of DS foetuses may increase the risk of acquisition of GATA1 
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mutations, subsequently providing the mutated clone with a proliferative 
advantage, which ultimately causes TMD.  
III.2. Gene expression study in foetal liver samples 
 
The foetal liver (FL) is the major haematopoietic organ during embryonic 
development, while in adults haematopoiesis occurs exclusively in the bone 
marrow. A study from Li et al. has hypothesized that the foetal liver represents 
the milieu where a transient megakaryocytic progenitor that expresses GATA-
1s hyperproliferates, explaining why DS-TMD and AMKL (both characterized 
by the exclusive presence of GATA-1s) occur in a restricted time frame (Li et 
al., 2005). 
Two articles from independent groups have also recently compared foetal liver 
haematopoiesis in DS material with euploid controls matched for gestational 
age and sex. Both groups observed an increased frequency of 
megakaryocyte-erythroid progenitors in second trimester samples, leading to 
the hypothesis that trisomy 21, independently from GATA-1 mutations, 
profoundly disturbs FL haematopoiesis creating an imbalance in lineage 
commitment that predisposes DS foetal liver cells for the acquisition of GATA-
1 mutations (Chou et al., 2008; Tunstall-Pedoe et al., 2008). 
In previous chapters, using a transchromosomic model of DS, I have 
presented evidence that: 1) the presence of an extra copy of trisomy 21 allows 
GATA-1s to exert a hyperproliferative effect on the megakaryocytic lineage 
(chapter I); 2) embryonic haematopoiesis is influenced by trisomy 21 in DS, 
and RUNX-1, which is encoded on HSA21, plays a role in this phenotype 
(chapter II). 
To gain insights into the molecular changes caused by trisomy 21 during foetal 
liver haematopoiesis, I performed a qRT-PCR study to quantify the level of 
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expression of a panel of genes associated with haematopoiesis in DS primary 
samples. Six DS livers were compared to euploid controls matched for sex 
and gestational age. Samples were part of two separate collections of frozen 
tissues from therapeutically terminated DS or euploid pregnancies, and they 
were all from the second trimester. Table 3.2 shows characteristics of the 
samples used in this analysis. 
 
DS sample Matched euploid control 
R-595300M                    M, 18 Wks MRC 11253                      M, 20.4 Wks 
M-B59593M                   M, N.A. MRC 1113                        M, 21.4 Wks 
I-P9437M                       M, 20 Wks MRC 1114                        M, 21.1 Wks 
C-9599F                         F, 20 Wks MRC 11097                       F, 20 Wks 
P-696400M                    M, 20 Wks MRC 11252                      M, 20.4 Wks 
N-P0047 M                    M, 18 Wks MRC 11259                      M, 20.4 Wks 
 
Table 3.2. Characteristics of primary samples used in this study. Table indicates patient 
identification number, sex and gestational age. Matched samples are reported on the same line. 
N.A. indicates that data for that sample is not available. M stands for male, F for female, Wks for 
weeks. 
 
Initially, all samples were screened for the presence of mutations in GATA-1 
(data not shown). All DS-foetal livers were wild type for GATA-1, which 
allowed for the investigation of the effect of trisomy 21 (without overt 
mutations) on foetal haematopoiesis. Markers analysed in this study included 
CD41 and GATA-1, RUNX-1, GATA-2 and c-KIT. Besides being a master 
player directing the onset and function of haematopoietic stem cells, GATA-2 
is a key regulator of the mekagaryocyte lineage (Huang et al., 2009b) and is 
up-regulated in blast cells from DS-AMKL (Bourquin et al., 2006). GATA-1 and 
CD41 were analysed for their specific role in megakaryopoiesis.  
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Fig. III.7. Analysis of mRNA levels of haematopoietic markers in foetal livers from DS and 
euploid controls. Figure shows expression levels of markers associated with 
megakaryopoiesis in foetal livers from DS and matched euploid controls, as detected by qRT-
PCR analysis. Data are presented as average levels of mRNA normalised to GAPDH in 
duplicate samples. 
 
RUNX-1 levels were assessed because of its function in establishment of 
definitive haematopoiesis and in megakaryopoiesis, but also because of its 
presence on HSA21, whereas c-KIT was studied as an indicator of early 
haematopoietic progenitors in FL (Ogawa et al., 1993; Teyssier-Le Discorde et 
al., 1999). Figure III.7 and III.8 show the results of the analysis. Data are 
presented as mean mRNA values of duplicate samples, normalised to the 
housekeeping gene GAPDH. Each DS sample is shown with its matched 
euploid control. 
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Fig. III.8. Analysis of mRNA levels of c-KIT in foetal livers from DS and euploid controls. 
Figure shows expression levels of c-KIT in foetal livers from DS and matched euploid controls. 
Data are presented as average levels of mRNA normalised to GAPDH in duplicate samples. 
 
Differences between DS and normal foetal liver samples with respect to 
RUNX-1, GATA-1, GATA-2, CD41 and c-KIT expression were analysed with 
the Wilcoxon signed-rank test. The correlation between markers was tested by 
the linear regression test (Pearson correlation coefficient) performed on ratios 
of levels of mRNA for a given gene in DS to normal controls. All p values were 
two-tailed. 
Tunstall Pedoe et al. and Chou et al. reported contradictory results regarding 
levels of expression of RUNX-1 in total RNA extracted from DS foetal livers 
(Tunstall-Pedoe et al., 2008; Chou et al., 2008).  Bourquin et al. observed that 
RUNX-1 levels are not augmented in DS-AMKL blasts compared to non-DS 
AMKL leukaemic cells (Bourquin et al., 2006). Given the presence of a third 
copy of this gene on the supernumerary HSA21, I predicted an increased level 
of RUNX-1 mRNA in specific DS tissues, such as the foetal liver. Wilcoxon 
signed-rank tests performed on the six matched pairs of foetal livers included 
in this analysis showed that RUNX-1 mRNA levels are higher in the DS foetal 
livers than in the euploid controls (p value = 0.01). There was no statistically 
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significant difference in the levels of GATA-1, GATA-2 and CD41 between the 
two sets of samples. However, a significant increase in levels of mRNA for c-
KIT was observed in DS samples compared to the controls (p value = 0.04).  
Analysis of the correlation between levels of the markers revealed a positive 
correlation (linear relation) between GATA-1 levels and CD41 levels (r=0.8; p 
value=0.02). Indeed, GATA-1 has been previously shown to regulate the 
expression of CD41 through direct binding to its promoter (Gaines et al., 
2000). No significant correlations were observed among the other markers. It 
is worth noting that levels of the markers analysed were heterogeneous, 
making it difficult to reach statistical significance even when a trend was 
apparent comparing matched data (see levels of RUNX-1 and GATA-2, which 
were increased in at least the same three DS samples compared to matched 
euploid controls). This might be due to individual characteristics of the 
samples (e.g., age, sex of the samples), but could also be due to differences 
in the integrity of the samples and quality of archived material. 
Several conclusions can be drawn from these data. First, RUNX-1 is 
overexpressed in foetal liver of DS, supporting the hypothesis that early 
haematopoietic development in DS is influenced by the increased gene 
dosage of RUNX-1. Furthermore, because of the concomitant increase of 
CD41 and GATA-1 in some of the samples, it is possible that (at least in some 
DS foetuses) an increased number of megakaryocytes might present in 
trisomic foetal livers. The increased levels of c-KIT would suggest that 
immature haematopoietic precursors are more numerous in DS foetal livers 
than in euploid controls. This is further supported by the data from Tunstall-
Pedoe et al., who, apart from describing a skewing of oligolineage progenitor 
numbers towards an increased number of MEPs, demonstrated that overall 
clonogenic ability of FL CD34+ from DS foetal liver is increased compared to 
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euploid controls, and that the replating ability of CFU-GEMM (the more 
immature type of colonies) is augmented in DS samples. 
III.3. Final remarks 
 
Results presented in this chapter highlight the importance of utilising primary 
samples to validate data obtained from in vitro models of DS. Despite the fact 
that valuable insights could be drawn from the transchromosomic model, there 
are conspicuous differences between mouse models of DS and the human 
disease. Being able to integrate information from two complementary 
approaches provides a more detailed view for some of the phenotypes 
associated with DS, and gives the possibility to define a more specific role for 
genes on HSA21 in causing these phenotypes. 
Despite the limited conclusions that can be drawn from just one case, the first 
part of this chapter shows that there can be an abnormal proliferation of 
trisomic megakaryocytes in absence of GATA-1 mutations. A more extensive 
analysis of similar cases may reveal that this event is more frequent in DS 
foetal livers than previously appreciated, supporting the hypothesis that 
trisomy 21 creates the condition for GATA-1s to exert its oncogenic potential 
on the megakaryocytic lineage selectively in the milieu of the foetal liver.  
Gene expression data revealed that RUNX-1 is overexpressed in DS foetal 
livers compared with matched euploid controls. The limited size of the 
samples analysed and the variability associated with primary samples are a 
caveat for this approach. However, given the role of RUNX-1 in both the 
generation of HSCs and the megakaryocytic lineage, it is intriguing to 
postulate that this gene might play a role in determining the haematopoietic 
phenotypes seen in DS. Integrating data presented here with results obtained 
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from other primary sample collections is likely to more specifically define a role 
for RUNX-1 and other candidate genes on HSA21 in these phenotypes. 
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IV. Elucidating a role for JAK3 in the pathogenesis of 
DS-Leukaemia 
IV.1. Janus Kinases (JAKs) and haematological malignancies  
 
The four mammalian Janus kinase (JAK) family members JAK1, JAK2, JAK3 
and TYK2 are non-receptor protein tyrosine kinases that are crucial for 
cytokine receptor signaling in blood formation and immune response. 
Members of this family share a highly conserved structure; JAKs have seven 
defined regions of homology, called JAK homology (JH) domains (JH1-7). The 
carboxyl terminus contains the kinase and pseudokinase domains, termed 
JH1 and JH2, respectively. The JH1 domain contains all the typical features of 
a catalytic tyrosine kinase. In contrast, the JH2 pseudokinase domain, also 
called kinase-like domain, is highly homologous to the kinase domain but 
lacks characteristic residues of active tyrosine kinases, and it is therefore 
catalytically inactive. JH3 and JH4 domains share homology with Src-
homology-2 (SH2) domains. Functional studies have demonstrated that the 
SH2 domain in JAKs have scaffolding rather than signaling roles. The JH5-
JH7 (N-terminal region) domains contain a predicted FERM (band 4.1, ezrin, 
radixin and moesin)-like motif, which is supposed to play a role in mediating 
the interaction between JAKs and their cytokine receptors (Vainchenker et al., 
2008).  
A single recurrent mutation in the JAK2 tyrosine kinase (JAK2V617F) has 
been identified in >90% of patients with polycythemia vera (PV) and in a 
significant proportion of patients with essential thrombocythemia (ET) and 
primary myelofibrosis (PMF) (Levine et al., 2005; Baxter et al., 2005). 
Subsequent studies of JAK2V617F-negative myeloproliferative disorders have 
identified mutations in JAK2 exon 12, also resulting in constitutive activation of 
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JAK2 (Scott et al., 2007). Recently, somatically acquired mutations clustering 
around the R683 residue in the pseudokinase domain of JAK2 have been 
described in approximately 20% of patients with Down’s syndrome-associated 
acute lymphoblastic leukaemia, revealing a specific association between 
constitutional trisomy 21 and JAK2 mutations, which is similar to that of GATA-
1 mutations with DS-AMKL (Bercovich et al., 2008). 
Several somatic gain-of-function mutations in JAK1 have been reported in as 
much as 18% of patients with adult T-ALL (Flex et al., 2008). Three of the 
reported mutations induced IL-3 independence in Ba/F3 cells and IL-9 
independent resistance to dexamethasone-induced apoptosis in T-cell 
lymphoma cell lines. Of these mutations, the one with the strongest activating 
potential is the A634D mutation in the pseudokinase domain of JAK1, at a 
position predicted to affect the inhibition exerted by the pseudokinase domain 
on the kinase domain. 
JAK3 is the only JAK kinase that binds to γc, the common signaling subunit of 
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptor complexes. Most cases of 
human severe combined immunodeficiency (SCID) are caused by inherited 
loss-of-function mutations in γc (X-SCID), JAK3 or the IL-7-receptor genes 
(Candotti et al., 1997). 
Patients with JAK3 or γc mutations typically display the same phenotype, 
which is the absence of T and NK cells and impaired function of B cells. 
Mutations located in each of the domains of JAK3 have been identified. No hot 
spots have been reported; however, the majority of JAK-3 loss-of-function 
mutations associated with SCID are located in the JH2 pseudokinase domain 
(O'Shea et al., 2004). 
In 2006, Walters et al. reported three acquired mutations in JAK3 in samples 
from both DS and non-DS AMKL (Walters et al., 2006). Each of the described 
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mutations constitutively activates JAK3 and confers cytokine-independent 
growth properties to the Ba/F3 cells, and causes a disease resembling human 
AMKL once transplanted into recipient mice. These data suggest that 
activating mutations of JAK3 are an important event in the pathogenesis of 
AMKL. Selective chemical inhibitors of JAK3, already in clinical use as 
immunosuppressives (Changelian et al., 2003) have therefore been proposed 
as a therapeutic concept for AMKL (Walters et al., 2006). 
IV.2. Performing a screen for JAK3 mutations in DS-TMD and 
AMKL samples 
 
Trisomy 21 and acquired mutations in GATA-1, an erythroid-megakaryocyte 
transcription factor encoded on chromosome X, have been reported to coexist 
in blast cells in both DS-TMD and AMKL (Wechsler et al., 2002; Groet et al., 
2003). Despite the presence of these two genetic lesions, which are common 
to both forms of DS-leukaemia, factors that predispose one-third of the TMD 
patients to subsequently develop AMKL, and additional molecular events that 
are necessary for progression from TMD to AMKL, remain largely unknown 
(Hitzler and Zipursky, 2005; Muntean et al., 2006). 
In order to explore whether mutations of JAK3 can be considered a 
pathogenic event in the progression from TMD to AMKL, I performed a 
mutational analysis of JAK3 on a collection of samples from DS-AMKL and 
DS-TMD with a known GATA-1 mutational status. Results from this analysis 
are presented in this chapter. 
 
III.1.1. Describing novel JAK3 mutations in DS-TMD and AMKL 
 
JAK-3 mutational analysis was performed on surplus clinical materials from 
DS-TMD and AMKL received from specialized centers in Europe. For the vast 
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majority of samples, gDNA and RNA had been previously extracted for 
assessment of mutational status of GATA-1. Table 3.3 indicates 
characteristics of patients included in this study (last column lists the type of 
GATA-1 mutation observed in clinical samples) and nature of the material 
(gDNA or CDNA) used for the analysis. 
 
Patient  Material Blasts 
percentage  
GATA-1 mutations 
 
DS-TL (TMD1) cDNA 85 270-271ins7bp 
DS-TL (TMD1) gDNA 85 270-271ins7bp 
DS-TL (TMD2) gDNA 50 
259dup34bp,305dup4bp, 
307ins8bp 
DS-TL (TMD3) cDNA 60 161C>T, STOP 
DS-TL (TMD6) cDNA ND Splice Δ-exon2 
DS-TL (TMD8) cDNA 50 344-345ins2bp 
DS-TL (TMD10) cDNA 98 245-266del22bp 
DS-TL (TMD11) cDNA 78 263delG 
DS-TL (TMD15) gDNA ND 259dup34bp 
DS-AML-M7 (AMKL1) cDNA 50 270-271ins7bp 
DS-AML-M7 (AMKL4) cDNA 40 Splice Δ-exon2 
DS-AML-M7 (AMKL5) cDNA 95 251delT 
DS-AML-M7 (AMKL7) cDNA 60 Splice -Δexon2 
DS-AML-M7 (AMKL8) cDNA >50 197G>T, STOP 
DS-AML-M7 (AMKL11) cDNA 50 262-263ins7bp 
DS-AML-M7 (AMKL12) gDNA 20 285-286ins19bp 
DS-AML-M7 (AMKL13) gDNA ND 298-299ins5bp 
DS-AML-M7 (AMKL14) gDNA ND WT 
 
Table 3.3. Patients table modified from De Vita et al. (BJH, 2007). Table lists the clinical 
samples used in this study. Materials used for JAK3 mutational analysis were total cDNA or 
genomic DNA (gDNA). GATA-1 mutation status of the samples included in the study is shown. 
Splice Δ-exon 2 indicates that only a shorter product of GATA-1 was detected by RT-PCR, 
resulting from a splicing event skipping the entire exon 2. ND indicates not determined; WT, wild 
type; ins, insertion; dup, duplication; del, deletion. 
 
The sequence of JAK3 in samples from 8 DS-TMD and 8 DS-AMKL patients 
was analysed. For 3 TMD patients and 2 AMKL patients, genomic DNA was 
available. In these samples all 24 exons of JAK3 were sequenced, and no 
mutations were detected. The remaining patient samples (11) were available 
as cDNA. 
In these samples, the entire coding sequence of JAK3 was studied by using 5 
pairs of overlapping primers. Seven out of eleven samples in this subset 
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presented mutations in the JAK3 transcript. Figure IV.1 shows different JAK3 
mutations detected in this study and their consequences on the JAK3 protein 
structure. Interestingly, 3 patients (TMD3, TMD11 and AMKL4) showed a 
large (592 bp) deletion eliminating the C-terminal 192 amino acids (exons 20-
24). This region includes the JH1 kinase domain, which is essential for the 
kinase function of JAK3. Mutations resulting in a premature stop codon in 
exon 21 were shown to completely abolish JAK3 kinase activity in a patient 
with SCID (Mella et al., 2001); even smaller deletions in the JH1 domain have 
been reported to abolish the kinase activity of the JAK3 protein (Lai et al., 
1995). 
Two of the patients (TMD8 and AMKL1) showed alternatively spliced forms of 
JAK3, eliminating a large portion of the FERM region from the protein. The 
predicted start codon for the alternatively spliced cDNAs in these patients is at 
amino acid (aa) position 235 in exon 6 of JAK3. The alternatively spliced 
product was absent from the remission sample from patient AMKL-1, 
indicating that this change was specific for the leukaemic clone. The large 
deletion and the splicing variants were confirmed by cloning and sequencing 
of the RT-PCR products (the chromatogram in Figure IV.1 is derived from the 
cloned RT-PCR products for patients TMD8 and TMD11). One out of one 
clone from patient TMD8 showed the alternative splicing, and one out of four 
clones from patient TMD11 showed the large deletion. In chromatograms from 
sequences of cDNA synthesized from uncloned samples, the peaks of the 
alternatively spliced and of the deleted product were approximately half the 
height of the wild-type sequence, reflecting the proportion of blasts in the total 
population. 
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Fig. IV.1. JAK3 mutations in DS-TMD and DS-AMKL samples. Panel A shows 
electropherograms revealing JAK3 mutations in Down syndrome patients with transient 
myeloproliferative disorder (TMD) and acute megakaryoblastic leukaemia (AMKL). Patients 
TMD3, TMD6 and AMKL5 showed single nucleotide substitutions in presentation sample cDNA. 
In TMD8, alternative splicing removes exons 2-5 from the transcript, possibly removing the 234 
N-terminal amino acids. In TMD11 a 592 bp deletion removes the C-terminal 192 amino acids. 
Chromatograms of sequences from patients TMD8 and TMD11 are derived from cloned RT-
PCR products (sequencing analysis on cDNA from presentation samples shows wild-type JAK3 
sequence in addition to the mutation). Panel B shows predicted consequences of the mutations 
on the structural organization of the JAK3 protein. Boxes represent the 7 domains (JH1-JH7) of 
the JAK3 protein, arrowheads point to single nucleotide substitutions, whereas middle and lower 
diagrams show the consequences on the protein structure of the C-terminus 592 aa deletion 
and of the alternative splicing of exon 2-5. 
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Apart from containing a 592 amino acid deletion in the C-terminus, patient 
TMD3 had a single nucleotide substitution (P151R) in the FERM domain that 
had been previously reported among the loss-of-function inherited mutations 
in patients with SCID (O'Shea et al., 2004). It was impossible to establish 
whether this patient was a compound heterozygote for the two mutations or 
had two independent mutations on the same chromosome. 
 
       Patient       Material  JAK3 mutations      Outcome 
TMD1 cDNA WT CR (>5 yrs) 
TMD1 gDNA WT CR (>5 yrs) 
TMD2 gDNA WT CR (>10 yrs) 
TMD3 cDNA P151R,  
2851-3442del592 
CR (>10 yrs) 
TMD6 cDNA P434R CR (>10 yrs) 
TMD8 cDNA Splice exon2-5 NA 
TMD10 cDNA WT Died with TMD 
TMD11 cDNA 2851-3442del592 CR (>4 yrs) 
TMD15 gDNA WT NA 
AMKL-1 cDNA Splice exon2-5 CR (>7 yrs) 
AMKL-4 cDNA 2851-3442del592 Died during 
therapy 
AMKL-5 cDNA A573V Died during 
therapy 
AMKL-7 cDNA WT Died during 
therapy 
AMKL-8 cDNA WT NA 
AMKL-11 cDNA WT NA 
AMKL-12 gDNA WT NA 
AMKL-13 gDNA WT NA 
AMKL-14 gDNA WT NA  
Table 3.4. Table indicating JAK3 mutations and clinical outcome of patients included in 
this study. Table indicates patients, nature of the material used for JAK3 mutational analysis 
and clinical outcome of analysed patients. NA indicates not available; CR, complete remission 
(in brackets number of years); WT, wild type; del, deletion. 
 
Patient TMD6 contained a P434R substitution in the SH2 domain. The 
function of this domain is not completely understood, and binding partners 
have not yet been identified. Patient AMKL5 showed an A573V substitution, 
directly adjacent to A572V, one of the mutations described from Walters et al., 
as an activating (gain-of-function) mutation (Walters et al., 2006). 
Table 3.4 summarizes the mutations in JAK3 detected in this study and the 
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clinical outcome of patients analysed. 
IV.3. Final remarks  
IV.3.1. A revised role for JAK3 mutations in the pathogenesis of DS-
TMD and AMKL 
 
 
According to the “multistep” view of leukaemogenesis, acute leukaemias arise 
from the cooperation between one class of mutations that interferes with 
differentiation, such as loss-of-function mutations in haematopoietic 
transcription factors, and a second class of mutations that confers a 
proliferative advantage to cells, such as activating mutations in tyrosine 
kinases (Gilliland and Tallman, 2002). 
Walters et al. described gain-of-function JAK3 mutations in AMKL and 
demonstrated that these mutations have oncogenic potential both in vitro and 
in vivo. These findings would argue in favour of a cooperating effect of JAK3 
activating mutations with GATA-1 mutations in the context of DS-
leukaemogenesis. Walters et al. also suggested the use of a recently 
developed selective small molecule inhibitor of JAK3 as a therapeutic option 
for AMKL (Walters et al., 2006). 
Data presented in this chapter reveal a more complex spectrum of JAK3 
mutations (gain-of-function as well as loss-of-function) associated with both 
DS-TMD and AMKL. 
The following conclusions can be drawn from experimental evidence here 
presented. First, because mutations of JAK3 are present in both DS-TMD and 
DS-AMKL, they are unlikely to constitute the “third hit” responsible for 
progression of DS-TMD to DS-AMKL. 
Functional consequences of the described mutations have not been assessed. 
However, the nature of some of them (big deletions or alternative splicing 
events altering the architecture of the JAK3 protein) suggests that they would 
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result in a loss-of-function phenotype, which doesn’t support their role as 
cooperating events promoting proliferation of a clone, which has already 
acquired mutations causing a block in differentiation. These considerations 
argue against a therapeutic role for JAK3 inhibition in DS leukaemia. 
Finally, since 3/3 DS-TMD patients for whom relevant data were available 
(TMD3, TMD6 and TMD11) are all in spontaneous complete remission (for 
>10, >10 and >4 years, respectively), past the age typical for progression to 
AMKL, JAK3 mutations do not seem to constitute a predictive factor for the 
progression from TMD to AMKL. 
 
IV.3.2. Further studies on the role of activating mutations of tyrosine 
kinases in DS-leukaemia 
 
 
After or at the same time as data presented in this chapter were published,  
further studies reported contradictory evidence for a role for JAK3 in the 
pathogenesis of DS-TMD and AMKL. Kiyoi et al. described two additional 
AMKL patients (one with DS and one without DS) with mutations in the same 
domain of JAK3 (JH2 pseudokinase domain) shown to harbour activating 
mutations. They also reported a single DS-TMD patient with a mutation in a 
different JAK3 domain, without examining the functional consequences of this 
mutation. 
 Norton et al. screened a collection of 16 DS-AMKL and TMD samples and 
could not detect any mutation in JAK3. However, these results might be due to 
technical differences in the way this study was conducted (the authors 
screened only genomic DNA using a denaturing high-performance liquid 
chromatography platform for their study) (Norton et al., 2007). JAK2 and c-mpl 
were also analysed in the same set of samples, with no additional mutations 
found.  
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Sato et al. described two additional JAK3 point mutations in the DS-AMKL cell 
line MGS. One mutation was in the pseudokinase domain and the other in the 
SH2 domain of JAK3. The authors showed that both mutations were on the 
same allele in MGS and tested the transforming potential of these mutations 
individually and in combination using the Ba/F3 assay, concluding that both 
mutations were gain-of-function and that their transforming potential was 
higher when they were both present (Sato et al., 2008). The authors of this 
study also identified a novel point mutation in a TMD patient. This mutation 
was in the FERM domain of JAK3 and was shown to have a weaker 
transforming potential than the two novel mutations identified in the AMKL cell 
line. In addition, the authors tested the effect of two novel JAK3 inhibitors (less 
toxic than the one proposed in (Changelian et al., 2003)) and reinforced the 
idea of a therapeutic inhibition of JAK3 in DS-TMD and AMKL patients. Based 
on these findings, the authors suggested a role for JAK3 mutations in the 
progression from TMD to AMKL; however they could not give substance to 
this hypothesis by analysing sequential samples from individual TMD and 
AMKL patients.  
Lastly, Malinge et al. investigated the mutational status of the tyrosine kinases 
JAK2, JAK3, KIT, FLT-3 and MPL in DS and non-DS AMKL and in two TMD 
samples (Malinge et al., 2008). The authors reported a JAK-3 activating 
mutation in one DS-AMKL sample and the presence of the V617F JAK2 
mutation in another DS-AMKL, concluding that (despite the small size of 
samples analysed) mutations in tyrosine kinases might contribute to DS-
leukaemogenesis. Interestingly, examination of a unique non-DS AMKL 
patient with a FLT3 mutation showed that he harboured an additional 
chromosome 21 and a mutated GATA-1 gene, further strengthening the idea 
of an oncogenic cooperation between tyrosine kinases signaling and GATA1s 
in the trisomic context. Authors of this study also identified a novel mutation of 
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the MPL cytokine receptor (MPLT487A) in a non–DS-AMKL patient, and 
proposed that it might be specific for megakaryoblastic diseases, since it was 
not present in 30 other AML samples. Study of the MPLT487A mutant showed 
that this mutation was able to induce a myeloproliferative-like disease (MPD) 
in mice, underscoring a link between MPD and AMKL outside of the trisomic 
context. 
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4. General discussion 
 
DS is a complex condition with variable degrees of penetrance of different 
phenotypes. This broad spectrum of phenotypes is caused by the presence of 
a third copy of the entire human chromosome 21. Not all of the more than 400 
genes on HSA21 contribute to phenotypes of DS, therefore a definition of the 
trisomic increase compared to natural variation in expression levels in the 
euploid population, as well as a spatial and temporal map of expression of 
these genes are crucial in determining their role in specific pathogenic process 
associated with trisomy 21. 
Although the incidence of solid tumours is strikingly reduced at every age in 
DS, the risk of developing all types of leukaemia is highly increased in the DS 
population compared to the euploid counterpart. This increase is most 
prominent in early childhood and is contributed by both lymphoid and myeloid 
leukaemias, but the mechanisms underlying this increased risk, or the HSA21 
genes causing them, remain unknown. The incidence of ALL is approximately 
20-fold higher in children with DS than in the euploid population. As for AML, 
the relative risk of developing a particular subtype, the FAB-M7 AML or acute 
megakaryoblastic leukaemia (AMKL), is estimated to be 500 times higher in 
children with DS than in the general population (Zipursky et al., 1992). 
Approximately 1/10 of DS newborns present in the first few weeks of life a 
transient form of megakaryocytic leukaemia (TMD), which in the vast majority 
of cases self-regresses. However, as many as 30% of the patients with TMD 
will develop within 4 years a full-blown AMKL, characterised by 
megakaryocytic blasts with the same morphological and immunophenotypical 
features of TMD. Both TMD and AMKL present with a constitutional trisomy 21 
and acquired mutations of GATA-1 leading to the elimination of its full-length 
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form and to the exclusive production of GATA-1s, a partially functional form of 
this crucial megakaryocytic-erythroid transcription factor encoded on the X 
chromosome. It is clear that both these events are needed for the 
leukaemogenic transformation, but the contribution of individual genes on 
HSA21 to the development of leukaemia in DS has not yet been defined. 
In this study, an ES cell line generated by introducing an extra copy of a freely 
segregating HSA21 in the mouse euploid backgound was employed to assess 
developmental effects of trisomy 21 on the megakaryocytic lineage. The 
transchromosomic ES cells used in this study, namely 47-1, contain virtually 
all the genes on HSA21 and therefore represent the most comprehensive 
cellular model of DS so far generated. This system has been previously 
employed to model in vitro some of the other phenotypes associated with DS 
(Canzonetta et al., 2008; Mensah et al., 2007), however no data on the 
haematopoietic and megakaryocytic differentiation of trisomic ES cells are 
available to date.  
The results presented in this thesis show that an efficient generation of MKs 
from ES cells could be carried out on both the euploid and trisomic cells. 
Megakaryocytes generated in vitro from trisomic cells did not show 
morphological or numerical abnormalities compared to the ones derived from 
the euploid control (Figure I.2 and I.3).  On a molecular level, megakaryocytes 
derived from the two populations of ES cells expressed mRNA of appropriate 
genes associated with megakaryopoiesis and down-regulated the levels of at 
least one pluripotency factor (OCT-4) in a similar fashion (Figure I.4). 
Canzonetta et al. have recently demonstrated that trisomy 21 causes an 
unbalance in the regulatory network maintaining pluripotency in 
undifferentiated ES cells by the effect of DYRK1A (a gene on HSA21) on 
NRSF/REST (a TF which is a master regulator of neurogenesis and has 
recently been implicated in the circuitry of pluripotency/differentiation of ES 
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cells). Levels of NANOG and SOX-2 are sensitive to the gene dose effect of 
DYRK1A in transchromosomic ES cells, however levels of OCT-4 are 
unaffected. Therefore OCT-4 down-regulation was chosen as a further 
parameter to measure the efficiency of the megakaryocyte differentiation 
protocol utilized in my experiments.  
An interesting finding of my study was that during megakaryocytic 
differentiation, transchromosomic ES cells showed a 3 fold higher transcript 
level of GATA-1 than the euploid (D3) control (Figure I.6). In yeast, it has been 
demonstrated that high level of transcription of a gene can trigger the 
acquisition of spontaneous mutations (Datta and Jinks-Robertson, 1995). It is 
intriguing to speculate that the presence of one or more genes on HSA21 
might drive an abnormal transcription of GATA-1 that increases the chance of 
acquiring mutations in GATA-1. Alternatively, augmented levels of GATA-1 
might be responsible for, or a reflection of, an increased commitment of 
haematopoietic precursors towards the megakaryocytic lineage. Either one of 
these possible explanation for this phenotype (increased GATA-1 mRNA 
levels per cell, or higher number of GATA-1s expressing cells) could be a 
predisposing condition for a significantly increased chance of occurrence of 
GATA-1 mutations in DS. 
When I tested the clonogenic potential of trisomic megakaryocytes, I did not 
observe any numerical difference compared to the euploid cells, although I 
noticed a striking tendence of these cells to form macroscopic colonies (larger 
than 50,000 pp2) containing more undifferentiated cells (Figure I.7 and I.8).  
Macroscopic colonies formed by foetal liver progenitors, or ES cells, 
expressing GATA-1s have been previously reported as a proof of the 
hyperproliferative potential of the truncated form of GATA-1 (Li et al., 2005). In 
my study, the hyperproliferative tendency of megakaryocytes derived from 
transchromosomic ES cells at late stages of the differentiation process was 
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not due to acquired mutations of GATA-1 (Figure 1.9), but was instead 
attributable to the trisomy 21. It might be argued that this phenotype would be 
more robust if the number, rather than the morphology, of the megakaryocytic 
colonies formed by an equal number of progenitors was augmented by the 
presence of a supernumerary chromosome 21. In a similar type of assay 
(Figure I.14), ectopic expression of GATA-1s in trisomic cells indeed 
significantly augmented the number of megakaryocytic colonies compared to 
the empty vector, whereas this difference was not significant when comparing 
euploid cells transfected with GATA-1s and with the control vector. 
Taken together, these data suggest that trisomy 21 is a condition, which can 
per se influence the properties of the megakaryocytic lineage, and 
exacerbates the hyperproliferative effect of GATA-1s on the megakaryocytic 
lineage.  In order to confer a significant growth advantage to megakaryocytes, 
GATA-1s, which also influences to less extent the euploid cells, requires the 
presence of a preexisting predisposing background, which is provided by 
trisomy 21.  
Data presented in this thesis support a paradigm shift in thinking about DS-
TMD and AMKL. The “classical view” by Li et al. postulated that GATA-1 
mutation occurs randomly at a constant rate even in disomy, conferring little or 
no proliferative advantage to euploid foetal liver progenitors. In the presence 
of trisomy 21, however, the pre-malignant clone carrying a mutation in GATA-
1 would acquire a profound growth advantage, ultimately leading to TMD. In 
this thesis, I support the alternative hypothesis that trisomy 21 is a leukaemia-
predisposing condition and suggest that abnormalities of the megakaryocytic 
compartment might precede and favour the acquisition of GATA-1 mutations 
necessary for the development of leukaemia in DS. 
The case of hydrops foetalis with abnormal proliferation of the megakaryocytic 
lineage reported in chapter III provides a further in vivo-correlate for this view, 
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as a demonstration that trisomy 21 alone can cause hyperproliferation of the 
megakaryocytic lineage in DS. Furthermore, at least two independent studies 
published last year (Chou et al., 2008; Tunstall-Pedoe et al., 2008) suggested 
that trisomy 21 increases the number of MEPs in DS foetal livers. Moreover, at 
the time of writing this thesis, a report by Cabelof et al. reinforced the idea that 
trisomy is a condition that predisposes cells to acquire mutations in GATA-1 
by postulating that increased oxidative stress and defective DNA repair are 
two independent mechanisms contributing to the acquisition of GATA-1 
mutations in DS. Through analysis of foetal livers from DS aborted materials, 
the authors suggested that increased dosage of some genes on HSA21 (such 
as SOD1 and CBS) might cause increased DNA damage and a decrease in 
DNA repair ultimately leading to GATA-1 mutations (Cabelof et al., 2009).  
On a more general note, results presented in the first part of this thesis also 
demonstrate that haematopoietic differentiation in vitro of transchromosomic 
ES cells is a viable approach to identify phenotypes caused by the presence 
of trisomy 21. Despite the trans-species nature of the system, this study 
confirms that human genes on HSA21 are expressed and exert an effect on 
appropriate cellular target in the transchromosomic model (Figure I.5), as 
suggested by the recent systematic study on regulation of human gene 
expression in a mouse context by (Wilson et al., 2008). 
One of the major advantages of the tranchromosomic approach is that once in 
vitro phenotypes are described, they can be mapped to a candidate region, or 
even a single gene, on HSA21 combining the use of segmentally trisomic ES 
cells and human-specific RNAi silencing (Canzonetta et al., 2008). For the 
increased transcriptional levels of GATA-1 and the formation of macroscopic 
TPO-dependent colonies, these combined approaches are likely to identify a 
region responsible for these phenotypes. For the cooperation between GATA-
1s and trisomy 21 during megakaryocytic differentation, a more appropriate 
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approach would be to retrovirally silence human genes on HSA21 by shRNA, 
overcoming the fact that the megakaryocytic differentiation protocol used for 
this set of experiments lasts longer than the effective time range of the siRNA 
silencing by oligonucleotide transfection. 
Given its proven utility in addressing developmental disturbances caused by a 
supernumerary chromosome 21, the transchromosomic system was also 
employed in this study to test whether trisomy 21 would affect early 
mesodermal commitment and haematopoietic differentiation of the ES cells. 
One of the consequences of the perturbance of REST levels caused by the 
action of DYRK1A in transchromosomic ES cells is the premature and 
aberrant expression of differentiation-driving TFs of the mesoderm and the 
endoderm embryonic lineages (Canzonetta et al., 2008). Considering that 
haematopoietic cells originate from mesoderm during embryogenesis, it is 
intriguing to speculate that this early skewing of embryonic choices might be 
responsible for aberrant differentiation programs during mesodermal and 
haematopoietic commitment of trisomic ES cells. My study shows that 
although FLK-1 mRNA levels (indicative of the number of mesodermal 
progenitors during early stages of haematopoietic commitment) of the DS ES 
cells are not significantly different from the levels in the euploid control (Figure 
II.3), subsequent stages of the haematopoietic differentiation are profoundly 
affected by the presence of trisomy 21.  
Transchromosomic ES cells displayed higher transcriptional levels of TIE-2, c-
KIT and GATA-2 (Figure II.4). According to the most recent publications in the 
field, expression of these genes reflects two separate stages of the 
haematopoietic differentiation of ES cells, both present in the mesodermal 
colonies at day 5. According to recently published data, the co-expression of 
TIE-2 and c-KIT and absence of CD41 identifies the haemogenic endothelium 
stage, which corresponds to the formation of a specialized set of precursors of 
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endothelial origin capable of giving rise to HSCs (Lancrin et al., 2009), 
whereas GATA-2 influences the haematopoietic commitment of differentiating 
ES cells and is required for proliferation and survival of early HSCs (Lugus et 
al., 2007; Tsai and Orkin, 1997). One of the limitations of this study was that 
the transcriptional signature deregulated in trisomic ES cells was only partially 
confirmed by the identification of a population of individual cells expressing the 
above-mentioned markers. A CD41-c-KIT+ population was proven to be 
numerically bigger in the transchromosomic ES cells after five days of 
haematopoietic differentiation than in the euploid control (Figure II.5), however 
a simultaneous FACS staining for the other markers analyzed could not be 
performed for technical and logistical reasons. On the other hand, because the 
working hypothesis was to compare two different ES cell lines and to evaluate 
the effect of trisomy 21 on early stages of the development of the 
haematopoietic lineage, data presented in this study are sufficient to draw 
some valid conclusions. 
If a supernumerary HSA21 affects molecular profiling of markers crucial to the 
ontogenesis of HSC, this should have some consequences on the number or 
functional ability of HSCs/immature haematopoietic progenitors. Using a 
limited dilution assay, I could demonstrate that the number of haematopoietic 
colonies derived from the DS ES cells was higher than from the control 
euploid cells (Figure II.6). Remarkably, adult Ts65Dn mice (a partially trisomic 
model of DS) display an increased LSK (lineage- Sca-1+c-KIT+) compartment 
in the bone marrow compared to the wild type littermates, indicating a 
deregulation of the haematopoietic stem cell pool (Kirsammer et al., 2007). 
When I assessed the functional capability of the trisomic haematopoietic 
progenitors using a colony forming assay, I didn’t detect any abormalities in 
the ability of haematopoietic progenitors to form erythroid or myeloid colonies, 
showing that differentiation potential along different haematopoietic lineages 
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was preserved in the transchromosomic system. However the number of 
mixed colonies, indicative of the number of immature progenitors, was 
significanty augmented in the trisomic cells, possibly reflecting a deceleration 
in the speed of lineage commitment caused by trisomy 21 in multipotent 
haematopoietic progenitors (Figure II.8). 
Next, harnessing the potential of the transchromosomic system, I aimed to 
identify which gene or region on HSA21 was responsible for the observed 
perturbance in the expression of markers driving haematopoietic ontogenesis 
from trisomic ES cells. Between all the genes on HSA21, RUNX-1 appeared 
one of the most appealing candidates because of its fundamental role in the 
establishment of definitive haematopoiesis (Okuda et al., 1996). Growing lines 
of evidence suggest that RUNX-1 is not required for the formation of the 
haemogenic endothelium, but is necessary for the haematopoietic 
specification from this specialized set of cells (Sakai et al., 2009; Lancrin et al., 
2009). In agreement with these reports, my results exclude a role for an 
increased gene dosage of RUNX-1 in the augmented generation of 
haemogenic endothelial cells, but show that the presence of a third copy of 
RUNX-1 is necessary to influence GATA-2 levels, possibly exerting an overall 
effect on the number of haematopoietic progenitors generated by trisomic ES 
cells. These conclusions were based on the reduction to disomy of the gene in 
transchromosomic ES cells by means of the human-specific RNAi silencing 
and are corroborated by transcriptional data obtained in segmentally trisomic 
ES cells.  The fact that the panel of transchromosomic ES cells used to map 
the transcriptional phenotype might contain other complex rearrangements 
cannot be ruled out at this stage, and leaves open the possibility that RUNX-1 
might not be sufficient, or might not be the only contributor to this phenotype. 
Furthermore, it is possible to conclude that the tyrosine kinase DYRK1A (on 
HSA21) responsible for the original skewing of embryonic lineages through 
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regulation of levels of NRSF/REST (Canzonetta et al., 2008), does not affect 
the increased generation of the haemogenic endothelium in the 
transchromosomic system, as this phenomenon cannot be observed in the cell 
line 39-5, a segmental ES cell line which contains a third copy of this gene but 
harbours deletions affecting several other regions.  
The overall effect of trisomy 21 on haematopoietic development is that there is 
an increased generation of multipotent haematopoietic progenitors. It could be 
argued that this unbalanced pool of precursors might constitute a “sensitized” 
target for acquisition of mutations (JAK-2, JAK-3, GATA-1 or other) 
responsible for leukaemic transformation of both lymphoid and myeloid 
lineages. Alternatively and/or additionally, abnormal expression of lineage-
specific transcription factors driven by trisomy 21 further down the way (as 
shown for GATA-1) might influence lineage choices of this augmented pool of 
progenitors, with the consequence of a numerical increase of specific 
compartments that therefore become more prone to acquire further 
leukaemogenic hits. 
Data generated in the transchromosomic system point towards the definition 
of a complex complement of in vitro phenotypes (attributable to the presence 
of an extra copy of HSA21), which might be independent or interrelated and 
synergistically cooperating. Individual phenotypes within this complex 
complement might be caused by the same or different genes/regions on 
HSA21. This thesis provides mapping data for at least two of these 
phenotypes, identifying at least two genes independently responsible for these 
two phenotypes.  
Figure 4.1 emphasizes the novel phenotypes identified during haematopoietic 
differentiation of the transchromosomic ES cells and outlines the multi-faceted 
effects of trisomy 21 during this process. The novel phenotypes warrant a 
validation of their relevance in vivo, keeping in mind that their occurrence 
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might be variable and influenced by HSA21 genomic content and regulation of 
gene expression. For example, using primary foetal liver samples, I could 
confirm that RUNX-1 is overexpressed in DS tissues (that is compatible with 
its potential role as a player in determining the early haematopoietic stages-
phenotype), but I could not demonstrate a significant increase in the mRNA 
levels of GATA-1 in these samples. This might be due to the limited size of 
samples analyzed, but also to discrepancies between the mouse and human 
situations. The top part of the Figure 4.1 shows that a combined effect of at 
least 3 trisomic genes from HSA21 could contribute to the stochastic process 
ultimately resulting in an increased cell number of the haematopoietic stem 
cell compartment. This increase has an in vivo correlate in an observation of 
the increased LSK (lineage-Sca-1+c-KIT+) compartment in the bone marrow of 
Ts65Dn (partial DS model mice) compared to the wild type littermates 
(Kirsammer et al., 2007). The initial disturbance caused by trisomy of 
DYRK1A, via NRSF/REST pathway, increases the endodermal and 
mesodermal progenitor pools at the expense of neuroectodermal progenitor 
lineages (Canzonetta et al., 2008). This skewing is likely to cause an increase 
in the mesodermal lineage progenitors in vivo. My experiments, starting from 
the same number of mesodermal colonies, demonstrate a further effect that 
leads to the increase of cells with a molecular signature of haemogenic 
endothelium. My analysis of partially trisomic ES cells shows that this 
phenomenon cannot be attributed to either DYRK1A or RUNX1, and therefore 
must be caused by another (unknown) HSA21 gene present in a third copy. 
Synergistically with this, an increased commitment of haemogenic endothelial 
cells to functional HSCs is also shown in my experiments, demonstrating that 
trisomy of RUNX1 is necessary for this cellular phenotype.  
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Fig. 4.1. Multiple effects of trisomy 21 on HSCs ontogenesis and on the megakaryocytic lineage 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The combined action of all of these cellular phenotypes, not ruling out 
potential additional trisomy 21 effects, leads to an increased number of HSCs, 
that have an increased propensity to generate more immature multipotent 
precursors of haematopoietic lineages, as demonstrated by my limited dilution 
assay. I propose that all of these factors combined create an increased 
chance for the occurrence of additional leukaemogenic mutations, which could 
explain the increased risk of childhood leukaemias of all types in DS.  
The bottom part of the figure IV.1 focuses on the megakaryocytic lineage, the 
cellular substrate of the DS-associated TMD and AMKL. At this level, my 
experiments uncover three separate additional cellular phenotypes that may 
be caused by the same or different HSA21 genes. I propose that these effects 
additionally create conditions of a high risk of acquisitions of the GATA1 
mutations. When the nature of acquired mutations generates GATA1s, such 
cells acquire a further proliferative boost provided by yet another (unknown) 
trisomic HSA21 gene. 
This last phenotype may be caused by the trisomy of the HSA21 gene ERG, 
as recently published data show (Salek-Ardakani et al., 2009). In the absence 
of GATA1 mutations, these combined effects on the megakaryocytic lineage 
lead to a hyperproliferative state, perhaps depending on the variant of the 
overall level of expression of the culprit HSA21 genes, and/or their interactors. 
The clinical outcome of such a hyperproliferative state can, in extreme cases, 
be very similar to the full-blown TMD, even in the absence of GATA1 
mutations, as the case of the hydrops foetalis described in this thesis, and 
recently published data on DS foetal liver progenitors (Tunstall-Pedoe et al., 
2008; Chou et al., 2008) would suggest. 
Lastly, the final part of this work aimed to address a role for JAK-3 in the 
pathogenesis of DS megakaryocytic leukaemia. A puzzling aspect of this 
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disease is that, although in the vast majority of DS newborns with TMD the 
abnormal megakaryoblastic proliferation self-regresses, as many as 30% of 
these patients will develop a more aggressive acute leukaemia within a few 
years. It is clear that further unidentified hits are required for the progression of 
malignancy of the TMD clone that harbours an extra HSA21 and mutations in 
GATA-1. Previous data had suggested a role for JAK-3 in this progression 
(Walters et al., 2006), however analysis of primary samples reported in 
chapter IV and results from independent groups (Kiyoi et al., 2007) (Sato et 
al., 2008) generated simultaneously, or after this study, allow to exclude that 
the evolution of TMD to AMKL might be ascribable to activating mutations of 
this gene, because they are present in both DS-TMD and AMKL primary 
samples. Furthermore, this study identifies for the first time loss-of-function 
mutations of JAK3, demonstrating that the proposed therapeutic inhibition of 
this tyrosine kinase is not an effective approach for DS leukaemia.  
In conclusion, this thesis provides a comprehensive analysis of the effects of 
trisomy 21 on haematopoietic development with a special focus on the 
megakaryocytic lineage, and identifies novel phenotypes that might be 
relevant to the occurrence of leukaemia while providing a viable approach to 
dissect the contribution of individual gene/regions of HSA21 in determining 
these phenotypes.  
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4.1. Summary of conclusions   
• Megakaryocytes can be derived in vitro from transchromosomic ES cells at the 
same rate and with the same morphological properties as from the euploid 
control. However, during megakaryocytic differentiation, trisomy 21 drives an 
increased expression of the transcription factor GATA-1, which might 
predispose these cells to acquire mutations of the gene. Trisomy 21 alone, 
independently of mutations in GATA-1, is also responsible for the formation of 
macroscopic megakaryocytic colonies with a hyperproliferative tendency.  
• Overexpression of GATA-1s exacerbates the hyperproliferative effect seen in 
megakaryocytic colonies derived from trisomic progenitors. Number of 
megakaryocytic colonies generated by transchromosomic progenitors 
expressing GATA-1s is significantly higher than the number generated from 
trisomic cells transduced with a control vector. Although this increase is also 
induced by GATA-1s in euploid progenitors, the difference between disomic 
cells transfected with GATA-1s or an empty vector is not significant.   
• Ontogenesis of HSCs from mesodermal precursors is profoundly affected by 
trisomy 21. The presence of a supernumerary copy of HSA21 causes an 
increased formation of haemogenic endothelial cells and an increased 
commitment towards the haematopoietic lineage, with the overall 
consequence of the formation of more trisomic immature haematopoietic 
progenitors. 
 
• A third copy of at least two independent genes on HSA21 is required for the 
increased generation of trisomic haematopoietic progenitors from mesodermal 
precursors. Trisomy of a gene other than RUNX-1 or DYRK1A is required for 
the increased formation of haemogenic endothelial cells, whereas trisomy of 
RUNX-1 is necessary for the regulation of the mRNA levels of GATA-2 
(controlling the haematopoietic commitment), which ultimately results in the 
increased formation of trisomic immature haematopoietic progenitors. 
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• Mutations in JAK3 can occur in both DS-TMD and AMKL; therefore they are 
not required for the progression of malignancy of DS leukaemia. Furthermore, 
both gain- as well as loss-of-function mutations of JAK3 are present in primary 
DS samples, undermining a role for a therapeutic inhibition of JAK3 in this 
disease. 
 
• A new paradigm for leukaemogenesis in DS is established in this thesis. 
Trisomy 21 influences haematopoiesis (in general) and the megakaryocytic 
lineage (in particular) at several levels. Three copies of more than one gene 
on HSA21 are required for these effects and the overall consequence of these 
independent or inter-related events is compatible with an increased 
predisposition to acquire further leukaemogenic mutations in all 
haematopoietic lineages. 
  200 
5. References   
Aardema, M.J., Crosby, L.L., Gibson, D.P., Kerckaert, G.A., and LeBoeuf, R.A. 
(1997). Aneuploidy and consistent structural chromosome changes associated with 
transformation of Syrian hamster embryo cells. Cancer Genet Cytogenet 96, 140-
150. 
Agarwala, K.L., Ganesh, S., Suzuki, T., Akagi, T., Kaneko, K., Amano, K., Tsutsumi, 
Y., Yamaguchi, K., Hashikawa, T., and Yamakawa, K. (2001). Dscam is associated 
with axonal and dendritic features of neuronal cells. J Neurosci Res 66, 337-346. 
Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O'Marcaigh, A., Wynn, 
R., Stevens, R., Addison, M., King, D., et al. (2004). Natural history of GATA1 
mutations in Down syndrome. Blood 103, 2480-2489. 
Ait Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., 
Rossier, J., Personnaz, L., Creau, N., Blehaut, H., et al. (2007). Classification of 
human chromosome 21 gene-expression variations in Down syndrome: impact on 
disease phenotypes. Am J Hum Genet 81, 475-491. 
Akashi, K., Traver, D., Miyamoto, T., and Weissman, I.L. (2000). A clonogenic 
common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-
197. 
Allen, G., Benda, C.E., Book, J.A., Carter, C.O., Ford, C.E., Chu, E.H., Hanhart, E., 
Jervis, G., Langdon-Down, W., Lejeune, J., et al. (1961). Mongolism. Am J Hum 
Genet 13, 426. 
Antonarakis, S.E. (1991). Parental origin of the extra chromosome in trisomy 21 as 
indicated by analysis of DNA polymorphisms. Down Syndrome Collaborative Group. 
N Engl J Med 324, 872-876. 
Antonarakis, S.E., Adelsberger, P.A., Petersen, M.B., Binkert, F., and Schinzel, A.A. 
(1990). Analysis of DNA polymorphisms suggests that most de novo dup(21q) 
chromosomes in patients with Down syndrome are isochromosomes and not 
translocations. Am J Hum Genet 47, 968-972. 
Antonarakis, S.E., Avramopoulos, D., Blouin, J.L., Talbot, C.C., Jr., and Schinzel, 
A.A. (1993). Mitotic errors in somatic cells cause trisomy 21 in about 4.5% of cases 
and are not associated with advanced maternal age. Nat Genet 3, 146-150. 
Antonarakis, S.E., Lyle, R., Dermitzakis, E.T., Reymond, A., and Deutsch, S. 
(2004). Chromosome 21 and down syndrome: from genomics to pathophysiology. 
Nat Rev Genet 5, 725-738. 
 
  201 
Antonarakis, S.E., Petersen, M.B., McInnis, M.G., Adelsberger, P.A., Schinzel, A.A., 
Binkert, F., Pangalos, C., Raoul, O., Slaugenhaupt, S.A., Hafez, M., et al. (1992). 
The meiotic stage of nondisjunction in trisomy 21: determination by using DNA 
polymorphisms. Am J Hum Genet 50, 544-550. 
Arinobu, Y., Mizuno, S., Chong, Y., Shigematsu, H., Iino, T., Iwasaki, H., Graf, T., 
Mayfield, R., Chan, S., Kastner, P., et al. (2007). Reciprocal activation of GATA-1 
and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid 
and myelolymphoid lineages. Cell Stem Cell 1, 416-427. 
Arron, J.R., Winslow, M.M., Polleri, A., Chang, C.P., Wu, H., Gao, X., Neilson, J.R., 
Chen, L., Heit, J.J., Kim, S.K., et al. (2006). NFAT dysregulation by increased 
dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600. 
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jorgensen, H.F., John, R.M., Gouti, 
M., Casanova, M., Warnes, G., Merkenschlager, M., et al. (2006). Chromatin 
signatures of pluripotent cell lines. Nat Cell Biol 8, 532-538. 
Baird, P.A., and Sadovnick, A.D. (1989). Life tables for Down syndrome. Hum 
Genet 82, 291-292. 
Balkany, T.J., Downs, M.P., Jafek, B.W., and Krajicek, M.J. (1979). Hearing loss in 
Down's syndrome. A treatable handicap more common than generally recognized. 
Clin Pediatr (Phila) 18, 116-118. 
Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., 
Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., et al. (2005). Acquired mutation 
of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 
1054-1061. 
Baxter, L.L., Moran, T.H., Richtsmeier, J.T., Troncoso, J., and Reeves, R.H. (2000). 
Discovery and genetic localization of Down syndrome cerebellar phenotypes using 
the Ts65Dn mouse. Hum Mol Genet 9, 195-202. 
Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., 
Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., et al. (2008). Mutations of JAK2 
in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 
1484-1492. 
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., 
Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure 
marks key developmental genes in embryonic stem cells. Cell 125, 315-326. 
Boker, L.K., Blumstein, T., Sadetzki, S., Luxenburg, O., Litvak, I., Akstein, E., and 
Modan, B. (2001). Incidence of leukemia and other cancers in Down syndrome 
subjects in Israel. Int J Cancer 93, 741-744. 
Borzillo, G.V., Ashmun, R.A., and Sherr, C.J. (1990). Macrophage lineage switching 
of murine early pre-B lymphoid cells expressing transduced fms genes. Mol Cell Biol 
10, 2703-2714. 
  202 
Bouilloux, F., Juban, G., Cohet, N., Buet, D., Guyot, B., Vainchenker, W., Louache, 
F., and Morle, F. (2008). EKLF restricts megakaryocytic differentiation at the benefit 
of erythrocytic differentiation. Blood 112, 576-584. 
Bourquin, J.P., Subramanian, A., Langebrake, C., Reinhardt, D., Bernard, O., 
Ballerini, P., Baruchel, A., Cave, H., Dastugue, N., Hasle, H., et al. (2006). 
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia 
by gene expression profiling. Proc Natl Acad Sci U S A 103, 3339-3344. 
Bovicelli, L., Orsini, L.F., Rizzo, N., Montacuti, V., and Bacchetta, M. (1982). 
Reproduction in Down syndrome. Obstet Gynecol 59, 13S-17S. 
Boyer, L.A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L.A., Lee, T.I., Levine, 
S.S., Wernig, M., Tajonar, A., Ray, M.K., et al. (2006). Polycomb complexes repress 
developmental regulators in murine embryonic stem cells. Nature 441, 349-353. 
Brown, A.S., Feingold, E., Broman, K.W., and Sherman, S.L. (2000). Genome-wide 
variation in recombination in female meiosis: a risk factor for non-disjunction of 
chromosome 21. Hum Mol Genet 9, 515-523. 
Broxmeyer, H.E., Srour, E.F., Hangoc, G., Cooper, S., Anderson, S.A., and Bodine, 
D.M. (2003). High-efficiency recovery of functional hematopoietic progenitor and 
stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci  
U S A 100, 645-650. 
Cabelof, D.C., Patel, H.V., Chen, Q., van Remmen, H., Matherly, L.H., Ge, Y., and 
Taub, J.W. (2009). Mutational spectrum at GATA1 provides insights into 
mutagenesis and leukemogenesis in down syndrome. Blood. 
Cai, Z., de Bruijn, M., Ma, X., Dortland, B., Luteijn, T., Downing, R.J., and Dzierzak, 
E. (2000). Haploinsufficiency of AML1 affects the temporal and spatial generation of 
hematopoietic stem cells in the mouse embryo. Immunity 13, 423-431. 
Calligaris, R., Bottardi, S., Cogoi, S., Apezteguia, I., and Santoro, C. (1995). 
Alternative translation initiation site usage results in two functionally distinct forms of 
the GATA-1 transcription factor. Proc Natl Acad Sci U S A 92, 11598-11602. 
Candotti, F., Oakes, S.A., Johnston, J.A., Giliani, S., Schumacher, R.F., Mella, P., 
Fiorini, M., Ugazio, A.G., Badolato, R., Notarangelo, L.D., et al. (1997). Structural 
and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 
90, 3996-4003. 
Cantor, A.B., and Orkin, S.H. (2002). Transcriptional regulation of erythropoiesis: an 
affair involving multiple partners. Oncogene 21, 3368-3376. 
Canzonetta, C., Mulligan, C., Deutsch, S., Ruf, S., O'Doherty, A., Lyle, R., Borel, C., 
Lin-Marq, N., Delom, F., Groet, J., et al. (2008). DYRK1A-dosage imbalance 
perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate 
in Down syndrome. Am J Hum Genet 83, 388-400. 
  203 
Carmichael, C.L., Majewski, I.J., Alexander, W.S., Metcalf, D., Hilton, D.J., Hewitt, 
C.A., and Scott, H.S. (2009). Hematopoietic defects in the Ts1Cje mouse model of 
Down syndrome. Blood 113, 1929-1937. 
Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, 
W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., et al. (2003). 
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. 
Science 302, 875-878. 
Chen, C.Z., Li, L., Lodish, H.F., and Bartel, D.P. (2004). MicroRNAs modulate 
hematopoietic lineage differentiation. Science 303, 83-86. 
Chen, L., and Daley, G.Q. (2008). Molecular basis of pluripotency. Hum Mol Genet 
17, R23-27. 
Chen, M.J., Yokomizo, T., Zeigler, B.M., Dzierzak, E., and Speck, N.A. (2009). 
Runx1 is required for the endothelial to haematopoietic cell transition but not 
thereafter. Nature 457, 887-891. 
Cherry, S.R., Biniszkiewicz, D., van Parijs, L., Baltimore, D., and Jaenisch, R. 
(2000). Retroviral expression in embryonic stem cells and hematopoietic stem cells. 
Mol Cell Biol 20, 7419-7426. 
Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J.C., and Keller, G. (1998). A 
common precursor for hematopoietic and endothelial cells. Development 125, 725-
732. 
Chou, S.T., Opalinska, J.B., Yao, Y., Fernandes, M.A., Kalota, A., Brooks, J.S., 
Choi, J.K., Gewirtz, A.M., Danet-Desnoyers, G.A., Nemiroff, R.L., et al. (2008). 
Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 112, 
4503-4506. 
Chrast, R., Scott, H.S., Papasavvas, M.P., Rossier, C., Antonarakis, E.S., Barras, 
C., Davisson, M.T., Schmidt, C., Estivill, X., Dierssen, M., et al. (2000). The mouse 
brain transcriptome by SAGE: differences in gene expression between P30 brains 
of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. 
Genome Res 10, 2006-2021. 
Cox, D.R., Smith, S.A., Epstein, L.B., and Epstein, C.J. (1984). Mouse trisomy 16 as 
an animal model of human trisomy 21 (Down syndrome): production of viable 
trisomy 16 diploid mouse chimeras. Dev Biol 101, 416-424. 
Crider, K.S., Olney R.S., and Cragan J.D. (2008). Trisomies 13 and 18: Population 
Prevalences, Characteristics, and Prenatal Diagnosis, Metropolitan Atlanta, 1994–
2003. Am Journ of Med Genetics Part A 146A: 820–826 
 
 
 
  204 
Crispino, J.D., Lodish, M.B., MacKay, J.P., and Orkin, S.H. (1999). Use of altered 
specificity mutants to probe a specific protein-protein interaction in differentiation: 
the GATA-1:FOG complex. Mol Cell 3, 219-228. 
Cuthbert, A.P., Trott, D.A., Ekong, R.M., Jezzard, S., England, N.L., Themis, M., 
Todd, C.M., and Newbold, R.F. (1995). Construction and characterization of a 
highly stable human: rodent monochromosomal hybrid panel for genetic 
complementation and genome mapping studies. Cytogenet Cell Genet 71, 68-76. 
Daley, G.Q. (2003). From embryos to embryoid bodies: generating blood from 
embryonic stem cells. Ann N Y Acad Sci 996, 122-131. 
Datta, A., and Jinks-Robertson, S. (1995). Association of increased spontaneous 
mutation rates with high levels of transcription in yeast. Science 268, 1616-1619. 
Davisson, M.T., Schmidt, C., and Akeson, E.C. (1990). Segmental trisomy of murine 
chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol 
Res 360, 263-280. 
de Bruijn, M.F., Speck, N.A., Peeters, M.C., and Dzierzak, E. (2000). Definitive 
hematopoietic stem cells first develop within the major arterial regions of the mouse 
embryo. EMBO J 19, 2465-2474. 
Delabar, J.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., 
Noel, B., and Sinet, P.M. (1993). Molecular mapping of twenty-four features of 
Down syndrome on chromosome 21. Eur J Hum Genet 1, 114-124. 
Dierssen, M., Fillat, C., Crnic, L., Arbones, M., Florez, J., and Estivill, X. (2001). 
Murine models for Down syndrome. Physiol Behav 73, 859-871. 
Doetschman, T.C., Eistetter, H., Katz, M., Schmidt, W., and Kemler, R. (1985). The 
in vitro development of blastocyst-derived embryonic stem cell lines: formation of 
visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87, 27-45. 
Down, J.L. (1995). Observations on an ethnic classification of idiots. 1866. Ment 
Retard 33, 54-56. 
Dowton, S.B., Beardsley, D., Jamison, D., Blattner, S., and Li, F.P. (1985). Studies 
of a familial platelet disorder. Blood 65, 557-563. 
Dzierzak, E., and Speck, N.A. (2008). Of lineage and legacy: the development of 
mammalian hematopoietic stem cells. Nat Immunol 9, 129-136. 
Elagib, K.E., Racke, F.K., Mogass, M., Khetawat, R., Delehanty, L.L., and Goldfarb, 
A.N. (2003). RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic 
differentiation. Blood 101, 4333-4341. 
Epstein, C.J. (2001). Down Syndrome (Trisomy 21) In The metabolic and molecular 
bases of inherited disease, 8th edition (New York, McGraw-Hill.) 
  205 
Epstein, C.J., Hofmeister, B.G., Yee, D., Smith, S.A., Philip, R., Cox, D.R., and 
Epstein, L.B. (1985). Stem cell deficiencies and thymic abnormalities in fetal mouse 
trisomy 16. J Exp Med 162, 695-712. 
Era, T., Takagi, T., Takahashi, T., Bories, J.C., and Nakano, T. (2000). 
Characterization of hematopoietic lineage-specific gene expression by ES cell in 
vitro differentiation induction system. Blood 95, 870-878. 
Eto, K., Leavitt, A.L., Nakano, T., and Shattil, S.J. (2003). Development and 
analysis of megakaryocytes from murine embryonic stem cells. Methods Enzymol 
365, 142-158. 
Eto, K., Murphy, R., Kerrigan, S.W., Bertoni, A., Stuhlmann, H., Nakano, T., Leavitt, 
A.D., and Shattil, S.J. (2002). Megakaryocytes derived from embryonic stem cells 
implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci U S A 99, 12819-
12824. 
Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential 
cells from mouse embryos. Nature 292, 154-156. 
Ferkowicz, M.J., Starr, M., Xie, X., Li, W., Johnson, S.A., Shelley, W.C., Morrison, 
P.R., and Yoder, M.C. (2003). CD41 expression defines the onset of primitive and 
definitive hematopoiesis in the murine embryo. Development 130, 4393-4403. 
Ferreira, R., Ohneda, K., Yamamoto, M., and Philipsen, S. (2005). GATA1 function, 
a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25, 1215-1227. 
Ferrer, I., and Gullotta, F. (1990). Down's syndrome and Alzheimer's disease: 
dendritic spine counts in the hippocampus. Acta Neuropathol (Berl) 79, 680-685. 
Fisher, A.G. (2002). Cellular identity and lineage choice. Nat Rev Immunol 2, 977-
982. 
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, 
C., Fodale, V., Clappier, E., Paoloni, F., et al. (2008). Somatically acquired JAK1 
mutations in adult acute lymphoblastic leukemia. J Exp Med 205, 751-758. 
Forestier, E., Izraeli, S., Beverloo, B., Haas, O., Pession, A., Michalova, K., Stark, 
B., Harrison, C.J., Teigler-Schlegel, A., and Johansson, B. (2008). Cytogenetic 
features of acute lymphoblastic and myeloid leukemias in pediatric patients with 
Down syndrome: an iBFM-SG study. Blood 111, 1575-1583. 
Fournier, R.E., and Ruddle, F.H. (1977). Microcell-mediated transfer of murine 
chromosomes into mouse, Chinese hamster, and human somatic cells. Proc Natl 
Acad Sci U S A 74, 319-323. 
Fuentes, J.J., Pritchard, M.A., Planas, A.M., Bosch, A., Ferrer, I., and Estivill, X. 
(1995). A new human gene from the Down syndrome critical region encodes a 
proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 4, 
1935-1944. 
  206 
Fujita, Y., Nishimura, M., Taniwaki, M., Abe, T., and Okuda, T. (2001). Identification 
of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c 
and its expression in early hematopoietic development. Biochem Biophys Res 
Commun 281, 1248-1255. 
Fujiwara, Y., Browne, C.P., Cunniff, K., Goff, S.C., and Orkin, S.H. (1996). Arrested 
development of embryonic red cell precursors in mouse embryos lacking 
transcription factor GATA-1. Proc Natl Acad Sci U S A 93, 12355-12358. 
Gaines, P., Geiger, J.N., Knudsen, G., Seshasayee, D., and Wojchowski, D.M. 
(2000). GATA-1- and FOG-dependent activation of megakaryocytic alpha IIB gene 
expression. J Biol Chem 275, 34114-34121. 
Galante, M., Jani, H., Vanes, L., Daniel, H., Fisher, E.M., Tybulewicz, V.L., Bliss, 
T.V., and Morice, E. (2009). Impairments in motor coordination without major 
changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum 
Mol Genet 18, 1449-1463. 
Gamis, A.S., and Hilden, J.M. (2002). Transient myeloproliferative disorder, a 
disorder with too few data and many unanswered questions: does it contain an 
important piece of the puzzle to understanding hematopoiesis and acute 
myelogenous leukemia? J Pediatr Hematol Oncol 24, 2-5. 
Garzon, R., Pichiorri, F., Palumbo, T., Iuliano, R., Cimmino, A., Aqeilan, R., Volinia, 
S., Bhatt, D., Alder, H., Marcucci, G., et al. (2006). MicroRNA fingerprints during 
human megakaryocytopoiesis. Proc Natl Acad Sci U S A 103, 5078-5083. 
Glasson, E.J., Sullivan, S.G., Hussain, R., Petterson, B.A., Montgomery, P.D. and 
Bittles, A.H. (2002). The changing survival profile of people with Down’s syndrome: 
implications for genetic counselling. Clin Genet., 62, 390–393. 
Ge, Y., LaFiura, K.M., Dombkowski, A.A., Chen, Q., Payton, S.G., Buck, S.A., 
Salagrama, S., Diakiw, A.E., Matherly, L.H., and Taub, J.W. (2008). The role of the 
proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. 
Leukemia 22, 521-529. 
Gilliland, D.G., and Tallman, M.S. (2002). Focus on acute leukemias. Cancer Cell 1, 
417-420. 
Goldacre, M.J., Wotton, C.J., Seagroatt, V., and Yeates, D. (2004). Cancers and 
immune related diseases associated with Down's syndrome: a record linkage study. 
Arch Dis Child 89, 1014-1017. 
Granholm, A.C., Sanders, L.A., and Crnic, L.S. (2000). Loss of cholinergic 
phenotype in basal forebrain coincides with cognitive decline in a mouse model of 
Down's syndrome. Exp Neurol 161, 647-663. 
Grasso, M., Giovannucci Uzielli, M.L., Pierluigi, M., Tavellini, F., Perroni, L., and 
Dagna Bricarelli, F. (1989). Isochromosome not translocation in trisomy 21q21q. 
Hum Genet 84, 63-65. 
  207 
Groet, J., Ives, J.H., Jones, T.A., Danton, M., Flomen, R.H., Sheer, D., Hrascan, R., 
Pavelic, K., and Nizetic, D. (2000). Narrowing of the region of allelic loss in 21q11-
21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-
specific protease gene from the deleted segment. Genes Chromosomes Cancer 27, 
153-161. 
Groet, J., McElwaine, S., Spinelli, M., Rinaldi, A., Burtscher, I., Mulligan, C., 
Mensah, A., Cavani, S., Dagna-Bricarelli, F., Basso, G., et al. (2003). Acquired 
mutations in GATA1 in neonates with Down's syndrome with transient myeloid 
disorder. Lancet 361, 1617-1620. 
Groet, J., Mulligan, C., Spinelli, M., Serra, A., McElwaine, S., Cotter, F.E., Dagna-
Bricarelli, F., Saglio, G., Basso, G., and Nizetic, D. (2005). Independent clones at 
separable stages of differentiation, bearing different GATA1 mutations, in the same 
TMD patient with Down syndrome. Blood 106, 1887-1888. 
Habets, G.G., Scholtes, E.H., Zuydgeest, D., van der Kammen, R.A., Stam, J.C., 
Berns, A., and Collard, J.G. (1994). Identification of an invasion-inducing gene, 
Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like 
proteins. Cell 77, 537-549. 
Hammerle, B., Vera-Samper, E., Speicher, S., Arencibia, R., Martinez, S., and 
Tejedor, F.J. (2002). Mnb/Dyrk1A is transiently expressed and asymmetrically 
segregated in neural progenitor cells at the transition to neurogenic divisions. Dev 
Biol 246, 259-273. 
Hasle, H., Clemmensen, I.H., and Mikkelsen, M. (2000). Risks of leukaemia and 
solid tumours in individuals with Down's syndrome. Lancet 355, 165-169. 
Hassold, T., Abruzzo, M., Adkins, K., Griffin, D., Merrill, M., Millie, E., Saker, D., 
Shen, J. and Zaragoza, M. (1996). Human aneuploidy: incidence, origin, and 
etiology. Environ Mol Mutagen 28, 167–175. 
Hassold, T., and Hunt, P. (2001). To err (meiotically) is human: the genesis of 
human aneuploidy. Nat Rev Genet 2, 280-291. 
Hassold, T.J., and Jacobs, P.A. (1984). Trisomy in man. Annu Rev Genet 18, 69-
97. 
Helgason, C.D., Sauvageau, G., Lawrence, H.J., Largman, C., and Humphries, R.K. 
(1996). Overexpression of HOXB4 enhances the hematopoietic potential of 
embryonic stem cells differentiated in vitro. Blood 87, 2740-2749. 
Henry, E., Walker, D., Wiedmeier, S.E., and Christensen, R.D. (2007). 
Hematological abnormalities during the first week of life among neonates with Down 
syndrome: data from a multihospital healthcare system. Am J Med Genet A 143, 42-
50. 
  208 
Hermon, C., Alberman, E., Beral, V., and Swerdlow, A.J. (2001). Mortality and 
cancer incidence in persons with Down's syndrome, their parents and siblings. Ann 
Hum Genet 65, 167-176. 
Hernandez, D., Mee, P.J., Martin, J.E., Tybulewicz, V.L., and Fisher, E.M. (1999). 
Transchromosomal mouse embryonic stem cell lines and chimeric mice that contain 
freely segregating segments of human chromosome 21. Hum Mol Genet 8, 923-
933. 
Hill, D.A., Gridley, G., Cnattingius, S., Mellemkjaer, L., Linet, M., Adami, H.O., 
Olsen, J.H., Nyren, O., and Fraumeni, J.F., Jr. (2003). Mortality and cancer 
incidence among individuals with Down syndrome. Arch Intern Med 163, 705-711. 
Hirose, Y., Kudo, K., Kiyoi, H., Hayashi, Y., Naoe, T., and Kojima, S. (2003). 
Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of 
Down's syndrome. Leukemia 17, 2250-2252. 
Hitzler, J.K. (2007). Acute megakaryoblastic leukemia in Down syndrome. Pediatr 
Blood Cancer 49, 1066-1069. 
Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W., and Zipursky, A. (2003). GATA1 
mutations in transient leukemia and acute megakaryoblastic leukemia of Down 
syndrome. Blood 101, 4301-4304. 
Hitzler, J.K., and Zipursky, A. (2005). Origins of leukaemia in children with Down 
syndrome. Nat Rev Cancer 5, 11-20. 
Ho, C.Y., Otterud, B., Legare, R.D., Varvil, T., Saxena, R., DeHart, D.B., Kohler, 
S.E., Aster, J.C., Dowton, S.B., Li, F.P., et al. (1996). Linkage of a familial platelet 
disorder with a propensity to develop myeloid malignancies to human chromosome 
21q22.1-22.2. Blood 87, 5218-5224. 
Hoffmann, G.R., Dellarco, V.L., and Voytek, P.E. (1986). A review of the symposium 
on aneuploidy: etiology and mechanism. Environ Mutagen 8, 643-651. 
Hollanda, L.M., Lima, C.S., Cunha, A.F., Albuquerque, D.M., Vassallo, J., Ozelo, 
M.C., Joazeiro, P.P., Saad, S.T., and Costa, F.F. (2006). An inherited mutation 
leading to production of only the short isoform of GATA-1 is associated with 
impaired erythropoiesis. Nat Genet 38, 807-812. 
Holtzman, D.M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D.J., 
Daniels, S.E., Johnson, R.M., Chen, K., Sun, Y., Carlson, E., et al. (1996). 
Developmental abnormalities and age-related neurodegeneration in a mouse model 
of Down syndrome. Proc Natl Acad Sci U S A 93, 13333-13338. 
Houbaviy, H.B., Murray, M.F., and Sharp, P.A. (2003). Embryonic stem cell-specific 
MicroRNAs. Dev Cell 5, 351-358. 
  209 
Huang, H., Yu, M., Akie, T.E., Moran, T.B., Woo, A.J., Tu, N., Waldon, Z., Lin, Y.Y., 
Steen, H., and Cantor, A.B. (2009a). Differentiation-dependent Interactions between 
RUNX-1 and FLI-1 During Megakaryocyte Development. Mol Cell Biol. 
Huang, Z., Dore, L.C., Li, Z., Orkin, S.H., Feng, G., Lin, S., and Crispino, J.D. 
(2009b). GATA-2 reinforces megakaryocyte development in the absence of GATA-
1. Mol Cell Biol. 
Hulten, M.A., Patel, S.D., Tankimanova, M., Westgren, M., Papadogiannakis, N., 
Jonsson, A.M., and Iwarsson, E. (2008). On the origin of trisomy 21 Down 
syndrome. Mol Cytogenet 1, 21. 
Huret, J.L., and Leonard, C. (1997). Chromosome 21 and platelets: a gene dosage 
effect? Clin Genet 51, 140-141. 
Ichikawa, M., Asai, T., Chiba, S., Kurokawa, M., and Ogawa, S. (2004a). 
Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle 3, 
722-724. 
Ichikawa, M., Asai, T., Saito, T., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., 
Chiba, S., Ogawa, S., Kurokawa, M., et al. (2004b). AML-1 is required for 
megakaryocytic maturation and lymphocytic differentiation, but not for maintenance 
of hematopoietic stem cells in adult hematopoiesis. Nat Med 10, 299-304. 
Ito, E., Kasai, M., Hayashi, Y., Toki, T., Arai, K., Yokoyama, S., Kato, K., Tachibana, 
N., Yamamoto, M., and Yokoyama, M. (1995). Expression of erythroid-specific 
genes in acute megakaryoblastic leukaemia and transient myeloproliferative 
disorder in Down's syndrome. Br J Haematol 90, 607-614. 
Ives, J.H., Dagna-Bricarelli, F., Basso, G., Antonarakis, S.E., Jee, R., Cotter, F., and 
Nizetic, D. (1998). Increased levels of a chromosome 21-encoded tumour invasion 
and metastasis factor (TIAM1) mRNA in bone marrow of Down syndrome children 
during the acute phase of AML(M7). Genes Chromosomes Cancer 23, 61-66. 
Izraeli, S. (2008). Trisomy 21 tilts the balance. Blood 112, 4361-4362. 
Jackers, P., Szalai, G., Moussa, O., and Watson, D.K. (2004). Ets-dependent 
regulation of target gene expression during megakaryopoiesis. J Biol Chem 279, 
52183-52190. 
Jacobs, P.A. (1992). The chromosome complement of human gametes. Oxf Rev 
Reprod Biol 14, 47-72. 
Jacobs, P.A., Baikie, A.G., Court Brown, W.M., and Strong, J.A. (1959). The 
somatic chromosomes in mongolism. Lancet 1, 710. 
Jaffredo, T., Gautier, R., Eichmann, A., and Dieterlen-Lievre, F. (1998). Intraaortic 
hemopoietic cells are derived from endothelial cells during ontogeny. Development 
125, 4575-4583. 
  210 
Jaffredo, T., Nottingham, W., Liddiard, K., Bollerot, K., Pouget, C., and de Bruijn, M. 
(2005). From hemangioblast to hematopoietic stem cell: an endothelial connection? 
Exp Hematol 33, 1029-1040. 
Jezierski, A., Swedani, A., and Wang, L. (2007). Development of hematopoietic and 
endothelial cells from human embryonic stem cells: lessons from the studies using 
mouse as a model. ScientificWorldJournal 7, 1950-1964. 
Kadri, Z., Shimizu, R., Ohneda, O., Maouche-Chretien, L., Gisselbrecht, S., 
Yamamoto, M., Romeo, P.H., Leboulch, P., and Chretien, S. (2009). Direct binding 
of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during 
erythropoiesis. PLoS Biol 7, e1000123. 
Kearney, L., Gonzalez De Castro, D., Yeung, J., Procter, J., Horsley, S.W., Eguchi-
Ishimae, M., Bateman, C.M., Anderson, K., Chaplin, T., Young, B.D., et al. (2009). 
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome 
acute lymphoblastic leukemia. Blood 113, 646-648. 
Keller, G., Kennedy, M., Papayannopoulou, T., and Wiles, M.V. (1993). 
Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol 
Cell Biol 13, 473-486. 
Kelly, L.M., and Gilliland, D.G. (2002). Genetics of myeloid leukemias. Annu Rev 
Genomics Hum Genet 3, 179-198. 
Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M.M., and 
Crispino, J.D. (2007). Highly penetrant myeloproliferative disease in the Ts65Dn 
mouse model of Down syndrome. Blood 111(2), 767-75. 
Kitajima, K., Masuhara, M., Era, T., Enver, T., and Nakano, T. (2002). GATA-2 and 
GATA-2/ER display opposing activities in the development and differentiation of 
blood progenitors. EMBO J 21, 3060-3069. 
Kitajima, K., Tanaka, M., Zheng, J., Sakai-Ogawa, E., and Nakano, T. (2003). In 
vitro differentiation of mouse embryonic stem cells to hematopoietic cells on an OP9 
stromal cell monolayer. Methods Enzymol 365, 72-83. 
Kiyoi, H., Yamaji, S., Kojima, S., and Naoe, T. (2007). JAK3 mutations occur in 
acute megakaryoblastic leukemia both in Down syndrome children and non-Down 
syndrome adults. Leukemia 21, 574-576. 
Kohno, T., Kawanishi, M., Matsuda, S., Ichikawa, H., Takada, M., Ohki, M., 
Yamamoto, T., and Yokota, J. (1998). Homozygous deletion and frequent allelic 
loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. 
Genes Chromosomes Cancer 21, 236-243. 
Korbel, J.O., Tirosh-Wagner, T., Urban, A.E., Chen, X.N., Kasowski, M., Dai, L., 
Grubert, F., Erdman, C., Gao, M.C., Lange, K., et al. (2009). The genetic 
architecture of Down syndrome phenotypes revealed by high-resolution analysis of 
human segmental trisomies. Proc Natl Acad Sci U S A 106, 12031-12036. 
  211 
Korenberg, J.R., Chen, X.N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., 
Carpenter, N., Daumer, C., Dignan, P., Disteche, C., et al. (1994). Down syndrome 
phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S 
A 91, 4997-5001. 
Kuhl, C., Atzberger, A., Iborra, F., Nieswandt, B., Porcher, C., and Vyas, P. (2005). 
GATA1-mediated megakaryocyte differentiation and growth control can be 
uncoupled and mapped to different domains in GATA1. Mol Cell Biol 25, 8592-
8606. 
Kyba, M., Perlingeiro, R.C., and Daley, G.Q. (2002). HoxB4 confers definitive 
lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac 
hematopoietic progenitors. Cell 109, 29-37. 
Kyttala, S., Habermann, I., Minami, T., Ehninger, G., and Kiani, A. (2009). 
Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of 
Activated T cells in megakaryocytes. Br J Haematol 144, 395-408. 
Lai, K.S., Jin, Y., Graham, D.K., Witthuhn, B.A., Ihle, J.N., and Liu, E.T. (1995). A 
kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic 
and epithelial cancer cells. J Biol Chem 270, 25028-25036. 
Lamb, N.E., Freeman, S.B., Savage-Austin, A., Pettay, D., Taft, L., Hersey, J., Gu, 
Y., Shen, J., Saker, D., May, K.M., et al. (1996). Susceptible chiasmate 
configurations of chromosome 21 predispose to non-disjunction in both maternal 
meiosis I and meiosis II. Nat Genet 14, 400-405. 
Lamb, N.E., Yu, K., Shaffer, J., Feingold, E., and Sherman, S.L. (2005). Association 
between maternal age and meiotic recombination for trisomy 21. Am J Hum Genet 
76, 91-99. 
Lancrin, C., Sroczynska, P., Stephenson, C., Allen, T., Kouskoff, V., and Lacaud, G. 
(2009). The haemangioblast generates haematopoietic cells through a haemogenic 
endothelium stage. Nature 457, 892-895. 
Lange, B.J., Kobrinsky, N., Barnard, D.R., Arthur, D.C., Buckley, J.D., Howells, 
W.B., Gold, S., Sanders, J., Neudorf, S., Smith, F.O., et al. (1998). Distinctive 
demography, biology, and outcome of acute myeloid leukemia and myelodysplastic 
syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 
and 2891. Blood 91, 608-615. 
Langebrake, C., Creutzig, U., and Reinhardt, D. (2005). Immunophenotype of Down 
syndrome acute myeloid leukemia and transient myeloproliferative disease differs 
significantly from other diseases with morphologically identical or similar blasts. Klin 
Padiatr 217, 126-134. 
Lee, T.I., Jenner, R.G., Boyer, L.A., Guenther, M.G., Levine, S.S., Kumar, R.M., 
Chevalier, B., Johnstone, S.E., Cole, M.F., Isono, K., et al. (2006). Control of 
developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 
301-313. 
  212 
Legare, R.D., Lu, D., Gallagher, M., Ho, C., Tan, X., Barker, G., Shimizu, K., Ohki, 
M., Lenny, N., Hiebert, S., et al. (1997). CBFA2, frequently rearranged in leukemia, 
is not responsible for a familial leukemia syndrome. Leukemia 11, 2111-2119. 
Lejeune, J., Turpin, R., and Gautier, M. (1959). Mongolism; a chromosomal disease 
(trisomy). Bull Acad Natl Med 143, 256-265. 
Lemarchandel, V., Ghysdael, J., Mignotte, V., Rahuel, C., and Romeo, P.H. (1993). 
GATA and Ets cis-acting sequences mediate megakaryocyte-specific expression. 
Mol Cell Biol 13, 668-676. 
Lensch, M.W., and Daley, G.Q. (2006). Scientific and clinical opportunities for 
modeling blood disorders with embryonic stem cells. Blood 107, 2605-2612. 
Lessard, J., Faubert, A., and Sauvageau, G. (2004). Genetic programs regulating 
HSC specification, maintenance and expansion. Oncogene 23, 7199-7209. 
Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, 
T.J., Wlodarska, I., Clark, J.J., Moore, S., et al. (2005). Activating mutation in the 
tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid 
metaplasia with myelofibrosis. Cancer Cell 7, 387-397. 
Li, Z., Godinho, F.J., Klusmann, J.H., Garriga-Canut, M., Yu, C., and Orkin, S.H. 
(2005). Developmental stage-selective effect of somatically mutated leukemogenic 
transcription factor GATA1. Nat Genet 37, 613-619. 
Lightfoot, J., Hitzler, J.K., Zipursky, A., Albert, M., and Macgregor, P.F. (2004). 
Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down 
syndrome. Leukemia 18, 1617-1623. 
Ling, K.W., Ottersbach, K., van Hamburg, J.P., Oziemlak, A., Tsai, F.Y., Orkin, S.H., 
Ploemacher, R., Hendriks, R.W., and Dzierzak, E. (2004). GATA-2 plays two 
functionally distinct roles during the ontogeny of hematopoietic stem cells. J Exp 
Med 200, 871-882. 
Loughran, S.J., Kruse, E.A., Hacking, D.F., de Graaf, C.A., Hyland, C.D., Willson, 
T.A., Henley, K.J., Ellis, S., Voss, A.K., Metcalf, D., et al. (2008). The transcription 
factor Erg is essential for definitive hematopoiesis and the function of adult 
hematopoietic stem cells. Nat Immunol 9, 810-819. 
Lugus, J.J., Chung, Y.S., Mills, J.C., Kim, S.I., Grass, J., Kyba, M., Doherty, J.M., 
Bresnick, E.H., and Choi, K. (2007). GATA2 functions at multiple steps in 
hemangioblast development and differentiation. Development 134, 393-405. 
Lux, C.T., Yoshimoto, M., McGrath, K., Conway, S.J., Palis, J., and Yoder, M.C. 
(2008). All primitive and definitive hematopoietic progenitor cells emerging before 
E10 in the mouse embryo are products of the yolk sac. Blood 111, 3435-3438. 
Lyle, R., Bena, F., Gagos, S., Gehrig, C., Lopez, G., Schinzel, A., Lespinasse, J., 
Bottani, A., Dahoun, S., Taine, L., et al. (2009). Genotype-phenotype correlations in 
  213 
Down syndrome identified by array CGH in 30 cases of partial trisomy and partial 
monosomy chromosome 21. Eur J Hum Genet 17, 454-466. 
Ma, Z., Morris, S.W., Valentine, V., Li, M., Herbrick, J.A., Cui, X., Bouman, D., Li, Y., 
Mehta, P.K., Nizetic, D., et al. (2001). Fusion of two novel genes, RBM15 and 
MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28, 
220-221. 
Malinge, S., Ben-Abdelali, R., Settegrana, C., Radford-Weiss, I., Debre, M., 
Beldjord, K., Macintyre, E.A., Villeval, J.L., Vainchenker, W., Berger, R., et al. 
(2007). Novel activating JAK2 mutation in a patient with Down syndrome and B-cell 
precursor acute lymphoblastic leukemia. Blood 109, 2202-2204. 
Malinge, S., Izraeli, S., and Crispino, J.D. (2009). Insights into the manifestations, 
outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113, 
2619-2628. 
Malinge, S., Ragu, C., Della-Valle, V., Pisani, D., Constantinescu, S.N., Perez, C., 
Villeval, J.L., Reinhardt, D., Landman-Parker, J., Michaux, L., et al. (2008). 
Activating mutations in human acute megakaryoblastic leukemia. Blood 112, 4220-
4226. 
Malkin, D., Brown, E.J., and Zipursky, A. (2000). The role of p53 in megakaryocyte 
differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet 
Cytogenet 116, 1-5. 
Mann, D.M. (1988). The pathological association between Down syndrome and 
Alzheimer disease. Mech Ageing Dev 43, 99-136. 
Martin, D.I., and Orkin, S.H. (1990). Transcriptional activation and DNA binding by 
the erythroid factor GF-1/NF-E1/Eryf 1. Genes Dev 4, 1886-1898. 
Martin, D.I., Zon, L.I., Mutter, G., and Orkin, S.H. (1990). Expression of an erythroid 
transcription factor in megakaryocytic and mast cell lineages. Nature 344, 444-447. 
Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci 
U S A 78, 7634-7638. 
McElwaine, S., Mulligan, C., Groet, J., Spinelli, M., Rinaldi, A., Denyer, G., Mensah, 
A., Cavani, S., Baldo, C., Dagna-Bricarelli, F., et al. (2004). Microarray transcript 
profiling distinguishes the transient from the acute type of megakaryoblastic 
leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating 
marker. Br J Haematol 125, 729-742. 
Mella, P., Schumacher, R.F., Cranston, T., de Saint Basile, G., Savoldi, G., and 
Notarangelo, L.D. (2001). Eleven novel JAK3 mutations in patients with severe 
combined immunodeficiency-including the first patients with mutations in the kinase 
domain. Hum Mutat 18, 355-356. 
  214 
Mensah, A., Mulligan, C., Linehan, J., Ruf, S., O'Doherty, A., Grygalewicz, B., 
Shipley, J., Groet, J., Tybulewicz, V., Fisher, E., et al. (2007). An additional human 
chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic 
stem cells in a teratoma model. BMC Dev Biol 7, 131. 
Mikkelsen, M. (1977). Down syndrome: cytogenetical epidemiology. Hereditas 86, 
45-50. 
Mikkola, H.K., Fujiwara, Y., Schlaeger, T.M., Traver, D., and Orkin, S.H. (2003). 
Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse 
embryo. Blood 101, 508-516. 
Mikkola, H.K., and Orkin, S.H. (2006). The journey of developing hematopoietic 
stem cells. Development 133, 3733-3744. 
Minegishi, N., Suzuki, N., Yokomizo, T., Pan, X., Fujimoto, T., Takahashi, S., Hara, 
T., Miyajima, A., Nishikawa, S., and Yamamoto, M. (2003). Expression and domain-
specific function of GATA-2 during differentiation of the hematopoietic precursor 
cells in midgestation mouse embryos. Blood 102, 896-905. 
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., 
Maruyama, M., Maeda, M., and Yamanaka, S. (2003). The homeoprotein Nanog is 
required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 
631-642. 
Moore, C.S. (2006). Postnatal lethality and cardiac anomalies in the Ts65Dn Down 
syndrome mouse model. Mamm Genome 17, 1005-1012 
Moore, M.A., Shieh, J.H., and Lee, G. (2006). Hematopoietic cells. Methods 
Enzymol 418, 208-242. 
Morice, E., Andreae, L.C., Cooke, S.F., Vanes, L., Fisher, E.M., Tybulewicz, V.L., 
and Bliss, T.V. (2008). Preservation of long-term memory and synaptic plasticity 
despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn 
Mem 15, 492-500. 
Morita, S., Kojima, T., and Kitamura, T. (2000). Plat-E: an efficient and stable 
system for transient packaging of retroviruses. Gene Ther 7, 1063-1066. 
Morris, J.K. and Alberman E. (2009). Trends in Down's syndrome live births and 
antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from 
the National Down Syndrome Cytogenetic Register. BMJ Oct 26;339:b3794. 
doi: 10.1136/bmj.b3794.  
 
 
Muntean, A.G., and Crispino, J.D. (2005). Differential requirements for the activation 
domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression 
and development. Blood 106, 1223-1231. 
  215 
Muntean, A.G., Ge, Y., Taub, J.W., and Crispino, J.D. (2006). Transcription factor 
GATA-1 and Down syndrome leukemogenesis. Leuk Lymphoma 47, 986-997. 
Muntean, A.G., Pang, L., Poncz, M., Dowdy, S.F., Blobel, G.A., and Crispino, J.D. 
(2007). Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte 
growth and polyploidization. Blood 109, 5199-5207. 
Murphy, M., and Epstein, L.B. (1992). Down syndrome (DS) peripheral blood 
contains phenotypically mature CD3+TCR alpha, beta+ cells but abnormal 
proportions of TCR alpha, beta+, TCR gamma, delta+, and CD4+ CD45RA+ cells: 
evidence for an inefficient release of mature T cells by the DS thymus. Clin Immunol 
Immunopathol 62, 245-251. 
Nakano, T., Kodama, H., and Honjo, T. (1994). Generation of lymphohematopoietic 
cells from embryonic stem cells in culture. Science 265, 1098-1101. 
Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, 
I., Scholer, H., and Smith, A. (1998). Formation of pluripotent stem cells in the 
mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-
391. 
Norton, A., Fisher, C., Liu, H., Wen, Q., Mundschau, G., Fuster, J.L., Hasle, H., 
Zeller, B., Webb, D.K., O'Marcaigh, A., et al. (2007). Analysis of JAK3, JAK2, and 
C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of 
Down syndrome blasts in children with Down syndrome. Blood 110, 1077-1079. 
Nottingham, W.T., Jarratt, A., Burgess, M., Speck, C.L., Cheng, J.F., Prabhakar, S., 
Rubin, E.M., Li, P.S., Sloane-Stanley, J., Kong, A.S.J., et al. (2007). Runx1-
mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-
regulated enhancer. Blood 110, 4188-4197. 
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M.L., Cooke, S., Sesay, 
A., Modino, S., Vanes, L., Hernandez, D., et al. (2005). An aneuploid mouse strain 
carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 
2033-2037. 
O'Shea, J.J., Husa, M., Li, D., Hofmann, S.R., Watford, W., Roberts, J.L., Buckley, 
R.H., Changelian, P., and Candotti, F. (2004). Jak3 and the pathogenesis of severe 
combined immunodeficiency. Mol Immunol 41, 727-737. 
Ogawa, M., Nishikawa, S., Yoshinaga, K., Hayashi, S., Kunisada, T., Nakao, J., 
Kina, T., Sudo, T., and Kodama, H. (1993). Expression and function of c-Kit in fetal 
hemopoietic progenitor cells: transition from the early c-Kit-independent to the late 
c-Kit-dependent wave of hemopoiesis in the murine embryo. Development 117, 
1089-1098. 
Ohgaki, K., Iida, A., Kasumi, F., Sakamoto, G., Akimoto, M., Nakamura, Y., and 
Emi, M. (1998). Mapping of a new target region of allelic loss to a 6-cM interval at 
21q21 in primary breast cancers. Genes Chromosomes Cancer 23, 244-247. 
  216 
Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G., and Downing, J.R. (1996). 
AML1, the target of multiple chromosomal translocations in human leukemia, is 
essential for normal fetal liver hematopoiesis. Cell 84, 321-330. 
Olsen, A.L., Stachura, D.L., and Weiss, M.J. (2006). Designer blood: creating 
hematopoietic lineages from embryonic stem cells. Blood 107, 1265-1275. 
Olson, L.E., Roper, R.J., Baxter, L.L., Carlson, E.J., Epstein, C.J., and Reeves, R.H. 
(2004). Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn 
exhibit variable severity of cerebellar phenotypes. Dev Dyn 230, 581-589. 
Orkin, S.H. (2003). Priming the hematopoietic pump. Immunity 19, 633-634. 
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: an evolving paradigm for stem cell 
biology. Cell 132, 631-644. 
Orlovskaya, I., Schraufstatter, I., Loring, J., and Khaldoyanidi, S. (2008). 
Hematopoietic differentiation of embryonic stem cells. Methods 45, 159-167. 
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, 
H., Takatsuki, K., Kanno, T., Shigesada, K., et al. (1999). Biallelic and heterozygous 
point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with 
myeloblastic leukemias. Blood 93, 1817-1824. 
Oster, J., Mikkelsen, M., and Nielsen, A. (1975). Mortality and life-table in Down's 
syndrome. Acta Paediatr Scand 64, 322-326. 
Ottersbach, K., and Dzierzak, E. (2005). The murine placenta contains 
hematopoietic stem cells within the vascular labyrinth region. Dev Cell 8, 377-387. 
Pang, L., Xue, H.H., Szalai, G., Wang, X., Wang, Y., Watson, D.K., Leonard, W.J., 
Blobel, G.A., and Poncz, M. (2006). Maturation stage-specific regulation of 
megakaryopoiesis by pointed-domain Ets proteins. Blood 108, 2198-2206. 
Park, C., Ma, Y.D., and Choi, K. (2005). Evidence for the hemangioblast. Exp 
Hematol 33, 965-970. 
Paz-Miguel, J.E., Flores, R., Sanchez-Velasco, P., Ocejo-Vinyals, G., Escribano de 
Diego, J., Lopez de Rego, J., and Leyva-Cobian, F. (1999). Reactive oxygen 
intermediates during programmed cell death induced in the thymus of the 
Ts(1716)65Dn mouse, a murine model for human Down's syndrome. J Immunol 
163, 5399-5410. 
Penrose, L. (1933). The relative effects of paternal and maternal age in mongolism.  
J Genet 27, 219-224. 
Peters, D.G., Klucher, K.M., Perlingeiro, R.C., Dessain, S.K., Koh, E.Y., and Daley, 
G.Q. (2001). Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-
  217 
transformed hematopoietic cell line that induces leukemia in mice. Oncogene 20, 
2636-2646. 
Petersen, M.B., Adelsberger, P.A., Schinzel, A.A., Binkert, F., Hinkel, G.K., and 
Antonarakis, S.E. (1991). Down syndrome due to de novo Robertsonian 
translocation t(14q;21q): DNA polymorphism analysis suggests that the origin of the 
extra 21q is maternal. Am J Hum Genet 49, 529-536. 
Philip, R., Berger, A.C., McManus, N.H., Warner, N.H., Peacock, M.A., and Epstein, 
L.B. (1986). Abnormalities of the in vitro cellular and humoral responses to tetanus 
and influenza antigens with concomitant numerical alterations in lymphocyte 
subsets in Down syndrome (trisomy 21). J Immunol 136, 1661-1667. 
Pimanda, J.E., Ottersbach, K., Knezevic, K., Kinston, S., Chan, W.Y., Wilson, N.K., 
Landry, J.R., Wood, A.D., Kolb-Kokocinski, A., Green, A.R., et al. (2007). Gata2, 
Fli1, and Scl form a recursively wired gene-regulatory circuit during early 
hematopoietic development. Proc Natl Acad Sci U S A 104, 17692-17697. 
Prandini, P., Deutsch, S., Lyle, R., Gagnebin, M., Delucinge Vivier, C., Delorenzi, 
M., Gehrig, C., Descombes, P., Sherman, S., Dagna Bricarelli, F., et al. (2007). 
Natural gene-expression variation in Down syndrome modulates the outcome of 
gene-dosage imbalance. Am J Hum Genet 81, 252-263. 
Preudhomme, C., Renneville, A., Bourdon, V., Philippe, N., Roche-Lestienne, C., 
Boissel, N., Dhedin, N., Andre, J.M., Cornillet-Lefebvre, P., Baruchel, A., et al. 
(2009). High frequency of RUNX1 biallelic alteration in acute myeloid leukemia 
secondary to familial platelet disorder. Blood 113, 5583-5587. 
Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, 
J.L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000). High 
incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha 
B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired 
trisomy 21. Blood 96, 2862-2869. 
Pui, C.H., Raimondi, S.C., Borowitz, M.J., Land, V.J., Behm, F.G., Pullen, D.J., 
Hancock, M.L., Shuster, J.J., Steuber, C.P., Crist, W.M., et al. (1993). 
Immunophenotypes and karyotypes of leukemic cells in children with Down 
syndrome and acute lymphoblastic leukemia. J Clin Oncol 11, 1361-1367. 
Purton, L.E., and Scadden, D.T. (2007). Limiting factors in murine hematopoietic 
stem cell assays. Cell Stem Cell 1, 263-270. 
Rahmani, Z., Blouin, J.L., Creau-Goldberg, N., Watkins, P.C., Mattei, J.F., 
Poissonnier, M., Prieur, M., Chettouh, Z., Nicole, A., Aurias, A., et al. (1989). Critical 
role of the D21S55 region on chromosome 21 in the pathogenesis of Down 
syndrome. Proc Natl Acad Sci U S A 86, 5958-5962. 
Rainis, L., Toki, T., Pimanda, J.E., Rosenthal, E., Machol, K., Strehl, S., Gottgens, 
B., Ito, E., and Izraeli, S. (2005). The proto-oncogene ERG in megakaryoblastic 
leukemias. Cancer Res 65, 7596-7602. 
  218 
Ravid, K., Lu, J., Zimmet, J.M., and Jones, M.R. (2002). Roads to polyploidy: the 
megakaryocyte example. J Cell Physiol 190, 7-20. 
Ravindranath, Y. (2005). Down syndrome and leukemia: new insights into the 
epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 44, 1-7. 
Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., Andrews, T.D., Fiegler, 
H., Shapero, M.H., Carson, A.R., Chen, W., et al. (2006). Global variation in copy 
number in the human genome. Nature 444, 444-454. 
Reeves, R.H., Irving, N.G., Moran, T.H., Wohn, A., Kitt, C., Sisodia, S.S., Schmidt, 
C., Bronson, R.T., and Davisson, M.T. (1995). A mouse model for Down syndrome 
exhibits learning and behaviour deficits. Nat Genet 11, 177-184. 
Rex, A.P., and Preus, M. (1982). A diagnostic index for Down syndrome. J Pediatr 
100, 903-906. 
Rhodes, K.E., Gekas, C., Wang, Y., Lux, C.T., Francis, C.S., Chan, D.N., Conway, 
S., Orkin, S.H., Yoder, M.C., and Mikkola, H.K. (2008). The emergence of 
hematopoietic stem cells is initiated in the placental vasculature in the absence of 
circulation. Cell Stem Cell 2, 252-263. 
Richtsmeier, J.T., Baxter, L.L., and Reeves, R.H. (2000). Parallels of craniofacial 
maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217, 137-145. 
Roizen, N.J., and Patterson, D. (2003). Down's syndrome. Lancet 361, 1281-1289. 
Romeo, P.H., Prandini, M.H., Joulin, V., Mignotte, V., Prenant, M., Vainchenker, W., 
Marguerie, G., and Uzan, G. (1990). Megakaryocytic and erythrocytic lineages 
share specific transcription factors. Nature 344, 447-449. 
Ronan, A., Fagan, K., Christie, L., Conroy, J., Nowak, N.J., and Turner, G. (2007). 
Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical 
region. J Med Genet 44, 448-451. 
Rosenbauer, F., and Tenen, D.G. (2007). Transcription factors in myeloid 
development: balancing differentiation with transformation. Nat Rev Immunol 7, 
105-117. 
Sago, H., Carlson, E.J., Smith, D.J., Kilbridge, J., Rubin, E.M., Mobley, W.C., 
Epstein, C.J., and Huang, T.T. (1998). Ts1Cje, a partial trisomy 16 mouse model for 
Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci 
U S A 95, 6256-6261. 
Sago, H., Carlson, E.J., Smith, D.J., Rubin, E.M., Crnic, L.S., Huang, T.T., and 
Epstein, C.J. (2000). Genetic dissection of region associated with behavioral 
abnormalities in mouse models for Down syndrome. Pediatr Res 48, 606-613. 
  219 
Sakai, E., Kitajima, K., Sato, A., and Nakano, T. (2009). Increase of hematopoietic 
progenitor and suppression of endothelial gene expression by Runx1 expression 
during in vitro ES differentiation. Exp Hematol 37, 334-345. 
Salek-Ardakani, S., Smooha, G., de Boer, J., Sebire, N.J., Morrow, M., Rainis, L., 
Lee, S., Williams, O., Izraeli, S., and Brady, H.J. (2009). ERG is a megakaryocytic 
oncogene. Cancer Res 69, 4665-4673. 
Sanchez-Font, M.F., Bosch-Comas, A., Gonzalez-Duarte, R., and Marfany, G. 
(2003). Overexpression of FABP7 in Down syndrome fetal brains is associated with 
PKNOX1 gene-dosage imbalance. Nucleic Acids Res 31, 2769-2777. 
Satge, D., Sasco, A.J., and Lacour, B. (2003). Are solid tumours different in children 
with Down's syndrome? Int J Cancer 106, 297-298. 
Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, 
S., Migita, M., Morinaga, S., et al. (2008). Functional analysis of JAK3 mutations in 
transient myeloproliferative disorder and acute megakaryoblastic leukaemia 
accompanying Down syndrome. Br J Haematol 141, 681-688. 
Savage, A.R., Petersen, M.B., Pettay, D., Taft, L., Allran, K., Freeman, S.B., 
Karadima, G., Avramopoulos, D., Torfs, C., Mikkelsen, M., et al. (1998). Elucidating 
the mechanisms of paternal non-disjunction of chromosome 21 in humans. Hum 
Mol Genet 7, 1221-1227. 
Scholl, T., Stein, Z., and Hansen, H. (1982). Leukemia and other cancers, 
anomalies and infections as causes of death in Down's syndrome in the United 
States during 1976. Dev Med Child Neurol 24, 817-829. 
Schuringa, J.J., Wu, K., Morrone, G., and Moore, M.A. (2004). Enforced activation 
of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem 
cells that contribute to hematopoiesis in vivo. Stem Cells 22, 1191-1204. 
Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, 
P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., et al. (2007). JAK2 exon 12 
mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356, 
459-468. 
Shaffer, L.G., Jackson-Cook, C.K., Stasiowski, B.A., Spence, J.E., and Brown, J.A. 
(1992). Parental origin determination in thirty de novo Robertsonian translocations. 
Am J Med Genet 43, 957-963. 
Shaikh, T.H., Gai, X., Perin, J.C., Glessner, J.T., Xie, H., Murphy, K., O'Hara, R., 
Casalunovo, T., Conlin, L.K., D'Arcy, M., et al. (2009). High-resolution mapping and 
analysis of copy number variations in the human genome: A data resource for 
clinical and research applications. Genome Res. 9 (9),1682-90. 
Sherman, S.L., Freeman, S.B., Allen, E.G., and Lamb, N.E. (2005). Risk factors for 
nondisjunction of trisomy 21. Cytogenet Genome Res 111, 273-280. 
  220 
Sherman, S.L., Petersen, M.B., Freeman, S.B., Hersey, J., Pettay, D., Taft, L., 
Frantzen, M., Mikkelsen, M., and Hassold, T.J. (1994). Non-disjunction of 
chromosome 21 in maternal meiosis I: evidence for a maternal age-dependent 
mechanism involving reduced recombination. Hum Mol Genet 3, 1529-1535. 
Sherman, S.L., Takaesu, N., Freeman, S.B., Grantham, M., Phillips, C., Blackston, 
R.D., Jacobs, P.A., Cockwell, A.E., Freeman, V., Uchida, I., et al. (1991). Trisomy 
21: association between reduced recombination and nondisjunction. Am J Hum 
Genet 49, 608-620. 
Shi, S.R., Datar, R., Liu, C., Wu, L., Zhang, Z., Cote, R.J., and Taylor, C.R. (2004). 
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-
induced retrieval in alkaline solution. Histochem Cell Biol 122, 211-218. 
Shivdasani, R.A., Fujiwara, Y., McDevitt, M.A., and Orkin, S.H. (1997). A lineage-
selective knockout establishes the critical role of transcription factor GATA-1 in 
megakaryocyte growth and platelet development. EMBO J 16, 3965-3973. 
Simon, M.C., Pevny, L., Wiles, M.V., Keller, G., Costantini, F., and Orkin, S.H. 
(1992). Rescue of erythroid development in gene targeted GATA-1- mouse 
embryonic stem cells. Nat Genet 1, 92-98. 
Smith, D.J., Stevens, M.E., Sudanagunta, S.P., Bronson, R.T., Makhinson, M., 
Watabe, A.M., O'Dell, T.J., Fung, J., Weier, H.U., Cheng, J.F., et al. (1997). 
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice 
implicates minibrain in learning defects associated with Down syndrome. Nat Genet 
16, 28-36. 
Song, W.J., Sullivan, M.G., Legare, R.D., Hutchings, S., Tan, X., Kufrin, D., 
Ratajczak, J., Resende, I.C., Haworth, C., Hock, R., et al. (1999). Haploinsufficiency 
of CBFA2 causes familial thrombocytopenia with propensity to develop acute 
myelogenous leukaemia. Nat Genet 23, 166-175. 
Stankiewicz, M.J., and Crispino, J.D. (2009). ETS2 and ERG promote 
megakaryopoiesis and synergize with alterations in GATA-1 to immortalize 
hematopoietic progenitor cells. Blood 113, 3337-3347. 
Suh, M.R., Lee, Y., Kim, J.Y., Kim, S.K., Moon, S.H., Lee, J.Y., Cha, K.Y., Chung, 
H.M., Yoon, H.S., Moon, S.Y., et al. (2004). Human embryonic stem cells express a 
unique set of microRNAs. Dev Biol 270, 488-498. 
Sultan, M., Piccini, I., Balzereit, D., Herwig, R., Saran, N.G., Lehrach, H., Reeves, 
R.H., and Yaspo, M.L. (2007). Gene expression variation in Down's syndrome mice 
allows prioritization of candidate genes. Genome Biol 8, R91. 
Sussan, T.E., Yang, A., Li, F., Ostrowski, M.C., and Reeves, R.H. (2008). Trisomy 
represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. 
Nature 451, 73-75. 
  221 
Taub, J.W., Huang, X., Matherly, L.H., Stout, M.L., Buck, S.A., Massey, G.V., 
Becton, D.L., Chang, M.N., Weinstein, H.J., and Ravindranath, Y. (1999). 
Expression of chromosome 21-localized genes in acute myeloid leukemia: 
differences between Down syndrome and non-Down syndrome blast cells and 
relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 
94, 1393-1400. 
Taub, J.W., Mundschau, G., Ge, Y., Poulik, J.M., Qureshi, F., Jensen, T., James, 
S.J., Matherly, L.H., Wechsler, J., and Crispino, J.D. (2004). Prenatal origin of 
GATA1 mutations may be an initiating step in the development of megakaryocytic 
leukemia in Down syndrome. Blood 104, 1588-1589. 
Tchernia, G., Lejeune, F., Boccara, J.F., Denavit, M.F., Dommergues, J.P., and 
Bernaudin, F. (1996). Erythroblastic and/or megakaryoblastic leukemia in Down 
syndrome: treatment with low-dose arabinosyl cytosine. J Pediatr Hematol Oncol 
18, 59-62. 
Teller, J.K., Russo, C., DeBusk, L.M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, 
F., Scartezzini, P., Bertolini, S., Mann, D.M., Tabaton, M., et al. (1996). Presence of 
soluble amyloid beta-peptide precedes amyloid plaque formation in Down's 
syndrome. Nat Med 2, 93-95. 
Templado, C., Bosch, M., and Benet, J. (2005). Frequency and distribution of 
chromosome abnormalities in human spermatozoa. Cytogenet Genome Res 111, 
199-205. 
Teyssier-Le Discorde, M., Prost, S., Nandrot, E., and Kirszenbaum, M. (1999). 
Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression 
during human embryonic haemopoiesis. Br J Haematol 107, 247-253. 
Thaline, H.C., Pueschel, S.M. (1982). Cytogenetics in Down syndrome. In: Down 
Syndrome Advances in Biomedicine and the Behavioural Sciences R. S. M. 
Pueschel, J.E., Ware Press ed., p.133. 
Toki, T., Katsuoka, F., Kanezaki, R., Xu, G., Kurotaki, H., Sun, J., Kamio, T., 
Watanabe, S., Tandai, S., Terui, K., et al. (2005). Transgenic expression of BACH1 
transcription factor results in megakaryocytic impairment. Blood 105, 3100-3108. 
Tomizuka, K., Yoshida, H., Uejima, H., Kugoh, H., Sato, K., Ohguma, A., Hayasaka, 
M., Hanaoka, K., Oshimura, M., and Ishida, I. (1997). Functional expression and 
germline transmission of a human chromosome fragment in chimaeric mice. Nat 
Genet 16, 133-143. 
Tsai, F.Y., Keller, G., Kuo, F.C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F.W., and 
Orkin, S.H. (1994). An early haematopoietic defect in mice lacking the transcription 
factor GATA-2. Nature 371, 221-226. 
Tsai, F.Y., and Orkin, S.H. (1997). Transcription factor GATA-2 is required for 
proliferation/survival of early hematopoietic cells and mast cell formation, but not for 
erythroid and myeloid terminal differentiation. Blood 89, 3636-3643. 
  222 
Tunstall-Pedoe, O., Roy, A., Karadimitris, A., de la Fuente, J., Fisk, N.M., Bennett, 
P., Norton, A., Vyas, P., and Roberts, I. (2008). Abnormalities in the myeloid 
progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 
mutations. Blood 112, 4507-4511. 
Ugazio, A.G., Maccario, R., Notarangelo, L.D., and Burgio, G.R. (1990). 
Immunology of Down syndrome: a review. Am J Med Genet Suppl 7, 204-212. 
Vainchenker, W., Dusa, A., and Constantinescu, S.N. (2008). JAKs in pathology: 
role of Janus kinases in hematopoietic malignancies and immunodeficiencies. 
Semin Cell Dev Biol 19, 385-393. 
Vyas, P., Ault, K., Jackson, C.W., Orkin, S.H., and Shivdasani, R.A. (1999). 
Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93, 
2867-2875. 
Walters, D.K., Mercher, T., Gu, T.L., O'Hare, T., Tyner, J.W., Loriaux, M., Goss, 
V.L., Lee, K.A., Eide, C.A., Wong, M.J., et al. (2006). Activating alleles of JAK3 in 
acute megakaryoblastic leukemia. Cancer Cell 10, 65-75. 
Wang, J., Rao, S., Chu, J., Shen, X., Levasseur, D.N., Theunissen, T.W., and 
Orkin, S.H. (2006). A protein interaction network for pluripotency of embryonic stem 
cells. Nature 444, 364-368. 
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A.H., and Speck, N.A. 
(1996). Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the 
central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci     
U S A 93, 3444-3449. 
Wang, Y., Mulligan, C., Denyer, G., Delom, F., Dagna-Bricarelli, F., Tybulewicz, 
V.L., Fisher, E.M., Griffiths, W.J., Nizetic, D., and Groet, J. (2009). Quantitative 
proteomics characterization of a mouse embryonic stem cell model of Down 
syndrome. Mol Cell Proteomics 8, 585-595. 
Ward, O.C. (1999). John Langdon Down: the man and the message. Downs Syndr 
Res Pract 6, 19-24. 
Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M., 
and Crispino, J.D. (2002). Acquired mutations in GATA1 in the megakaryoblastic 
leukemia of Down syndrome. Nat Genet 32, 148-152. 
Weisel, K.C., Gao, Y., Shieh, J.H., and Moore, M.A. (2006). Stromal cell lines from 
the aorta-gonado-mesonephros region are potent supporters of murine and human 
hematopoiesis. Exp Hematol 34, 1505-1516. 
Weissman, I.L., Anderson, D.J., and Gage, F. (2001). Stem and progenitor cells: 
origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell 
Dev Biol 17, 387-403. 
  223 
Whyatt, D., Lindeboom, F., Karis, A., Ferreira, R., Milot, E., Hendriks, R., de Bruijn, 
M., Langeveld, A., Gribnau, J., Grosveld, F., et al. (2000). An intrinsic but cell-
nonautonomous defect in GATA-1-overexpressing mouse erythroid cells. Nature 
406, 519-524. 
Whyatt, D.J., Karis, A., Harkes, I.C., Verkerk, A., Gillemans, N., Elefanty, A.G., 
Vairo, G., Ploemacher, R., Grosveld, F., and Philipsen, S. (1997). The level of the 
tissue-specific factor GATA-1 affects the cell-cycle machinery. Genes Funct 1, 11-
24. 
Wiles, M.V., and Keller, G. (1991). Multiple hematopoietic lineages develop from 
embryonic stem (ES) cells in culture. Development 111, 259-267. 
Williams, R.S., and Matthysse, S. (1986). Age-related changes in Down syndrome 
brain and the cellular pathology of Alzheimer disease. Prog Brain Res 70, 49-67. 
Wilson, A., Murphy, M.J., Oskarsson, T., Kaloulis, K., Bettess, M.D., Oser, G.M., 
Pasche, A.C., Knabenhans, C., Macdonald, H.R., and Trumpp, A. (2004). c-Myc 
controls the balance between hematopoietic stem cell self-renewal and 
differentiation. Genes Dev 18, 2747-2763. 
Wilson, M.D., Barbosa-Morais, N.L., Schmidt, D., Conboy, C.M., Vanes, L., 
Tybulewicz, V.L., Fisher, E.M., Tavare, S., and Odom, D.T. (2008). Species-specific 
transcription in mice carrying human chromosome 21. Science 322, 434-438. 
Wiseman, F.K., Alford, K.A., Tybulewicz, V.L., and Fisher, E.M. (2009). Down 
syndrome--recent progress and future prospects. Hum Mol Genet 18, R75-83. 
Wisniewski, K.E., Dalton, A.J., McLachlan, C., Wen, G.Y., and Wisniewski, H.M. 
(1985). Alzheimer's disease in Down's syndrome: clinicopathologic studies. 
Neurology 35, 957-961. 
Wolf, D., and Goff, S.P. (2009). Embryonic stem cells use ZFP809 to silence 
retroviral DNAs. Nature 458, 1201-1204. 
Yamamoto, N., Uzawa, K., Yakushiji, T., Shibahara, T., Noma, H., and Tanzawa, H. 
(2001). Analysis of the ANA gene as a candidate for the chromosome 21q oral 
cancer susceptibility locus. Br J Cancer 84, 754-759. 
Yamamoto, T., Isomura, M., Xu, Y., Liang, J., Yagasaki, H., Kamachi, Y., Kudo, K., 
Kiyoi, H., Naoe, T., and Kojma, S. (2006). PTPN11, RAS and FLT3 mutations in 
childhood acute lymphoblastic leukemia. Leuk Res 30, 1085-1089. 
Yanagida, M., Osato, M., Yamashita, N., Liqun, H., Jacob, B., Wu, F., Cao, X., 
Nakamura, T., Yokomizo, T., Takahashi, S., et al. (2005). Increased dosage of 
Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 
mice. Oncogene 24, 4477-4485. 
  224 
Yang, Q., Rasmussen, S.A., and Friedman, J.M. (2002). Mortality associated with 
Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 
359, 1019-1025. 
Yang, S., Delgado, R., King, S.R., Woffendin, C., Barker, C.S., Yang, Z.Y., Xu, L., 
Nolan, G.P., and Nabel, G.J. (1999). Generation of retroviral vector for clinical 
studies using transient transfection. Hum Gene Ther 10, 123-132. 
Zhang, W.J., Park, C., Arentson, E., and Choi, K. (2005). Modulation of 
hematopoietic and endothelial cell differentiation from mouse embryonic stem cells 
by different culture conditions. Blood 105, 111-114. 
Zipursky, A. (2003). Transient leukaemia--a benign form of leukaemia in newborn 
infants with trisomy 21. Br J Haematol 120, 930-938. 
Zipursky, A., Poon, A., and Doyle, J. (1992). Leukemia in Down syndrome: a 
review. Pediatr Hematol Oncol 9, 139-149. 
Zon, L.I., Yamaguchi, Y., Yee, K., Albee, E.A., Kimura, A., Bennett, J.C., Orkin, 
S.H., and Ackerman, S.J. (1993). Expression of mRNA for the GATA-binding 
proteins in human eosinophils and basophils: potential role in gene transcription. 
Blood 81, 3234-3241. 
Zwaan, C.M., Kaspers, G.J., Pieters, R., Ramakers-Van Woerden, N.L., den Boer, 
M.L., Wunsche, R., Rottier, M.M., Hahlen, K., van Wering, E.R., Janka-Schaub, 
G.E., et al. (2000). Cellular drug resistance profiles in childhood acute myeloid 
leukemia: differences between FAB types and comparison with acute lymphoblastic 
leukemia. Blood 96, 2879-2886.    
 
  225 
6. Appendix  
6.1. Vectors, plasmids and oligos  
 
The GATA-1s-MSCV construct was generated by cloning FLAG-tagged 
GATA-1s into the BglII and XhoI site of the MSCV-PURO (mouse stem cell 
virus) retroviral vector (Clontech). Map of the vector is provided below. 
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A schematic view of the constructs used for the optimization of the 
transduction protocol is provided below. 
 
 
 
Plasmids HIT60 and CVG encode the viral components gag-pol and env, 
respectively. They were employed in the triple transfection approach in 
combination with the retroviral vector MSCV-IRES-GFP (MIG). MIG was 
derived from the MSCV backbone by replacing the puromycin resistance 
cassette with a green fluorescent protein (GFP) tag. 
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Target sequences for the hRUNX-1 oligos used in the RNAi experiments were 
as follows: 
 
RUNX-1/1 GACAUCGGCAGAAACUAGA 
RUNX-1/2 CACCGCAAGUCGCCACCUA 
RUNX-1/3 CAAAUUGAAAUGACGGUAU 
RUNX-1/4 GGCGAUAGGUCUCACGCAA 
 
Sequence for the control (non-targeting) RNAi was: 
UAAUGUAUUGGAACGCAUATT  
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6.2. List of units and abbreviations  
µg Microgram 
µl Microlitre 
µM Micromolar 
µm Micron 
ACHE               Acetylcholinesterase 
AD Alzheimer disease 
ALL acute lymphocytic leukaemia 
AMKL acute megakaryocytic leukaemia 
AML acute myeloid leukaemia 
AGM                    aorta-gonad-mesonephros 
APC Allophycocyanin 
AV Atrioventricular 
APC                 adenomatous polyposis coli 
BAC                 bacterial artificial chromosome 
BACH-1           basic leucine zipper transcription factor 1 
BM bone marrow 
bp base pair 
CBS cystathionine β-synthase  
cDNA Complementary DNA 
CFU                 colony forming unit 
CFU-E             colony forming unit erythroid 
CFU-GM          colony forming unit granulocyte-macrophage 
CFU-GEMM colony forming unit granulocyte-erythrocyte-monocyte-megakaryocyte 
CFU-MK colony forming unit megakaryocytes 
CLP                 common lymphoid progenitor 
CMP                common myeloid progenitor 
CNS central nervous system 
Ct                     cycle threshold 
DAB                 3,3 diaminobenzidine 
del Deletion 
DEPC diethyl pyrocarbonate 
DMEM Dulbecco’s modified Eagle’s medium 
dNTPS deoxynucleotides 
DNA deoxyribonucleic acid 
DS Down syndrome 
DSCR Down syndrome critical region 
DSCR1 Down syndrome critical region 1 
DTT                Dithiothreitol 
dup Duplication 
DYRK1A dual-specificity tyrosine phosphorylation-regulated kinase 1A 
E                      embryonic day 
EB embryoid body 
ECM extracellular matrix 
ENU N-ethyl-N-nitrosurea 
EPO                 Erythropoietin 
EpoR               erythropoietin receptor 
eQTL Expression Quantitative Trait Locus 
ES cell embryonic stem cell 
EST expressed sequence tag 
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EtOH                Ethanol 
FACS               fluorescence-activated cell sorter 
FISH                fluorescent in situ hybridization 
FAM 5-carboxyfluorescein 
FCS foetal calf serum 
FFPE               Formalin fixed paraffin embedded 
FITC fluorescein isothiocyanate 
FWD Forward 
FL                    foetal liver  
FLK-1               foetal liver kinase 1 
G Gram 
G418 Geneticin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GATA-1 GATA-binding protein 1 
GATA-2           GATA-binding protein 2 
GFP green fluorescent protein 
GMP                granulocyte-macrophage progenitor 
H&E Haematoxylin and Eosin 
HF Hydrops foetalis 
Hr Hour 
HRP Horse radish peroxydase 
HSA human chromosome 
HSC                 Haematopoietic stem cell 
HPC Haematopoietic progenitor cell 
ICM inner cell mass 
IL                     Interleukin 
JAK                  Januse kinase 
KDa Kilodalton 
LIF leukaemia inhibitory factor 
LOH loss of heterozygosity 
LTP long-term potentiation 
M Molar 
M-CSF macrophage colony-stimulating factor  
Mb                  mega base pair 
MDS myelodysplastic syndrome 
MEP                 megakaryocyte-erythroid progenitor 
Mg Milligram 
Min(s) minute(s) 
MK                   Megakaryocyte 
mM Millimolar 
mm2 millimetre square 
MMU mouse chromosome 
mRNA messenger RNA 
MSCV murine stem cell virus 
NaOAC               sodium acetate 
Neo neomycin  
ng Nanogram 
nM Nanomolar 
NSCLC non-small cell lung carcinoma 
ºC Degrees Celsius 
OCT-4 Octamer-binding transcription factor 4 
pp2 square pixel 
PB                    peripheral blood 
  230 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PI                     propidium iodide 
Q-PCR quantitative PCR 
rER                   rough endoplasmic reticulum 
REST               RE1-silencing transcription factor 
REV Reverse 
RNA ribonucleic acid 
RT room temperature 
RT-PCR reverse transcription-polymerase chain reaction 
SDS sequence detection system 
sec(s) second(s) 
s.e.m. standard error of the mean 
SOD1 superoxide dismutase 1 
T Translocation 
t21 trisomy 21 
TC tissue culture 
TF                    transcription factor 
TL transient leukaemia 
TIAM1 T-cell lymphoma invasion and metastasis-1 
TIE-2                endothelium-specific receptor tyrosine kinase 2 
TK                    Tyrosine kinase 
Tm melting temperature 
TMD transient myeloproliferative disorder 
tRNA transfer RNA 
TPO                 Thrombopoietin 
TSG tumour suppressor gene 
U Unit 
UV Ultraviolet 
vWF von Willebrand Factor 
WB western blotting 
YAC                 yeast artificial chromosome 
XMMCT irradiation microcell-mediated chromosome transfer 
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6.3. Publications 
 
The two first-author publications reported in this appendix were produced 
between June 2006 and the time of submission of this thesis and were 
obtained from work carried out toward the completion of my PhD at Queen 
Mary, University of London.  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Loss-of-function JAK3 mutations in TMD and AMKL of Down
syndrome
Megakaryoblastic leukaemia occurring in Down Syndrome
(DS) children appears in two forms: a self-regressing,
pre-leukaemic hyperproliferative state known as transient
myeloproliferative disorder (TMD) affecting 10% of DS
neonates, and the progressive and potentially lethal acute
megakaryoblastic leukaemia (AMKL), which develops in 20–
30% of TMD patients 1–3 years later (Hitzler & Zipursky,
2005; Muntean et al, 2006). As such, this disease represents an
interesting system for understanding the pathogenesis and
progression of myeloid leukaemias in general. A combination
of trisomy 21 and acquired mutations in GATA1, eliminating
its full length product, have been reported to co-exist in the
proliferating cells of all patients with this type of leukaemia
(Wechsler et al, 2002; Groet et al, 2003). Factors that predis-
pose 10% of DS to this disease, factors that predispose a third
of the TMD patients to AMKL, and additional molecular
events that are necessary for progression from TMD to AMKL
remain largely unknown (McElwaine et al, 2004; Hitzler &
Zipursky, 2005; Muntean et al, 2006).
Walters et al (2006) reported three acquired mutations in
AMKL (DS and non-DS), each rendering Janus kinase3 (jak3)
constitutionally active. Each of these activating mutations was
capable of oncogenically transforming cells, as well as
conferring features of AMKL to mice. Recently, Kiyoi et al
(2007) found two additional AMKL patients (a DS and a non-
DS) with mutations in the same domain of jak3 (JH2/
pseudokinase domain), shown to harbour activating muta-
tions. They also reported a single DS-TMD patient with a
mutation in the JH7 domain, the functional consequences of
which were not examined. Although representing a limited
number of patients, taken together, these data propose jak3-
activation as an important event in the pathogenesis of AMKL,
compatible with acting as one of the possible ‘second hits’
leading to progression from TMD to AMKL. Selective chemical
inhibitors of jak3, already in clinical use as immunosuppres-
sives (Changelian et al, 2003), have therefore been proposed as
a therapeutic concept for AMKL (Walters et al, 2006).
Methods
Patients and samples
The project was approved by the ethical committee of the
North East London Strategic Health Authority. Samples were
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Summary
Acquired mutations activating Janus kinase 3 (jak3) have been reported in
Down syndrome (DS) and non-DS patients with acute megakaryoblastic
leukaemia (AMKL). This highlighted jak3-activation as an important event in
the pathogenesis of AMKL, and predicted inhibitors of jak3 as conceptual
therapeutics for AMKL. Of 16 DS-transient myeloproliferative disorder
(TMD)/AMKL patients tested, seven showed JAK3 mutations. Three
mutations deleted the kinase (JH1) domain, abolishing the main function
of jak3. Another patient displayed a mutation identical to a previously
reported inherited loss-of-function causing severe combined
immunodeficiency. Our data suggest that both gain-, and loss-of function
mutations of jak3 can be acquired in DS-TMD/AMKL.
Keywords: myeloproliferative disorder, tyrosine kinase, Janus kinase 3,
Down syndrome, acute megakaryoblastic leukaemia.
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surplus clinical, or archived clinical material collected by the
tissue bank of the Italian National Association for Paediatric
Haematology-Oncology (AIEOP) and the Italian National
Down’s Syndrome Association, (CEPIM), (samples kept by the
team of Galliera Genetic Bank, http://ggb.galliera.it/).
Informed written consent was obtained by the tissue banks
for all subjects. Other details about the samples used, including
methods for genomic DNA extraction, RNA extraction and
cDNA synthesis were previously published (Groet et al, 2003;
McElwaine et al, 2004; Groet et al, 2005).
Polymerase chain reaction amplification, sequencing and
sequence analysis
Amplification of the exons of JAK3 we performed by
polymerase chain reaction (PCR) with 5–10 ng of genomic
(g)DNA using 15 pairs of primers as indicated in Table SIA.
Reverse transcription (RT)-PCR was performed with 1 ll of
random primed cDNA using five pairs of overlapping primers,
spanning the JAK3 coding sequence (Table SIB). PCR condi-
tions were: 7Æ5 min at 95C; 35 cycles of 0Æ5 min at 95C,
0Æ5 min at 58C and 1 min at 72C; followed by 9 min at 72C.
Cycle sequencing was performed with an ABI BigDye termi-
nator V3Æ1 using an ABI3130XL automated sequencer (Applied
Biosystems, Foster City, CA, USA). Selected PCR products
were cloned using the TA cloning kit (Invitrogen, Carlsbad,
CA, USA) according to manufacturer’s recommendations, and
their sequence was verified as above.
Results
The sequence of JAK3 was analysed in presentation samples of
eight DS-TMD and eight DS-AMKL patients. Patient details
and results are summarised in Table I. gDNA was available for
three TMD patients and two AMKL patients. In these samples,
all exons of JAK3 sequenced and were all wild-type (Table I).
The remaining patient presentation samples (n ¼ 11) were
available as cDNA. In these, we found a high proportion (7/11)
with mutations in the JAK3 transcript (Table I). Interestingly,
three patients (TMD3, TMD11 and AMKL4) showed a large
(592 bp) deletion (see Fig 1), eliminating the most C-terminal
192 amino acids (exons 20-24). This includes the JH1 kinase
domain, which is essential for the kinase function of jak3.
Mutations resulting in a premature stop-codon in exon 21
were shown to completely abolish phosphorylation in a patient
with severe combined immunodeficiency (SCID) (Mella et al,
2001) and even smaller deletions in the JH1 domain abolish
the kinase activity of the protein (Lai et al, 1995). Another
mutation in patient TMD3 (P151R) was also reported among
the loss-of-function inherited mutations in patients with SCID
(reviewed in O’Shea et al, 2004). We were unable to ascertain
if the two mutations in TMD3 (C-terminal deletion and
P151R) result in a compound heterozygote, or are independent
mutation on the same chromosome. Patient AMKL5 showed
an A573V substitution, directly adjacent to the A572V
substitution reported to be an activating (gain-of-function)
mutation (Walters et al, 2006). Two patients (TMD8 and
Table I. Patient details and results. Presentation
samples from Down syndrome patients with
TMD or AMKL used in this study. The blast
percentages are indicated, together with the
mutations previously found in GATA1 (for a
more detailed description of these, see Groet
et al, 2003; McElwaine et al, 2004; Groet et al,
2005). The JAK3 mutations detected in this
study are indicated in the last column.
Patients Material Blast (%) GATA1 mutations JAK3 mutations
TMD1 gDNA 85 270-271ins7bp WT
TMD2 gDNA 50 259dup34bp,
305dup4bp,
307ins8bp
WT
TMD3 cDNA 60 161C>T, STOP P151R, 2851-3442del592
TMD6 cDNA ND splice D-exon2 P434R
TMD8 cDNA 50 344-345ins2bp splice Dexon2-5, Dexon3-5
TMD10 cDNA 98 245-266del22bp WT
TMD11 cDNA 78 263delG 2851-3442del592
TMD15 gDNA 20 259dup34bp WT
AMKL1 cDNA 50 270-271ins7bp splice Dexon3-5, Dexon3, 5
AMKL1 (rem) cDNA 0 WT WT
AMKL4 cDNA 40 splice D-exon2 2851-3442del592
AMKL5 cDNA 95 251delT A573V
AMKL7 cDNA 60 splice D-exon2 WT
AMKL8 cDNA >50 197G>T, STOP WT
AMKL11 cDNA 50 262-263ins7bp WT
AMKL13 gDNA 78 298-299ins5bp WT
AMKL14 gDNA 80 285-286ins19bp WT
TMD, transient myeloproliferative disorder; AMKL, acute megakaryoblastic leukaemia; rem,
remission; cDNA, complementary DNA; gDNA, genomic DNA; ND, not determined; WT, wild
type; ins, insertion; dup, duplication; del, deletion; D-exon, exons missing in the alternative
splicing form.
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AMKL1) showed alternatively spliced forms of JAK3,
eliminating a large portion of the FERM region from the
protein. The predicted start codon, for the alternatively spliced
cDNAs is at amino acid position 235 in exon 6 of jak3. A
remission sample of AMKL1 did not show the alternatively
spliced products, indicating that this change was specific for
the leukaemic clone (Table I). The large deletion and the
splicing variants were confirmed by cloning and sequencing
the RT-PCR products (Fig 1A shows the chromatograms of
the cloned RT-PCR products for patients TMD8 and TMD11).
One out of one clone showed the alternative splicing in TMD8,
and one out of four clones showed the deletion in patient
TMD11. In chromatograms from sequences of whole presen-
tation samples’ cDNA (not shown) the peaks of the alternat-
ively spliced, and of the deleted product, were approximately
half the height of the wild-type sequence, reflecting the
proportion of blasts in the total population. Patient TMD6
contained a P434R substitution in the SH2 domain. The
function of this domain is not completely understood and
binding partners have not yet been identified. All the patients
had constitutional trisomy 21, and all had acquired mutations
in GATA1 (Table I, see also Groet et al, 2003; McElwaine et al,
2004; Groet et al, 2005).
Discussion
The Jak family is one of ten families of non-receptor tyrosine
kinases. All mammals have four members of this family: jak1,
jak2, jak3 and tyk2. These proteins have a C-terminal kinase
domain, a catalytically inactive pseudo-kinase domain, and
they bind cytokine receptors through amino-terminal FERM
domains. Upon binding of cytokines to their receptors, jaks are
(A)
(B)
Fig 1. (A) Sequence data chromatograms from JAK3 mutations in Down syndrome patients with transient myeloproliferative disorder (TMD) and
acute megakaryoblastic leukaemia (AMKL). Patients TMD3, TMD6 and AMKL5 showed substitutions in presentation sample cDNA. In TMD8,
alternative splicing removes exons 2-5 from the transcript, possibly removing 234 N-terminal amino acids. In TMD11 a 592 bp deletion removes the
192 most C-terminal amino acids. For both TMD8 and TMD11 the chromatograms are shown of the cloned RT-PCR products (RT-PCR analysis of
the presentation samples shows wild-type JAK3 sequence in addition to the mutation). (B) Predicted consequences of the mutations on the structural
organisation of the jak3 protein.
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activated and phosphorylate downstream targets, such as
members of the STAT family (Yamaoka et al, 2004).
Loss-of-function of jak3 is the basis of autosomal SCID. Upon
revision of the literature (O’Shea et al, 2004), we noted that,
among the mutations found in SCID patients, at least one
(V722I) was subsequently found to be an activating mutation
(Walters et al, 2006). Therefore, in SCID too, the observed
mutations can, in rare cases, be a gain-of-function, although by
far the majority is expected to confer a loss of function. The
gain-of-function mutations reported by Walters et al (2006)
had a transforming and oncogenic effect in vitro and in vivo,
and prompted the proposal of a recently developed selective
small molecule inhibitor of jak3 as a therapeutic for AMKL
(Changelian et al, 2003; Walters et al, 2006). Our data reveal a
more complex spectrum of mutations (gain-, as well as loss-of-
function), suggesting that a simple inhibition of jak3 may not
be the theoretically viable approach for all DS-AMKL patients.
The apparent difference in mutation frequency between
genomic DNA (0/5) and cDNA (7/11) can be explained by the
fact that with the current assay set-up, only the substitutions
would have been detected in genomic DNA. The number of
substitutions in genomic DNA compared with cDNA was not
statistically significant (0/5 and 3/11 respectively).
Taken together, our data allow several conclusions. Firstly,
both gain- and loss-of-function mutations in jak3 can be seen
in leukaemic samples of both DS-TMD and DS-AMKL
patients. Secondly, mutations are not the ‘second hit’ respon-
sible for progression of DS-TMD to DS-AMKL, as a similar
spectrum of mutations is found in both groups of patients.
Lastly, since 3/3 DS-TMD patients for which the relevant data
were available (TMD3, TMD6 and TMD11) are all in
spontaneous complete remission (for >11, >11 and >4 years
respectively), past the age typical for progression to AMKL, we
can conclude that their mutations were not a predictive factor
as to the progression from TMD to AMKL. Our data provides
additional facts, which are helpful in further elucidation of the
structural and pathological consequences of alternative forms
of this exciting protein.
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Thus, with regard to their known anticoagulant activities in
the regulation of blood coagulation, the PZ polymorphism
PZR255H and the ZPI polymorphisms ZPIK25R and ZPIS40G
appear to be functionally identical to their respective
WT counterparts. Although it is conceivable that PZ
and ZPI possess additional anticoagulant properties that
have not yet been discovered, our results are consistent
with genetic studies, which have not identified these
polymorphisms as significant risk factors for venous throm-
bosis (Rice et al, 2001; Van de Water et al, 2004; Corral et al,
2006).
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Megakaryocyte hyperproliferation without GATA1 mutation in
foetal liver of a case of Down syndrome with hydrops foetalis
A higher incidence of lymphocytic and myeloid leukaemias is
observed in children with Down syndrome (DS). The highest
difference in relative incidence (500·) is seen for megakaryo-
blastic leukaemia, which appears in two forms: a self-regress-
ing, pre-leukaemic hyperproliferative state known as transient
myeloproliferative disorder (TMD), affecting 10% of DS
neonates, and frank acute megakaryoblastic leukaemia
(AMKL) which develops in 20–30% of TMD patients over a
period of 2–4 years (Hitzler & Zipursky, 2005; Muntean et al,
2006). Trisomy 21 and in utero acquired mutations in GATA1
are observed in all cases of DS-TMD and DS-AMKL, and
co-exist in the proliferating myeloid cells (Wechsler et al, 2002;
Groet et al, 2003). Factors that predispose 10% of DS to this
disease, and additional events that are necessary for progres-
sion from TMD to AMKL, remain largely unknown (McElwa-
ine et al, 2004; Hitzler & Zipursky, 2005). GATA1 mutations in
DS-TMD can be detected in genomic DNA from foetal livers at
18–23 weeks of gestational age (Taub et al, 2004). To date,
acquired GATA1 mutations have never been reported in
neonatal TMD blasts that did not also carry a trisomy 21
(either as constitutional DS, or in individuals mosaic for
trisomy 21). The role of trisomy 21 remains to be fully
clarified. It appears to provide a cell-autonomous proliferative
advantage for the GATA1 mutant clones, but its possible
contribution to the increased risk of occurrence of GATA1
mutations has not been ruled out. We present an intriguing
case of a perinatal hydrops foetalis (HF) in DS, with
hyperproliferation of megakaryocytes in both foetal liver and
spleen, without a detectable GATA1 mutation.
The case was identified after screening the archival autopsy
collection of specimens at the Dept. of Pathology, University of
Split Medical School, for DS. All archived material was
consented for use in research, and the project was covered
by ethical approval from the North East London Health
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Authority. Records showed that this female premature was
delivered at 29 gestational weeks, with slight dysmorphic facial
features resembling DS, and lived for less than 1 h before
succumbing to severe generalised HF. Standard karyotype
analysis revealed the karyotype as trisomy 21 (47XX + 21).
Histopathological analysis of liver and spleen biopsies has
shown numerous clusters of large, multinucleated, cells with
megakaryocyte morphology in the sinusoids. Both tissues also
contained a greater than normal amount of haemosiderin
pigment, and a mild degree of fibrosis. There were no obvious
abnormalities in morphology or number of any other cell type
in liver, spleen or bone marrow (not shown). The type of
infiltrating cells was confirmed by performing an immunohis-
tochemical analysis of archived, paraffin-embedded tissues
from the liver and spleen biopsy specimens. As a control,
archived foetal liver biopsy of a therapeutically terminated DS
matched for sex and gestational age was used. Morphological
and immunohistochemical analysis of liver sections showed
numerous and widespread islands of apparent hyperprolifer-
ation of large cells, containing large cytoplasm and large, in
many cases multiple nuclei (Fig 1Aa,c,e). Cells showed
strongly positive staining with CD41 (Fig 1Ac,e). No such
islands were visible in the gestational age-matched DS foetal
liver, analysed as a comparison control (Fig 1Ab,d). Similar,
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Fig 1. (A) Morphological features of the megakaryocytic hyperproliferation in the liver of the Down syndrome case prematurely born with hydrops
foetalis. a,b: 400· magnification of the haemotoxylin-eosin staining of the liver specimen from the case (a); and a gestational age matched DS control
foetal liver (b). c,d,e: Immunohistochemical analysis of CD41 expression (200·) in the liver of the case (c), the DS control (d) the case in greater detail
(400·) (e). f: Negative control for the staining, omitting the primary antibody (liver specimen of the case at 400·). (B) Immunohistochemical analysis
of CD41 expression of the spleen of the case (200·). (C) Further analysis of the hyperproliferative cells in the liver of the case for the expression of von
Willebrand factor (200·) (a) and CD34 (200·) (b). Methods: After deparaffinization, 5 lm thick sections were incubated with polyclonal goat anti-
CD41 (Santa Cruz, Heidelberg, Germany) (1:500 dilution), polyclonal rabbit anti-von Willebrand (Dako, Ely, UK) (1:400 dilution) and monoclonal
mouse anti CD34 (Dako, Glostrup, Denmark A/S) (1:50 dilution). Immunoreactivity was developed with the Vectastain Elite ABC Kit (Vector
Laboratories, Peterborough, UK). Slides not incubated with the primary antibody served as negative controls. Sections were analyzed with the Leica
Application Suite software on a Leica Q5501W Microscope (Leica LTD, Heidelberg, Germany). (D) (i) Gel electrophoresis of PCR products obtained
from the liver DNA with primers spanning GATA1 exon 2. (ii) Chromatogram showing part of the wild type sequence of the PCR product from (i).
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though less numerous accumulations of hyperproliferating
large CD41+ cells were observed in the spleen (Fig 1B). The
cells from foetal liver were then analysed for the presence of
Von Willebrand factor (VWF) and CD34. The large hyper-
proliferative cells in the case liver were found to be VWF+
(Fig 1Ca) and CD34) (Fig 1Cb). The overall picture distin-
guishes this case from typical DS-TMD, the vast majority of
cases of which show a proliferation of immature megakaryo-
blasts, rarely multinucleated, which are VWF) and CD34+.
Genomic DNA was then extracted from the case’s liver
specimen after deparaffinization using a standard phenol–
chlorophorm precipitation. Amplification of GATA1 exon 2
(the site of all acquired DS-TMD mutations) and sequencing
of both DNA strands was performed as described (Groet et al,
2005). The amplified product of GATA1 exon2 was the correct
length, with a completely wild type sequence that showed no
signs of mutation (Fig 1D).
In summary, this is the first report of a case of HF in DS
with an apparent hyperproliferation of megakaryocytes in the
liver and spleen, without evidence of an acquired GATA1
mutation. Though insufficient sensitivity to detect a low
percentage cryptic GATA1 mutation due to technical limita-
tions remains theoretically a caveat, and conclusions based on
a single case are clearly limited anyway, the possibility of a
similar phenotype in a significant fraction of DS cannot be
excluded at this stage. Our preliminary results on RNA from
13 random DS foetal livers (unpublished data, histological
samples unavailable) identified at least two with unusually high
levels of CD41 transcript, compared to matched euploid
controls, while only wild type GATA1 sequence was obtained
in reverse transcription polymerase chain reaction (RT-PCR)
products from all cases. HF occurs in only 7% of TMD (Gassas
et al, 2005), and in 14% of all DS (Smrcek et al, 2001). In the
latter study, of 79 DS subjects, 11 cases of HF were detected,
and seven of those (64%) did not have TMD determined by
the umbilical blood cell count. This study was performed
before GATA1 mutations in DS had been discovered.
Taken together, these data maintain the possibility that
hyperproliferation of megakaryocyte-like cells could occur in
DS foetal liver, without an overt TMD, in the absence of
GATA1 mutation. This hyperproliferation could be distinct
from TMD, in that the cells appeared more mature.
Nevertheless, it is an intriguing possibility that unknown
events different from GATA1 mutation may initiate this
hyperproliferation, and that augmented megakaryopoiesis in
a fraction of DS foetuses may increase the risk of acquisition
of GATA1 mutations, subsequently providing the mutated
clone with a proliferative advantage over all others, causing
TMD. Human chromosome 21 harbours several genes with
important physiological roles in haematopoietic, particularly
megakaryocytic differentiation (Rainis et al, 2005) (BACH1,
ERG), and also a known co-operative function with GATA1
(RUNX1). These (and/or other genes or other genetic
elements, such as microRNAs) could play a role in altering
the rate of erythroid/megakaryocytic differentiation, thereby
increasing the risk of occurrence of GATA1 mutations.
Further studies are clearly needed to put these hypotheses to
the test.
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